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EPIDEMIOLOGY AND RISK FACTORS
Cutaneous melanoma is the most aggressive type of skin cancer and originates from 
melanocytes of the skin. It can present as four histopathological subtypes: superficial 
spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous 
melanoma.1 Over 50.000 melanoma-related deaths are registered worldwide annually and 
about 232.100 new cases are diagnosed. The incidence rates are generally increasing 
over the past 50 years.2 The risk factors for melanoma include intermittent exposure to 
sunlight, sunburns and indoor tanning beds.3-5 Besides the environmental factors, several 
phenotypic and genetic characteristics of an individual account for the risk of melanoma. 
They include fair skin, light eye and hair colour, propensity for freckles, presence of solar 
lentigines as a sign of actinic damage, the presence of melanocytic and dysplastic nevi and 
familial history of cutaneous melanoma.6-9 
GENETIC ALTERATIONS IN MELANOMA
Cutaneous melanoma has one of the highest mutational burdens among all types of 
cancer, approximately 38.3 mutations/Mb with many ultraviolet signature mutations (C>T).10,11 
Melanomagenesis may follow a sequential genetic model from a visible pre-existing lesion 
but most melanomas develop de novo. BRAF V600E mutations are often already present in 
benign nevus, while the intermediate lesions harbour NRAS mutations and other additional 
mutations such as in the TERT gene promoter.12 According to TCGA, 52% of melanomas 
harbour BRAF mutations, 28% present RAS mutations, 15% have mutation in the NF1 gene 
and the remaining 10% are the triple-wild-type for the BRAF, RAS and NF1 genes (triple-
WT) melanomas. Low-frequency loss-of-function driver mutations in cell-cycle regulation 
and chromatin remodelling genes (CDKN2A and ARID2) as well as in PTEN or TP53 genes 
are required for triple-WT advanced melanoma.12-14 Also activating hotspot mutations in KIT, 
CTNNB1 and EZH2 genes were found in this subgroup.11,13 TERT-promoter mutations occurred 
in 72-83% of the BRAF, NRAS and NF1 mutant subtypes, but only 7% in triple-WT melanomas.13
Regarding copy number alterations, the BRAF mutant subtype shows amplifications of BRAF, 
MITF, PD-L1 genes. As expected, for NRAS mutated subtype present the highest amplification 
of NRAS. The triple-WT subtype was significantly enriched for the amplification of 4q12 including 
KIT, co-amplification of PDGFRA and KDR, as well as CDK4, CCND1, MDM2 and TERT.13 
Overall, the mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K) 
pathways, RB1/CDKN2A cell-cycle pathways and MDM2/TP53 apoptosis pathways are the 




FIGURE 1. Schematic representation of the different layers and the cells that constitute the epidermis 
(top) and the stages in the development and progression of melanoma (bottom). Figure composed with 
Servier Medical Art images (https://smart.servier.com/).
PROGNOSIS AND TREATMENT




I for thin localized tumours, stage II a thick localized tumour, at stage III there are nodal 
metastases and stage IV for those with distant metastases.15
For stage I melanoma tumour thickness is the main criterium to define a precise prognosis, 
along with ulceration.16,17 The first line of treatment for primary tumours consists of surgical 
excision with margins depending on Breslow thickness.18 The complete lymph node 
dissection is performed when there is lymph node metastatic disease (macrometastases), 
but is no longer performed for sentinel node-positive melanoma (micrometastases, stage 
IIIa) since it does not significantly reduce the mortality rate.19
The prognostic value of BRAF and NRAS mutations remains quite unclear.20,21 In general 
the NRAS mutant subset of melanomas are more aggressive and associated with poorer 
outcomes.20,22 However, no efficient targeted  therapy  has emerged so far for this group 
of patients.23  BRAF inhibitors are approved for advanced and metastatic BRAF-mutated 
melanomas, alone or in combination with MEK inhibitors (vemurafenib plus cobimetinib, 
dabrafenib plus trametinib and encorafenib plus binimetinib).24,25 BRAF amplifications and 
MEK1/2 mutations are the best described mechanisms that reactivate MAPK signaling pathway 
or activate PI3K-AKT pathway and resistance to targeted therapy remains a major issue.26 
KIT-mutant melanomas are commonly treated with imatinib or nilotinib. Immunotherapy in 
melanoma, especially the immune checkpoint inhibitors anti-CTLA4 (ipilimumab) and anti-
PD-1 (pembrolizumab and nivolumab), has shown to be highly effective, also in NRAS-mutant 
tumours.20,22 However, only a subset of patients has a complete response to this therapy 
and many of them show disease progression during treatment.18
FAMILIAL MELANOMA 
Approximately 10% of patients diagnosed with melanoma mention a positive family history 
for this malignancy. Familial melanoma is arbitrarily defined as the occurrence of three 
or more melanomas in multiple members of a family, with at least two diagnosed in 
first-degree relatives.27 Only approximately 50% of melanoma families can currently be 
attributed to pathogenic variants in high and medium penetrance melanoma genes such 
as CDKN2A, CDK4, BAP1, TERT, POT1, ACD, TERF2IP and MITF.28 CDKN2A gene is the 
major contributor to melanoma susceptibility with ~39% of the families being affected by 
genetic alterations in this gene. Some years later alterations in CDK4 gene were also 
discovered as a causative event in some melanoma families. Over the last few years, new 
approaches using genomic sequencing technologies gave rise to identification of new 
pathways dysregulated in melanoma. The CDK4 gene along with alterations in BAP1, MITF, 
TERT, POT1, ACD and TERF2IP constitute the genetic cause in about 10% of all familial 




half of the affected melanoma families. 
The diagnostic testing to melanoma still relies on CDKN2A and CDK4 susceptibility genes.29 
Clarifying the genetic basis of familial melanoma is clinically relevant as it would allow for 
genetic testing, risk estimation, counselling and targeted clinical surveillance of patients 
at high risk of melanoma. The genetic basis of familial melanoma might be uncovered by 
applying next generation sequencing methodology in families with a history of melanoma 
and by exploring different mechanisms of inheritance including heritable epigenetic 
alterations. 
EPIGENETICS
The term epigenetics refers to the changes in the genome, affecting gene function and 
expression, that do not affect the DNA sequence.30 
EPIGENETIC REGULATION OF GENE EXPRESSION
The epigenetic regulation of gene expression relies on three distinct levels: DNA (hydroxy)
methylation (covalent modifications of DNA bases), histone modifications (post-translational 
modifications on the amino-terminal tail of histones) and chromatin remodelling.31 
In the nucleus of eukaryotic cells, genomic DNA and histones form the nucleosomes, 
the basic complexes of chromatin. Different levels in chromatin organization have been 
described, from nucleosome array, an 11-nm “beads-on-a-string fiber” conformation, to a 
more condensed 30-nm chromatin fiber, after binding of H1 and H5 linker histones.32,33 
Chromatin plasticity and dynamics has an essential role in regulation of gene expression 
by influencing the binding of transcription factors.34 Active gene transcription takes place 
when chromatin is in the loose form, euchromatin, as this conformation enables the binding 
of transcription factors. However, when chromatin acquires a very condensed form, called 
heterochromatin, transcription is repressed.34 
Cancer genomes are characterized by hypermethylation of promoter CpG islands that 
interferes with transcription factors binding and enhances heterochromatin formation which 
therefore impair gene expression.35,36 Otherwise, methylation of CpG sites located in the 




FIGURE 2. Schematic representation of a gene promoter region in a normal cell and a cancer cell. The 
aberrant increase of methylation (hypermethylation) in the cancer cell often leads to transcriptional 
silencing of the gene.
DNA METHYLATION AND HYDROXYMETHYLATION IN CANCER
Epigenetic mechanisms are also involved with progression of melanoma. As mentioned, 
DNA methylation, histone modifications and chromatin remodelling complexes regulate 
gene expression programs. DNA methylation can be divided into de novo or maintenance of 
methylation upon cell division and is mainly regulated by DNA methyltransferases (DNMTs).38 
However, DNA methylation at CpG dinucleotides is not only mediated by DNMTs but 
additionally governed by DNA demethylation. DNA demethylation is the reverse process of 
methylation, thus consists in discarding the methyl groups from the CpG dinucleotides. This 
process can occur in a passive or an active way. Passive demethylation occurs when there is 
insufficient methyltransferase activity during replication. Active demethylation involves three 
consecutive steps of oxidation from 5-methylcytosine (mC) into 5-hydroxymethylcytosine (hmC), 
5-formylcytosine (fC) and 5-carboxylcytosine (caC) performed by the Ten Eleven Translocase 
(TET) family of dioxygenase enzymes.39,40 5-fC and 5-caC are then recognized by the thymine 
DNA glycosylase (TDG) that activates the base excision repair pathway responsible for the 
replacement of the altered cytosine by a ‘regular’ cytosine.41 TET1, TET2 and TET3 constitute 
the TET protein family and require α-ketoglutarate (αKG) as a co-substrate. In its turn, αKG 
is produced by isocitrate dehydrogenase (IDH)1, 2 and 3 proteins. While approximately 4% 
of all cytosines are methylated, only 0.1% - 0.7% of cytosine bases are hydroxymethylated in 
mammalian cells.42 At first, hmC was assigned as a mere intermediate in the demethylation. 
Nowadays, different studies have pinpointed strong arguments in favour of a proper hmC 
role in the cell: the stability of hmC in the genome of in vivo and cultured cells, specific hmC-




Although the low fraction of cytosines affected by this epigenetic modification throughout 
the genome, reduced levels of hmC in different cancer types, such as breast, liver, lung, 
pancreatic, colon, prostate, compared to precursor lesions were recently reported.47 Namely 
in melanoma it has been reported that low levels of hmC were associated with worse 
survival.48 The reasons behind hmC reduction have been explored by different approaches 
and targets. Some studies report that mutational inactivation and/or downregulation of TET2 
might explain the loss of hmC.48,49 Also IDH proteins seem to have a role in this depletion. 
While wild-type IDH protein produces αKG, the co-substrate of TET enzymes, the mutant IDH 
transforms αKG into R-2-hydroxyglutarate, a oncometabolite that is a competitive inhibitor 
of TET. However, only 10% of melanomas harbour mutations in IDH genes.50 Resetting the 
differential mC and hmC levels towards a functional demethylation pathway might be an 
interesting target to cancer therapy.51 
FIGURE 3. DNA methylation and demethylation pathways. Purple arrow: The enzyme DNA 
methyltransferase (DNMT3A/B and DNMT1) catalyzes the addition of a methyl group to the fifth carbon 
atom within the pyrimidine ring of the cytosine base to yield 5-methylcytosine (5-mC); Brown dashed 
arrows: passive demethylation during cell division. Black arrows: active demethylation pathway in 
which TET (TET1/2/3) proteins convert 5-mC into 5-hmC, 5-fC and 5-caC through three consecutive 
oxidation reactions. Then, 5-fC and 5-caC are recognized by thymine DNA glycosylase (TDG) proteins 
which activate the base excision repair (BER) pathway responsible for the replacement of the altered 
cytosine by a ‘regular’ cytosine. TET protein family require α-ketoglutarate (α-KG) as a co-substrate that 
is produced by wild-type isocitrate dehydrogenase (IDH) proteins. The mutant IDH transform it into R-2-





Throughout the last decade, the application of next generation sequencing methodology 
has identified new germline mutations, however it did not reveal all causative genetic 
alterations that might explain the predisposition to melanoma in families.52 For this reason, 
the attention has turned to different causes of inheritance including heritable epigenetic 
alterations. 
Epimutations have been defined as heritable changes in gene activity due to DNA 
modifications, not encompassing changes in the DNA sequence itself.53 It has been postulated 
to constitute an alternative mechanism to genetic mutation for cancer predisposition and 
commonly refers to constitutional promoter CpG island hypermethylation in all somatic cells 
of an individual.54 This mechanism of an inherited epigenetic alteration was firstly seen in 
patients of hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome), who were 
not affected by the inactivating mutations in DNA mismatch repair genes but by heritable 
promoter hypermethylation of the MLH1 gene.55-57 
Epimutations have been classified as primary, occurring in the absence of an underlying 
DNA sequence alteration, and secondary, when a genetic mutation triggers the occurrence 
of an epigenetic modification. Epimutations found in MSH2 and DAPK1 genes in HNPCC 
and familial chronic lymphocytic leukemia, respectively, are examples of secondary 
epimutations.58-60 
EPIGENETIC REGULATION OF AN ESSENTIAL GENE IN MELANOMA, TERT 
In the past few years, we have witnessed the growing importance of non-coding mutations 
in cancer.61 The telomerase reverse transcriptase (TERT) gene promoter (TERTp) mutations 
(chr5:1,295,228 C>T and chr5:1,295,250 C>T in hg19) are a recognized example. 
Approximately 90% of all human cancers share the transcriptional reactivation of the TERT 
gene.62,63 TERT encodes the catalytic subunit of the ribonucleoprotein telomerase and 
is capable of extending the repetitive, non-coding DNA sequence on terminal ends of 
chromosomes, the telomeres. Telomeres become shorter at each cell division, but through 
TERT reactivation, the cells keep the ability of extending their telomeres or prevent their 
shortening. This telomere maintenance is one of the hallmarks of cancer.64-66 
By creating new binding motifs for the transcription factor E26 transformation-specific/
ternary complex factor (ETS/TCF), the two point mutations in the TERTp lead to a two-
fold increase in TERT expression, resulting in maintenance of telomere length and 




mutually exclusive. They are located at −124 bp and –146 bp from the translation start site 
(chr5:1,295,228 C>T and chr5:1,295,250 C>T in hg19, respectively).68 
Aside from TERTp mutations, TERTp methylation has been widely explored. Remarkably, 
TERTp hypermethylation performs an opposite role enhancing gene expression, as 
transcriptional repressors rely on unmethylated promoter CpGs, such as CCCTC-binding 
factor (CTCF)/cohesin complex or MAZ.70-72 In combination with transcription factor binding, 
dissociation of the repressor may result in TERT expression.64,73-75
The methylation of a specific CpG in the TERTp region was found to be correlated with 
progression and poor prognosis in paediatric brain tumours and later with TERT expression 
in tumour samples with no somatic alterations.64,74
FIGURE 4. Schematic representation of TERT promoter region with the relative positions of 
cg11625005 (position 1,295,737 in hg19) to the TERTp mutations (position 1,295,228 and 1,295,250) and 
the transcription start site (TSS).
THESIS OUTLINE
With the present thesis we aim to reveal new melanoma susceptibility genes and heritable 
epigenetic alterations that could explain the melanoma predisposition in a significant 
proportion of melanoma-affected families in which the cause is still unknown. Moreover, we 
also intend to explore at which extent epigenetic alterations, namely the hydroxymethylation, 
are involved in the progression from benign lesions to melanoma. Finally we wonder what is 
the role of genetic and epigenetic mechanisms and their interplay in regulating TERT gene 




In Chapter 2, we aim to identify a new melanoma susceptibility gene, the genetic cause 
that co-segregates with melanoma in a family with multiple melanoma-affected members. 
In Chapter 3, we investigate whether inherited epigenetic events are potential explanation 
for melanoma predisposition in families with history of melanoma. 
In Chapter 4, we aim to find new diagnostic and prognostic markers based on differential 
hydroxymethylation patterns by comparing nevus and melanoma. 
In Chapter 5, we address how TERTp mutations and TERTp methylation along with chromatin 
accessibility are able to trigger TERT expression in healthy skin and melanoma cell lines. 
Finally in Chapter 6, a summary of Chapters 2 to 5 is presented in light to previous literature. 
We discuss to which extent the aforementioned aims have been met and what additional 
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A proportion of patients diagnosed with melanoma has a positive family history. Despite 
increasing knowledge on the genes responsible for familial clustering, the genetic basis 
in the majority of the families with an inherited predisposition to melanoma remains to 
be clarified. To identify novel melanoma-susceptibility genes we applied whole exome 
sequencing (WES) on DNA from two members of a family with four melanoma cases, not 
explained by established high penetrance melanoma-susceptibility genes. WES identified 
10 rare, co-segregating, predicted deleterious missense gene variants. Subsequent co-
segregation analysis revealed that only variants in the DOT1L (R409H) and the SLCO4C1 
(P597A) genes were present in the other two affected members of this family. DOT1L 
is a methyltransferase that methylates histone H3 lysine 79 (H3K79). It is involved in 
maintenance of genomic stability, since mutations in the DOT1L gene have been previously 
reported to compromise the removal of UV photoproducts in UV-irradiated melanocytes, 
thereby enhancing malignant transformation. We hypothesized that the presence of DOT1L 
R409H variant might be associated with an increased risk of melanoma, since we found co-
segregation of the DOT1L mutation in all four melanoma-affected family members. However, 
this missense variant did neither lead to detectable loss-of-heterozygosity nor reduction of 
histone methyltransferase activity in melanoma samples from mutation carriers nor altered 
UV-survival of mouse embryonic stem cells containing an engineered homozygous DOT1L 
R409H mutation. Although functional analysis of this rare co-segregating variant did not 
reveal compromised histone methyltransferase activity and UV exposure sensitivity, the 
role of DOT1L as melanoma susceptibility gene deserves further study.  
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Cutaneous melanoma is an aggressive form of skin cancer and the leading cause of death 
among all skin cancer patients.1 Approximately 10% of melanoma cases present familial 
clustering. In Europe, familial melanoma is defined as the occurrence of three or more 
melanomas in multiple members of a family, at least two of which are diagnosed in first-
degree relatives. Thus far only in ~50% of melanoma families the melanoma susceptibility 
can be attributed to a genetic defect in the high and medium penetrance melanoma genes 
such as CDKN2A, CDK4, BAP1, TERT, POT1, ACD, MITF and TERF2IP.2 Clarifying the genetic 
basis of melanoma predisposition is of major clinical importance since new genetic testing 
can be approved and more personalized surveillance offered to the patients.3 Exome-wide 
sequencing approaches can be valuable in the identification of putative new-melanoma 
susceptibility genes.4 
In the present study, we describe a Dutch family of which four family members were 
diagnosed with melanoma. Whole-exome sequencing (WES) of DNA from two family 
members identified a new germline missense variant c.G1226A:p.R409H in the DOT1L gene, 
that co-segregated with melanoma in all 4 affected family members. DOT1L is the unique 
histone methyltransferase responsible for methylating the nucleosome core on lysine 79 
of histone H3 (H3K79).5,6 The observed DOT1L variant appeared to be the most promising 
pathogenic variant since recently loss of DOT1L (by silencing or mutation) has been 
reported to promote melanomagenesis in a pre-clinical mouse model upon UV radiation.7 
The role of DOT1L in DNA damage repair pathway involves the transcriptional recovery 
through reactivation of RNA Pol II in mouse-derived cell lines8 and the recruitment of XPC 
for an efficient nucleotide excision repair in melanocytes and cell lines derived from human 
melanoma, thereby protecting melanocytes from the UV-induced transition to melanoma.7
We hypothesized that in the family under study, the R409H DOT1L variant represents a loss 




DNA from members of a Dutch family with four family members affected with melanoma 
was isolated from whole blood samples, a primary tumor and a brain metastasis. The study 
was approved by the Leiden University Medical Center institutional ethical committee 
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(LUMC, P00.117). The affected family members were tested negative for variants in the high 
penetrance genes CDKN2A and CDK4 and cases II.2 and III.3 were subjected to WES 
(Figure 1).
FIGURE 1. Family pedigree. The melanoma affected members are in dark grey color (II.1, II.2, III.2, 
III.3). The age of diagnosis is indicated in brackets. The melanoma cases subjected to whole-exome 
sequencing are indicated by an ‘WES’. 
WHOLE EXOME SEQUENCING
Whole-exome sequencing was performed using Agilent All-exon capture baits (Agilent, 
California) and sequenced on the Illumina platform at Sanger Institute, Cambridge, UK. The 
bioinformatics analysis and subsequent filtering steps were performed at Sanger Institute 
and later confirmed by our in-house bioinformatics pipeline. Briefly, the reads were aligned 
to the human genome build hg19 using BWA.9 To pass the filtering steps the variants needed 
to have a high-quality score (>30), to have high coverage (>40X), to be a nonsynonymous 
single nucleotide variant (SNV), to be heterozygous present in both samples, to have 
low ExAC frequency (<0.001), and needed to be predicted as deleterious and damaging 
by Polyphen and SIFT. Variants which did not fulfil all the filtering criteria were excluded, 




TABLE 1. Germline variants identified by whole exome sequencing shared by two affected family 
members of a 4 case Dutch melanoma family.
Gene Location Variant Amino acid substitution
SLCO4C1 Chr5: 101582978-101582978 G>C P597A
PEX6 Chr6: 42932102-42932102 G>A R972C; R884C
FBXL13 Chr7: 102462622-102462622 G>A S583L; S600L; S628L
NAIF1 Chr9: 130825802-130825802 G>A R297C
LAMC3 Chr9: 133914340-133914340 C>T R356C
CIT Chr12: 120152035-120152035 C>T V1383M; V1425M
FREM2 Chr13: 39433637-39433637 C>T R2477W
DOT1L Chr19: 2210729-2210729 G>A R409H
FUT1 Chr19: 49253896-49253896 C>A V215F
UMODL1 Chr21: 43508479-43508479 G>A V155M; V227M
CO-SEGREGATION ANALYSIS
All 10 variants were confirmed by Sanger sequencing using DNA from the 2 family members 
subjected to WES (II.2 and III.3, see Supplementary Figure S1). Briefly, 20-100 ng of DNA 
was amplified through a touchdown PCR using the Platinum Taq DNA Polymerase following 
the manufacturer’s instructions (Invitrogen, California, USA). The PCR product was cleaned-
up using the NucleoSpin Gel and PCR Clean-Up (Macherey-Nagel GmbH & Co. KG, 
Düren, Germany) according to manufacturer’s instructions. Then, Sanger sequencing was 
performed using 20-50 ng of purified DNA mixed with 1 mL of 10 mM of sequencing primer 
and nuclease-free water (B. Braun, Melsungen, Germany) up to 10 mL. Later on, we used 
the same approach to evaluate the co-segregation of these variants with melanoma in all 
affected family members (see Supplementary Figure S2 and Figure 2) 
FIGURE 2. Droplet digital PCR results showing the DOT1L mutation fraction in DNA samples extracted 
from whole blood samples [II.2, III.3 (both subjected to WES) and IV.1 and IV.2], a primary melanoma 
(II.1 FS) and a brain metastasis (III.2 FS). The mutation fraction is around 50% in mutation-carriers and 
around 0% in wild-type family members (II.5, II.6, III.4, III.5), as control samples. In a full section (III.2 
FS) of the brain metastasis, a mutation fraction of ~20% was found. The primary melanoma (II.1 FS) is 
mutated for DOT1L, however, no LOH was observed.
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LOSS OF HETEROZYGOSITY (LOH) ANALYSIS
Loss of heterozygosity was assessed by droplet digital PCR (ddPCR). Tumors from two family 
members were examined: a FFPE-derived primary melanoma biopsy from II.1 and a brain 
metastasis from III.2 (Figure 2). The DNA extraction was performed using Tissue Preparation 
System (Siemens, Germany) at the department of pathology, LUMC. Briefly, 10 ng of DNA 
was combined with 1X ddPCR Mut Assay DOT1L R409H (dHsaMDS130625855; Bio-Rad 
Laboratories, Inc., Hercules, California, USA), 1X ddPCR supermix for probes (no dUTP) (Bio-
Rad), 1U/mL MseI restriction enzyme [New England Biolabs, Inc. (NEB), Ipswich, MA, USA] 
diluted in its own buffer CutSmart (NEB) and nuclease-free water (B. Braun) up to 22 mL. To 
generate droplets the Automated Droplet Generator (Bio-Rad) was used, followed by the 
PCR using the cycling conditions for Bio-Rad’s C1000 Touch Thermal Cycler (Bio-Rad) with 
an annealing temperature of 55°C. The number of droplets was determined by the QX200 
Droplet Reader (Bio-Rad) and analysed using QuantaSoft version 1.7.4.0917 (Bio-Rad). 
IMMUNOHISTOCHEMISTRY
For immunohistochemistry (IHC, see Supplementary Figure S3), sections from FFPE-derived 
primary melanomas from II.1 and brain metastasis from III.2, along with EAF (ethanol, acetic 
acid, formol saline) fixed and paraffin embedded thymus tissues from mice with conditional 
deletion of Dot1L as described in 10 were pre-incubated with goat serum (Dako, Agilent 
Technologies, California, USA) for 30 minutes and then incubated overnight with H3K79me2 
antibody (1:8000 dilution, RRID:AB_158712611) followed by incubation with Dako EnVision+ 
System HRP labeled polymer anti-rabbit (Agilent Technologies) for 30 minutes. The slides 
were washed with phosphate-buffered saline, incubated with Dako 3,3’-diaminobenzidine 
(DAB) substrate chromogen system (dilution 1:50, Agilent Technologies), and counterstained 
with hematoxylin (Merck KGaA, Darmstadt, Germany).
CELL LINES GENERATION 
IB10 wild-type mouse embryonic stem cells (mESCs) were used to engineer site specific 
mutations using CRISPR/Cas9 to generate mESC lines expressing DOT1L R409H or the 
catalytic site mutant DOT1L G165R according to the protocol described by Harmsen et al.12 
IB10 mESCs were cultured on a feeder layer of irradiated murine embryonic fibroblasts 
(MEFs) in complete medium containing GMEM-BHK12 (Gibco/Thermo Fisher Scientific, 
Massachusetts, USA), 100 mM Sodium Pyrovate (Gibco), non-essential amino acids (Gibco) 
and 10% ES cell certified serum (HyClone/Thermo Fisher Scientific). This was complemented 
with 0.1 μM β-mercapthoethanol (Sigma-Aldrich, Missouri, USA) and mouse recombinant 
leukemia inhibitor factor (Merck KGaA). For transfection, cells were grown on gelatin coated 
plates in 60% BRL medium (150 mL Buffalo Rat Liver conditioned medium + 100 mL complete 




Oligonucleotides encoding the gRNAs are in Supplementary Table S1. Single strand 
homology directed repair (HDR) templates are in Supplementary Table S2. The repair 
templates were purchased from Sigma-Aldrich, all other oligonucleotides from Integrated 
DNA Technologies, Inc., Illinois, USA. The gRNAs were cloned into the px330.pgkpuro 
vector (a gift from Hein te Riele). A mixture of 0.1 μg CRISPR/Cas9 vector and 0.4 μg 
homology directed repair template in optiMEM (Gibco) with 1.25 μL TransIT LT1 (Mirus 
Bio LLC, Wisconsin, USA) was incubated for 15-20 min at room temperature and added 
to the cells. The next day cells were replated in 60% BRL medium containing 3.6 μg/mL 
puromycin. Two days later the medium was replaced with medium without puromycin. Cells 
were then sparsely seeded to grow single clones. After 1 week, single clones were selected 
and genomic DNA was isolated to validate the mutations, which also introduced restriction 
sites. The regions containing the R409H and G165R mutations were amplified using MyTaq 
Redmix (GC-Biotech B.V., Alphen aan den Rijn, The Netherlands) and the following primers: 
R409H – 5’TGCCTCAGCCTATGGTCTTGT and 5’TGGCACATGGCAGAGTCCCATA, for 
G165R – 5’ACTACACAGCCCATGAAGCTGA and 5’TGGTTAAGCAGCCACAACCCA. The PCR 
product containing the R409H region was digested with MIcI (Thermo Fisher Scientific) 
directly after amplification. PCR products containing the G165R region were purified using 
the QIAquick PCR purification kit (Qiagen, Hilden, Germany) according to the manufacturers 
protocol and then digested with BauI (Thermo Fisher Scientific). Clones that showed the 
expected digestion pattern were further validated using Sanger sequencing. For UV-
survival assays three clones with the R409H mutation were selected and two clones that 
had the G165R mutation, of which one had a homozygous G165R and one clone with a 
heterozygous G165R mutation and one nucleotide deletion causing a frame-shift in DOT1L. 
UV-SURVIVAL ASSAY
To assess UV sensitivity, we performed a colony formation assay upon UV-C exposure 
in wild-type and CRISPR/Cas9 engineered DOT1L mutant mESCs. For UV-survival assays 
mESCs were cultured in 60% BRL conditioned medium. One thousand cells were plated in 
a 10-cm dish and grown overnight. The next day cells were washed with PBS and exposed 
to UV-C irradiation (254 nm, UV-C irradiation chamber, Dr Gröbel UV-Elektronik, GmgH, 
Germany; dose range: 0.5, 1, 2, 4, 8 J/m2). After eight days of incubation the colonies were 
fixed and stained using Leishman’s eosin methylene blue solution modified (Merck KGaA). 
Colonies were counted with the ColCount (Oxford Optronix Ltd., Abingdon, UK).
WESTERN BLOT
Murine ESCs were grown in feeder-free conditions in serum free ES cell medium containing 
neurobasal medium (Thermo Fisher Scientific), DMEM/F12 (Thermo Fisher Scientific), N2 
supplement (Thermo Fisher Scientific), B27 (Thermo Fisher Scientific) and BSA (Thermo 
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Fisher Scientific) supplemented with GSK inhibitor CHIR99021 (BioConnect B.V., Huissen, 
The Netherlands) and MEK1&2 inhibitor PD0325901 (BioConnect) and cell pellets were 
frozen. Lysates were made using 1X SDS sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 
10% glycerol) and sonicated. Samples were boiled for 5 min in 5X SDS-sample buffer (250 
mM Tris-HCl pH 6.8, 10% SDS, 50% glycerol, 0.5 M DTT, 0.5% bromophenol blue) and 
separated on a 16% polyacrylamide gel. Separated proteins were transferred on a 0.45 
μm nitrocellulose membrane for 1h. Membranes were blocked using 2% Nutrilon (Nutricia/
Danone, Schiphol, The Netherlands) in Tris-buffered saline containing 0.05% Tween-20 
(TBST) for 1h and incubated overnight with anti-H3K79me1 (RRID: AB_2631105), anti-
H3K79me2 (RRID: AB_2631106) or anti-H3 (ab1791, Abcam, Cambridge, UK). All antibodies 
were diluted 1:100 in TBST containing 2% nutrilon. After incubation, the membranes were 
washed three times with TBST and incubated with IRDye 800CW goat anti-Rabbit igg (1:10 
000, Li-COR (RRID: AB_621843)) for 45 min in TBST with 2% nutrilon. Then, the membranes 
were washed three times with TBST and once in PBS and scanned using an LI-COR Odyssey 
IR Imager (LI-COR Biosciences, Nebraska, USA). Images were analysed using Image studio 
2.0 (LI-COR Biosciences). 
RESULTS
R409H, A NOVEL GERMLINE VARIANT OF THE DOT1L GENE IDENTIFIED IN A 4-CASE 
MELANOMA FAMILY 
Upon WES of the DNA from two melanoma cases (II.2 and III.3, Figure 1), 4892 heterozygote 
variants were found. The bioinformatics analysis encompassed the alignment to genome 
build hg19 and the above-mentioned filtering criteria. Frameshift and truncating variants were 
found but did not pass the ExAC filter. Only 10 rare, co-segregating, predicted deleterious 
missense variants in the genes SLCO4C1, PEX6, FBXL13, NAIF1, LAMC3, CIT, FREM2, DOT1L, 
FUT1, UMODL1 met our criteria (Table 1). The presence of these 10 germline variants in 
the two cases (II.2 and III.3) subjected to WES was confirmed by Sanger sequencing in 
DNA derived from blood leukocytes (see Supplementary Figure S1). Subsequently, co-
segregation of the variants was evaluated in other family members for whom DNA was 
available (II.1, 2, 5, 6; III. 2, 3, 4, 5; IV. 1, 2; data not shown). 
Only 2 out of 10 variants co-segregated with melanoma in all 4 affected relatives: c.C1789G:p.
P597A in SLCO4C1 gene and c.G1226A:p.R409H in DOT1L gene (see Supplementary Figure 
S2 and Figure 2). The SLCO4C1 gene encodes for a member of the organic anion transporting 
polypeptide (OATP) family. Human SLCO4C1 is involved in the membrane transport of 




a putative function for SLCO4C1 in cancer development is unclear. Only 2 studies describe 
SLCO4C1 mutation or silencing in head and neck cancers, affecting the platinum uptake 
and clearance.14,15 SLCO4C1 is not expressed in melanocytes and melanomas according to 
publicly available databases.16,17 Taken together, these reasons appear to exclude SLCO4C1 
as a candidate susceptibility gene for the family under investigation. 
DOT1L is the unique histone methyltransferase responsible for methylating the nucleosome 
core on H3K79. Based on the function of the DOT1L gene in UV-induced DNA damage 
repair and its reported role in melanoma development we considered the DOT1L gene 
variant a strong candidate responsible for melanoma susceptibility in this family. Additional 
rare and possibly deleterious variants were found in four sporadic and familial melanoma 
cases from the UK (Table 2). Moreover, the 19p13.3 locus, containing DOT1L gene, has been 
shown to be frequently deleted in metastatic melanoma cases.18 
TABLE 2. Additional DOT1L variants found in familial and sporadic melanoma cases from the UK.
Location Variant
Amino acid 
substitution Polyphen SIFT Allele frequency Familial vs. sporadic
Chr19: 2226478 G>A G1320R Possibly 
damaging
Deleterious 1.918e-5
Melanoma family with 
2 cases of melanoma 
and multiple primariesChr19: 2191090 A>T Y115F Probably 
damaging
Deleterious 0
Chr19: 2226839 G>C S1440T Benign Deleterious 0 Sporadic case, with 
early onset
Chr19: 2213960 C>T A591V Benign Tolerated 0 Melanoma family with 
3 cases of melanoma 
and multiple primaries
Chr19: 2217838 T>C L871P Probably 
damaging
Tolerated 0 Sporadic case, with 
early onset
ABSENCE OF LOH AND ALTERED METHYLTRANSFERASE CAPACITY IN TUMOR 
SAMPLES FROM MELANOMA-AFFECTED FAMILY MEMBERS
First, we assessed LOH of DOT1L p.R409H by Sanger sequencing and ddPCR analysis in a 
FFPE-derived primary melanoma biopsy from individual II.1 and melanoma brain metastasis 
from individual III.2. In the ddPCR result, the mutation fraction is about 50% in mutation-
carriers [II.2, III.3 (both subjected to WES) and IV.1 and IV.2, the youngest family members 
who did not develop melanoma yet] and close to 0% in wild-type family members (II.5, II.6, 
III.4 and III.5). We observed a low mutation fraction in the metastasis from III.2 (~20%) and a 
mutation fraction of about 56% in the primary tumor from II.1 (Figure 2). These numbers show 
an absence of LOH in the primary tumor and the brain metastasis. 
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Then, we checked whether this variant might be involved in a generation of a new splice 
site. Through Human Splicing Finder19, the splicing motif is not altered due to the nucleotide 
substitution. Therefore, there is no indication that this variant might have an impact on splicing. 
Since three previously reported somatic loss-of-function DOT1L mutations in melanoma 
affect the methyltransferase activity7, we aimed to assess whether the DOT1L mutation 
identified in our family disturbs DOT1L protein function by assessing H3K79 methylation via 
immunohistochemistry. A positive and negative controls derived from mouse thymus tissue 
were included to demonstrate the sensitivity of H3k79me antibody. A high percentage 
(~80%) of positive staining nuclei in primary melanoma from II.1 and brain metastasis from 
III.2 could be observed (see Supplementary Figure S3), indicating that the methyltransferase 
activity is only marginally, if at all, affected in the tumors.
R409H VARIANT DOES NOT SIGNIFICANTLY AFFECT THE UV SENSITIVITY 
We next determined cell survival upon treatment with UV-C radiation through a clonogenic 
assay with the use of wild-type and CRISPR/Cas9-engineered homozygous DOT1L 
p.R409H-mutant mESCs. No significant difference could be observed in survival after UV-
irradiation between DOT1L p.R409H-mutant and wild-type mESCs while DOT1L p.G165R 
mutant mESCs, expressing a catalytically inactive DOT1L protein showed reduced survival 
(Figure 3a). In mESCs, DOT1L p.R409H mutation did not lead to detectable loss of H3K79 
methylation, while methylation was completely lost in the G165R mutant (Figure 3b).
FIGURE 3. UV-survival assay of WT and DOT1L-mutant mouse embryonic stem cells (mESCs). (a) 
Colony formation capacity upon UV-C irradiation (dose range: 0.5, 1, 2, 4, 8 J/m2) in wild-type, DOT1L-
R409H and DOT1L-G165R mutated mESCs (n = 3 independent replicates, error bars represent s.d.) (b) 
Immunoblot analysis of H3K79me levels in the ESC clones used for UV-survival assay. Each lane shows 





Here, we report a novel missense germline mutation in the DOT1L gene shared by 
four first-degree family members diagnosed with melanoma with an early age of onset. 
Another variant in SLCO4C1 gene was found to co-segregate with melanoma in the family. 
However, the lack of evidence in association with cancer or expression in melanocytes did 
not encourage us to explore it further. On the other hand, DOT1L is a highly evolutionary 
conserved protein and is the unique histone methyltransferase responsible for mono-, 
di- and trimethylating the core of histone H3 on lysine 79 (H3K79).5,6,20 In addition, DOT1L 
regulates transcription elongation, establishes cell cycle checkpoints, and maintains 
genomic stability.21,22 Dysregulation of DOT1L has been associated with a number of cancers 
either as an oncogene or tumor suppressor gene.20
The DOT1L protein has been reported to interact with mixed lineage leukemia (MLL) 
fusion partners, such as AF4, AF9, AF10 and ENL, leading to H3K79 hypermethylation and 
transcriptional activation of target genes favoring leukemic transformation.23 Furthermore, 
DOT1L was described to interact with c-Myc-p300 complex to activate the epithelial–
mesenchymal transition (EMT) regulators in breast cancer progression.24 In addition, 
IL22/STAT3 signaling was reported to increase DOT1L expression, which subsequently 
increased the transcription of core stem cell genes, enhancing the cancer stemness and 
colorectal carcinogenesis, correlating with poor patient outcome.25 In all these studies, 
DOT1L functions as an oncoprotein. 
Recently, DOT1L has been described in colorectal cancer as an important player in DNA 
double-stand break repair via homologous recombination through γH2AX phosphorylation.26 
Also in melanoma a role for DOT1L in DNA damage repair has been envisioned. Three new 
mutations (M55L, P271L, and P505L) in the DOT1L gene that negatively affect the catalytic 
activity of the methyltransferase were identified.7 Loss of DOT1L (by silencing or mutation) 
impaired the DNA damage repair induced by UV-B radiation, thereby promoting melanoma 
development in vivo. The authors show that DOT1L promotes the assembly of the NER 
repair complex on chromatin by interacting with XPC and stimulating its recruitment to the 
DNA lesion but DOT1L is not involved in transcriptional regulation of the DNA repair genes.7 
Therefore, in human melanoma DOT1L seems to behave as a tumor suppressor gene. In 
mESCs carrying a catalytically inactive G165R mutant we also observed a protective role of 
DOT1L against UV radiation. 
In our study, the R409H variant in DOT1L gene, which protects melanocytes from the UV-
induced transition to melanoma, was identified upon WES of two members of a family with a 
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family history of melanoma. The R409H was confirmed in other two affected family members, 
therefore co-segregating with melanoma in all four first-degree melanoma-affected family 
members. Then, we functionally explored this variant but we could neither detect histone 
methyltransferase activity reduction in melanoma and mESCs nor an effect on UV-induced 
survival in mESCs. However, it is possible that dynamic changes in or alternative functions 
of H3K79me were missed in the assays used or that the role of R409 in melanocytes is 
not recapitulated in the cell model used here. Accordingly, two previously reported DOT1L 
variants (V135A and F243A) hardly showed a decrease of the DOT1L methyltransferase 
activity.27 R409 is located in a part of the DOT1L protein that is enriched for positively charged 
residues.28 This region contains a nuclear localization signal29 and is part of a C-terminal 
extension of the catalytic core of DOT1L that is required for nucleosome binding and DOT1L 
activity 28. Furthermore, lysine 410, adjacent to R409, was identified as a site that can be 
methylated by SUV39H1, suggesting that the function of this part of DOT1L may be subject 
to post-translational modifications. SUV39H1 targets RK sites30 and the R409H mutation 
disrupts this RK motif. However, very little is known about the interactions between the DOT1L 
C-terminal extension and the nucleosome. Recent efforts to elucidate the mechanisms of 
these interactions by determining the structure of DOT1L bound to nucleosomes have 
not yet revealed the molecular details.31-33 It has been reported that DOT1L only binds the 
ubiquinated nucleosome, which is dependent on H2BK120 monoubiquitination and H2A-
H2B acidic path, that subsequently enhances the catalytic function of the methyltransferase 
DOT1L.27 However, the lack of unequivocal structural information is most likely caused by 
the dynamic nature of the interactions between the DOT1L C-terminal extension of the 
catalytic core and the nucleosome. It could also be possible that the R409H mutation 
affects a methyltransferase-independent function of DOT1L. For example, budding yeast 
DOT1L functions as a transcription de-repressor, a histone chaperone and enhances H2B 
ubiquitination all independent of its methyltransferase activity.34-36 However, in mammalian 
cells this activity of DOT1L has been shown to be required for several critical functions, 
including reactivation of repressed genes upon targeting, cycle progression in lung cancer 
cell lines, and leukaemic transformation in CALM-AF10 MLL-rearranged leukemia.37-39 Taken 
together, methyltransferase-independent functions of DOT1L have been reported, but not 
in mammalian cells. Despite a lack of evidence for a direct functional effect of the R409H 
variant, several variants in DOT1L have been observed in independent familial and sporadic 
melanoma cases. Therefore, our finding reinforces the ones by Zhu et al.7 and we consider 
that is worthwhile to investigate the DOT1L variants in future WES and WGS studies involving 
large familial melanoma cohorts, albeit that further functional and structural analyses are 
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SUPPLEMENTARY TABLE S1. Table reporting the oligonucleotides used to encode the gRNAs for 
CRISPR/Cas9 in the generation of mESC lines. 
Oligonucleotide Sense Antisense
R409H guide 1 CACCGCTTGGGCCGCCCACGTTTC AAACGAAACGTGGGCGGCCCAAGC
R409H guide 2 CACCGGATGGCTGGCCGGAAACGT AAACACGTTTCCGGCCAGCCATCC
R409H guide 3 CACCGAGATGGCTGGCCGGAAACG AAACCGTTTCCGGCCAGCCATCTC
R409H guide 4 CACCGGGCTGGCCGGAAACGTGGG AAACCCCACGTTTCCGGCCAGCCC
G165R guide 1 CACCGTGTTTGTCGACCTGGGCAG AAACCTGCCCAGGTCGACAAACAC
G165R guide 2 CACCGTGGTGAGTGTCTTGCAGCA AAACTGCTGCAAGACACTCACCAC
SUPPLEMENTARY TABLE S2. Table with the single strand homology directed repair (HDR) templates 
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SUPPLEMENTARY FIGURE S1. Sanger Sequencing validation of the 10 germline variants found by 




SUPPLEMENTARY FIGURE S2. Co-segregation of the variants c.C1789G in SLCO4C1 gene and 
c.G1226A in DOT1L gene with melanoma in all 4 affected family members.  
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SUPPLEMENTARY FIGURE S3. Immunohistochemistry to evaluate the histone methyltransferase 
activity using an anti-H3K79me2 antibody (1:8000 dilution), that works cross-species. (a) Primary 
melanoma biopsy from family member II.1; (b) Brain metastasis from family member III.2; (c) Negative 
control – thymus tissue from a conditional DOT1L-knockout mouse; (d) Positive control – wild-type 
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Heritable epigenetic alterations have been proposed as an explanation for familial clustering 
of melanoma. Here we performed genome-wide DNA methylation analysis on affected 
family members not carrying pathogenic variants in established melanoma susceptibility 
genes, comparing with healthy volunteers. 
RESULTS
All melanoma susceptibility genes showed absence of epimutations in familial melanoma 
patients, and no loss of imprinting was detected. Unbiased genome-wide DNA methylation 
analysis revealed significantly different levels of methylation in single CpG sites. The 
methylation level differences were small and did not affect reported tumour predisposition 
genes. 
CONCLUSION
Our results provide no support for heritable epimutations as a cause of familial melanoma.
KEYWORDS 





Cutaneous melanoma is an aggressive form of skin cancer with a propensity to metastasize, 
causing significant mortality and health care expenditure. Approximately 10% of patients 
diagnosed with melanoma have a positive family history for this malignancy. In familial 
or hereditary melanoma, multiple melanoma cases aggregate in several generations of 
a family, consistent with an autosomal dominant inheritance pattern. A subset of familial 
melanoma cases is caused by germline mutations in the established high penetrance 
melanoma predisposition genes CDKN2A or CDK4. Recently, pathogenic variants in the 
BAP1, TERT, POT1, TERF2IP, ACD and MITF genes have been identified as a cause of familial 
melanoma. Several candidate melanoma susceptibility genes including POLE, GOLM1 and 
EBF3, have been reported.1-3 However, in more than half of affected families the cause of 
melanoma predisposition remains to be resolved despite much research effort. For this 
reason the attention has turned to different mechanisms of inheritance including heritable 
epigenetic alterations. Clarifying the genetic basis of familial melanoma is clinically relevant 
as it would allow for genetic testing, risk estimation and targeted clinical surveillance of 
patients at high risk of melanoma. 
Epimutations have been defined as a heritable changes in gene activity due to DNA 
modifications, not encompassing changes in the DNA sequence itself.4 It has been postulated 
to constitute an alternative mechanism to genetic mutation for cancer predisposition and 
commonly refers to constitutional promoter CpG island hypermethylation in all somatic 
cells of an individual.5 The best-described example in cancer is hereditary nonpolyposis 
colorectal cancer (HNPCC, Lynch syndrome) where cases not affected by inactivating 
mutations in DNA mismatch repair genes were found to be caused by heritable promoter 
hypermethylation of the MLH1 gene.6-8 Epimutations have been classified as primary, 
occurring in the absence of an underlying DNA sequence alteration, and secondary, when 
a genetic mutation triggers the occurrence of an epigenetic modification.9 Secondary 
epimutations in the MSH2 and DAPK1 gene have been identified in HNPCC and familial 
chronic lymphocytic leukemia, respectively.10-12
Genomic imprinting causes certain genes to be silenced by DNA and histone methylation in 
a parent of origin-specific manner, ensuring proper expression during development. Loss of 
imprinting is a distinct epigenetic mechanism of disease, associated with deregulated gene 
expression that can be implicated in cancer development.13 The association between loss-
of-imprinting at the IGF2–H19 locus at chromosome 11p15.5 and predisposition to Wilms 
tumour is an example of this epigenetic mechanism.14
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In familial melanoma we and others have shown absence of epimutation of the CDKN2A 
gene, the major high penetrance melanoma susceptibility gene.15,16 A previous study 
analysed methylation of 14 cancer-related genes in blood DNA from melanoma-prone 
family members. This analysis revealed no constitutional promoter hypermethylation, but 
reduced methylation of the TNFRSF10C promoter.17
In this study we aim to identify heritable epigenetic alterations that might account for familial 
clustering of melanoma in families where no genetic variants in established or candidate 
melanoma susceptibility genes were found. To this end a genome-wide methylation analysis 
of peripheral blood DNA from patients with familial melanoma was performed. We assessed 
promoter hypermethylation of recently identified melanoma susceptibility genes, loss of 
imprinting and performed an unbiased analysis of hypermethylated CpG sites and regions. 
RESULTS AND DISCUSSION 
Patients from 5 Dutch families with at least 3 melanoma cases in different generations 
were selected for this study (Table 1, pedigrees in Supplementary Figure S1). The presence 
of pathogenic gene variants in all currently established and candidate high penetrance 
melanoma susceptibility genes was assessed in all included cases using whole genome 
sequencing. No germline mutations were found in these genes. To examine DNA 
methylation, DNA from peripheral blood of 2 affected members of each family (n=10) was 
subjected to 450K Illumina arrays interrogating over 450,000 CpG sites (namely 483891 
probes after quality control) covering 99% of human genes following bisulfite conversion.18 
For comparative analysis we could make use of DNA methylation data obtained from 
peripheral blood samples of a reference group of 1000 healthy Dutch individuals included 
in the Biobank-based Integrative Omics Studies (BIOS) consortium analysed using similar 
450K arrays (raw data available from the European Genome-phenome Archive (EGA) under 
accession EGAS00001001077). All samples were compared individually to the reference 
group, while taking multiple testing into account using Bonferroni correction. 
First, we analysed the presence of promoter hypermethylation in the CDKN2A, CDK4, 
BAP1, TERT, POT1, TERF2IP, ACD, MBD4, POLH, MITF, MC1R, POLE, EBF3 and GOLM1 
melanoma susceptibility genes. All CpG sites designated by a probe located across the 
entire sequence of these melanoma susceptibility genes in the familial melanoma samples 
were compared with reference samples. No significant difference (≥ β-value average ± 5.65 
SD) in methylation level, hypermethylation nor hypomethylation was found at any of these 




TABLE 1. Clinical characteristics of patients/families involved in the genome-wide analysis.
Family
Number of CMM 
affected members Patient number
Degree of 
kinship
Age at melanoma 
diagnosis



























*multiple primary melanomas diagnosed.
The methylation status of imprinted genes in familial melanoma patients was then 
investigated. We checked all CpG sites in the entire gene sequence of all imprinted genes 
in humans (http://www.geneimprint.com/site/genes-by-species, accessed August 2019) 
interrogated by the arrays. The methylation levels of 4790 interrogated CpG sites located 
at these imprinted gene loci did not differ significantly (≥ β-value average ± 5.65 SD) from 
the BIOS reference samples (Supplementary Figure S2). Since the regulation of imprinted 
genes is largely dependent on methylation levels, and there is no significant difference in 
any of the familial melanoma patients compared to BIOS, we conclude that there was no 
indication of loss of imprinting. 
Following on analysis of candidate genes we performed an agnostic genome-wide analysis 
by comparing DNA methylation of all interrogated CpG sites in the familial melanoma patients 
with those in healthy subjects. We considered as potential epimutations CpG sites located in 
gene promoters (using probes assigned to promoter regions according to annotation provided 
by Illumina) with significantly aberrant methylation levels in both members of an affected family 
compared to BIOS control samples. Since all reported cancer predisposing epimutations 
were cases of constitutional promoter hypermethylation, we focused our analysis on this type 
of epigenetic event. All CpGs in promoters were assessed. Probes interrogating CpG sites 
lost due to single nucleotide variants, as identified using whole genome sequence data, were 
not included in the analysis of the affected samples. We identified 6 single CpGs in gene 
promoters with significantly higher β-values in both affected members of a melanoma family 
compared to healthy controls (Figure 2, Table 2, Supplementary Table S1). In healthy controls 
these CpG sites showed low average β-values consistent with absence of methylation. The 
CpG sites in the RABGGTB, SND1, SCAF11, ZNF638, THAP1 and SFSWAP genes showed 
significantly higher Δβ-values in both members of multiple families. 
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FIGURE 1. Methylation levels (β-value) across the entire sequence of all established melanoma 
predisposition genes. In the upper part of each plot, the gene structure is represented in dark red 
and promoter region (“Promoter_associated” feature retrieved from Illumina annotation) in blue. The 
light grey arrow represents the transcription direction of the gene. For each CpG, the BIOS values are 
represented by the black vertical line with upper (average + 1 SD) and lower limits (average – 1SD). The 
families are represented as a X of different colours (Family I – green, Family II – blue, Family III – yellow, 
Family IV – light purple, Family V – dark blue). To be considered as significantly different from the BIOS, 
the families symbols must go beyond the small black horizontal line (average ± 5.65 SD). Genes with 








Family I Family II Family III Family IV Family V
I_1 I_2 II_1 II_2 III_1 III_2 IV_1 IV_2 V_1 V_2
CpG ID Gene ID β-valuea Δβ-valueb
cg21812670 RABGGTB 0.06 0.30 0.38 0.34 0.30 0.36 0.26 0.39 0.32 0.39 0.30
cg26642667 SND1 0.06 0.25 0.30 0.33 0.22 0.35 0.16 0.37 0.29 0.34 0.27
cg04385631 SCAF11  0.02 0.14 0.00 0.00 0.22 0.00 0.22 0.23 0.00 0.22 0.28
cg21843755 ZNF638 0.11 0.16 0.21 0.18 0.07 0.20 0.10 0.21 0.16 0.23 0.21
cg03301282 THAP1 0.08 0.26 0.23 0.20 0.27 0.25 0.12 0.29 0.27 0.30 0.24
cg02470959 SFSWAP  0.05 0.18 0.20 0.18 0.16 0.19 0.17 0.21 0.21 0.20 0.17
a Represents the average β-value for the 1000 BIOS controls at each CpG site. 
b Represents the difference between BIOS average β-value and patient β-value at each CpG site
FIGURE 2. Methylation levels (β-value) in all 6 significant upregulated CpGs located in the promoter 
regions of the genes. In the upper part of each plot, the gene structure is represented in dark red 
and promoter region (“Promoter_associated” feature retrieved from Illumina annotation) in blue. The 
light grey arrow represents the transcription direction of the gene. For each CpG, the BIOS values are 
represented by the black vertical line with upper (average + 1 SD) and lower limits (average – 1SD). The 
families are represented as a X of different colours (Family I – green, Family II – blue, Family III – yellow, 
Family IV – light purple, Family V – dark blue). To be considered as significantly different from the BIOS, 
the families symbols must go beyond the small black horizontal line (average ± 5.65 SD). Genes with 
more than 10 CpG sites assessed by 450K array, were represented by 10 randomly selected CpGs. 
The upregulated CpG in each plot is aligned with a vertical light grey line and, in this case, the little 
horizontal lines become red since the families’ symbols exceeded these limits. 
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We assessed the methylation of contiguous interrogated CpG sites and for all 6 cases the 
hypermethylation was observed exclusively in the single identified CpG site, with neighbouring 
CpGs not showing significantly higher methylation levels. None of these genes have been 
reported as cancer predisposition genes by Rahman et al.19 Only one of the CpGs is located in 
a cancer-related gene, SND1, according to Cancer Gene Census (http://cancer.sanger.ac.uk/
census, accessed August 2019). This gene has no reported role in melanoma and functions as 
a gene fusion partner in certain malignancies. Given the established genetic heterogeneity, 
it is unlikely that the same epimutation would cause melanoma susceptibility in all 5 families. 
Together with the information about the function of the genes (Supplementary Table S1), we 
conclude that the identified hypermethylated CpG sites in these families do not appear to 
constitute plausible pathogenic high penetrance epimutation events. 
Additionally we evaluated CpG sites with significantly lower methylation levels in familial 
melanoma than in healthy control samples and found 35 hypomethylated CpGs in both 
members of a family. Fifteen CpG sites showed hypomethylation in all 5 families, suggestive 
of a batch effect as has been described for 450k methylation arrays (Supplementary Table 
S2).20 Of the 35 hypomethylated CpG sites only 2 were located in established cancer-related 
genes: BRCA1, an established breast and ovarian cancer susceptibility gene, and ROS1, 
encoding a receptor tyrosine kinase with a possible oncogenic role in melanoma.21 For 
both genes a single CpG site in the promoter demonstrated significantly lower methylation 
levels, with normal methylation of neighbouring CpG sites assessed by 450K array. For 
BRCA1 and for ROS1, the CpG site was not part of a predicted transcription factor binding 
motif.22 Hypomethylation of the BRCA1 gene promoter has never been associated with 
transcriptional downregulation and therefore reduced methylation of this single CpG site 
in the BRCA1 gene promoter is unlikely to have pathogenic significance. Expression of the 
ROS1 oncogene is not known to be regulated by promoter methylation, but high expression 
has been associated with histone modifications and EZH2 repression.23 β-values for the 
single CpG site in the distal promoter of the ROS1 gene were 0.87 in control samples and 
approximately 0.65 in familial melanoma DNA samples. We consider it possible, but unlikely 
that lower methylation levels of the single CpG site in the distal promoter ROS1 would 
cause familial melanoma. Similar to the finding of TNFRSF10C hypomethylation in familial 
melanoma patients from the US, that we could not detect in our patients, this finding might 
be analysed in a large number of melanoma families.17 
Since regions containing multiple CpG sites in promoters commonly work as units of 
transcriptional regulation we additionally tried to identify differentially methylated regions. 
For this we evaluated the average of all probes assigned to promoters for each gene 




array contains 13,715 genes with CpG probes assigned to promoters. The promoter of one 
gene (CCNI) showed significant higher methylation levels in 4 families, while promoters of 
the CD47 and USP46 genes had slightly higher methylation levels in 1 family each. Although 
statistically significant the averaged promoter methylation level (β-value) differences were 
minor, which does not support a relevant effect. 
In this study we analysed the possible occurrence of epimutations and loss of imprinting in 
familial melanoma using a genome-wide approach. A strength of the study is the selection 
of DNA samples from families with many affected members in multiple generations where 
no genetic cause could be identified and the availability of methylation data from a 
large cohort of 1000 Dutch healthy individuals for comparative analysis. There are some 
limitations to this study; the number of analysed families is small and our results do not 
exclude the possibility that pathogenic epimutations might occur in a small proportion of 
melanoma families. Secondly, the 450K arrays interrogate CpG sites in almost all gene 
promoters, but do not cover all potentially regulatory sequences. In addition, we analysed 
blood DNA for the occurrence of epimutations, but certain epimutations might occur only 
in specific cell types in a mosaic state. In these patients with familial melanoma we have 
not identified promoter hypermethylation of any melanoma predisposition gene, cancer 
predisposition gene or tumour suppressor gene. We have been able to determine several 
DNA methylation events that are candidate epimutations, methylation events shared by 
multiple members of a family that were not identified in healthy volunteers. However, it 
is not clear if the observed methylation alterations in these single CpG sites impact on 
expression of the respective genes. Based on the function of the genes and the fact that 
we did not identify a differentially methylated region, but only a single CpG site, we consider 
it is not plausible that any of the DNA methylation alterations that were detected constitute 
the cause of melanoma predisposition in these families. Moreover, given the established 
genetic heterogeneity, it is unlikely that the same epimutation would cause melanoma 
susceptibility in all 5 families. Therefore we consider the observed CpG sites with higher 
and lower detected methylation levels to represent rare variations with no pathogenic 
significance or possibly the result of batch array effects. Summarizing, our results of 
genome-wide analysis provide little or no support for a role of heritable DNA methylation 
alterations as a cause of familial melanoma.   
MATERIALS & METHODS 
We selected 5 unrelated Dutch families with 3 or more melanoma cases in multiple 
generations and tested negative for germline mutations in the established high penetrance 
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melanoma susceptibility genes CDKN2A, CDK4, BAP1, TERT, POT1, TERF2IP, ACD and 
MITF by next generation sequencing (Figure 1). Some patients had developed multiple 
melanomas. The majority of the melanomas was of the superficial spreading or nodular 
subtypes. The study was approved by the Leiden University Medical Center institutional 
ethical committee and was conducted according to the Declaration of Helsinki Principles. 
DNA from 2 affected members from 5 families was isolated from whole blood samples. 
DNA was bisulfite-converted using the EZ DNA methylation kit (Zymo Research, D5001) and 
hybridized to Illumina 450K arrays (Illumina). The reference group encompassed 1000 whole 
blood DNA samples of healthy individuals included in the Biobank-based Integrative Omics 
Studies (BIOS) Consortium analysed with Illumina 450K arrays under similar conditions.24 
The median age of patients during blood sampling was 54 years and for the 1000 healthy 
controls it was 55 years. Sample quality control was performed using MethylAid25, probes 
with a high detection P value (>0.01), probes with a low bead count (<3 beads), and probes 
with a low success rate (missing in >95% of the samples) were set to missing. Subsequently 
imputation26 was performed to impute the missing values. Functional normalization, as 
implemented in the minfi package, was used on a random subset of 1000 samples together 
with the melanoma samples.27 Detailed description of the 450K DNA methylation pre-
processing steps are available from the https://molepi.github.io/DNAmArray_workflow/. 
Sample specific aberrant melanoma CpGs were detected using a t-test for comparing a 
single melanoma case to the 1000 BIOS controls.28 In order to control for the number of 
tests a very stringent cut-off, 1.03x10-9(0.01/(number of probes on array*2)), was used. After 
the bioinformatic analysis a set of 13 hypermethylated CpGs and 164 hypomethylated CpG 
sites was obtained. The list of significant CpGs was further reduced by only considering 
significant co-segregating CpGs with an absolute β-value difference of 0.2 when compared 
to BIOS controls (Δβ-value ≥0.2 in 2 members of at least one family). To be considered as a 
putative epimutation a CpG should meet the following criteria. CpG probes on chromosome 
X were excluded (as they reflect X-chromosome inactivation in females). Only CpGs in 
promoter regions (retrieved from Illumina annotation for gene promoters, “promoter_
associated in regulatory_feature_group field”) of the genes were selected. Both members 
of a family were required to harbor the hypo/hypermethylation, since we are looking at high 
penetrance epigenetic events. A single nucleotide variant (SNV) must be within a window 
of 100 bp around the CpG (that can either influence/impair the probe binding or reveal 
the presence of a genetic variant around the epigenetically altered CpG, that in this case 
would be the so called “second epimutation”). The SNV data were retrieved from dbSNP 
Release 153. This resulted in 6 hypermethylated CpGs and 35 hypomethylated CpGs, which 
were compared with lists of cancer-related genes according to Cancer Gene Census (http://
cancer.sanger.ac.uk/census, accessed August 2019) and cancer predisposition genes 




part of predicted transcription factor binding motifs using the TFBIND tool.22 We also aimed 
at identifying differentially methylated regions. For that we assessed the probes assigned 
for promoter regions according to the annotation of 450K  array. There were 13,715 genes 
with probes assigned to promoters. On average each of these promoters contained 6.7 
probes. We averaged all the probes assigned for each gene promoter and compared with 
the average of the same promoter in BIOS controls. 
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SUPPLEMENTARY MATERIAL 
SUPPLEMENTARY TABLE S1. Methylation levels (β-value) and cancer genes information of all 6 
significant upregulated CpGs in all subjects (n=10). 











genes?cPosition CpG ID Gene ID Location 
I_1 I_2 II_1 II_2 III_1 III_2 IV_1 IV_2 V_1 V_2
β-value SD β-value β-value
chr1: 76251636 cg21812670 RABGGTB Promoter No 0.06 0.02 0.36 0.44 0.40 0.36 0.42 0.32 0.45 0.38 0.45 0.37
Beta-subunit of the enzyme 
that catalyzes the transfer of a 
geranylgeranyl groups to cysteine 
residues of Rab proteins.
NA NA
chr7: 127292389 cg26642667 SND1 5’UTR Yes 0.06 0.04 0.31 0.37 0.39 0.29 0.41 0.22 0.44 0.35 0.40 0.33
Transcriptional activator involved with 







chr12: 46385625 cg04385631 SCAF11  Promoter Yes 0.02 0.03 0.15 0.02 0.02 0.24 0.02 0.24 0.25 0.02 0.24 0.30 Splicing regulatory protein. It regulates the spliceosome assembly. NA NA
chr2: 71558577 cg21843755 ZNF638 Promoter No 0.11 0.02 0.26 0.32 0.29 0.17 0.31 0.21 0.32 0.27 0.34 0.32
Nucleoplasmic protein associated with 
packaging, transferring, or processing 
transcripts.
NA NA
chr8: 42698936 cg03301282 THAP1 Promoter No 0.08 0.03 0.34 0.31 0.28 0.35 0.33 0.19 0.37 0.34 0.38 0.32 DNA-binding transcription regulator and proapoptotic factor. NA NA
chr12: 132196036 cg02470959 SFSWAP  Promoter Yes 0.05 0.01 0.23 0.25 0.23 0.22 0.24 0.23 0.26 0.26 0.25 0.23
Splicing regulatory protein. It regulates 
the splicing of fibronectin and CD45 
genes. 
NA NA
a Data retrieved from GeneCard (https://www.genecards.org/)     
b Data retrieved from cancer predisposition genes reported by Rahman et al.19   
c Data retrieved from Cancer Gene Census - COSMIC (https://cancer.sanger.ac.uk/census)       
SUPPLEMENTARY TABLE S2. Methylation levels (β-value) and cancer genes information of all 35 
significant downregulated CpGs in all subjects (n=10).
         
BIOS controls




genesbPosition CpG ID Gene ID Location 
In CpG 
island?
I_1 I_2 II_1 II_2 III_1 III_2 IV_1 IV_2 V_1 V_2
β-value SD β-value β-value
chr1: 28416532 cg24509398 EYA3 proximal promoter No 0.86 0.05 0.52 0.45 0.49 0.46 0.42 0.50 0.44 0.48 0.42 0.47 NA NA
chr1: 43752185 cg19086488 C1orf210 proximal promoter No 0.83 0.03 0.65 0.63 0.64 0.65 0.62 0.68 0.60 0.63 0.62 0.67 NA NA
chr2: 237412985 cg21740507 IQCA1 distal promoter No 0.85 0.03 0.56 0.53 0.56 0.60 0.50 0.64 0.48 0.57 0.56 0.66 NA NA
chr2: 39003850 cg25348336 GEMIN6 distal promoter No 0.86 0.04 0.44 0.63 0.60 0.63 0.57 0.57 0.62 0.61 0.56 0.59 NA NA
chr2: 230933934 cg25621735 SLC16A14 proximal promoter No 0.87 0.03 0.62 0.59 0.62 0.65 0.62 0.69 0.58 0.62 0.57 0.64 NA NA
chr3: 155860278 cg25924827 KCNAB1 proximal promoter No 0.86 0.04 0.62 0.61 0.58 0.64 0.56 0.64 0.59 0.62 0.67 0.69 NA NA
chr4: 39186234 cg16401578 WDR19 distal promoter No 0.86 0.04 0.61 0.63 0.56 0.64 0.63 0.69 0.67 0.64 0.63 0.62 NA NA
chr5: 39220260 cg18740872 FYB proximal promoter No 0.81 0.05 0.51 0.49 0.45 0.54 0.47 0.57 0.47 0.50 0.46 0.49 NA NA
chr5: 36149258 cg25013978 LMBRD2 distal promoter No 0.88 0.04 0.60 0.52 0.52 0.60 0.56 0.63 0.49 0.61 0.50 0.59 NA NA
chr6: 137366545 cg08823985 IL20RA proximal promoter No 0.79 0.07 0.37 0.36 0.34 0.39 0.33 0.37 0.32 0.36 0.32 0.39 NA NA
chr6: 167704188 cg08904369 UNC93A proximal promoter No 0.85 0.03 0.62 0.62 0.56 0.61 0.57 0.69 0.60 0.63 0.59 0.61 NA NA
chr6: 117748486 cg12631085 ROS1 distal promoter No 0.87 0.03 0.63 0.62 0.64 0.67 0.57 0.75 0.61 0.70 0.64 0.66 NA oncogene fusion partner in multiple cancers
chr6: 32785740 cg19811863 HLA-DOB proximal promoter No 0.88 0.03 0.60 0.54 0.56 0.62 0.58 0.69 0.55 0.59 0.57 0.66 NA NA
chr7: 93534693 cg07547788 GNGT1 proximal promoter No 0.84 0.03 0.63 0.61 0.68 0.71 0.63 0.77 0.60 0.65 0.68 0.72 NA NA





SUPPLEMENTARY TABLE S1. Methylation levels (β-value) and cancer genes information of all 6 
significant upregulated CpGs in all subjects (n=10). 











genes?cPosition CpG ID Gene ID Location 
I_1 I_2 II_1 II_2 III_1 III_2 IV_1 IV_2 V_1 V_2
β-value SD β-value β-value
chr1: 76251636 cg21812670 RABGGTB Promoter No 0.06 0.02 0.36 0.44 0.40 0.36 0.42 0.32 0.45 0.38 0.45 0.37
Beta-subunit of the enzyme 
that catalyzes the transfer of a 
geranylgeranyl groups to cysteine 
residues of Rab proteins.
NA NA
chr7: 127292389 cg26642667 SND1 5’UTR Yes 0.06 0.04 0.31 0.37 0.39 0.29 0.41 0.22 0.44 0.35 0.40 0.33
Transcriptional activator involved with 







chr12: 46385625 cg04385631 SCAF11  Promoter Yes 0.02 0.03 0.15 0.02 0.02 0.24 0.02 0.24 0.25 0.02 0.24 0.30 Splicing regulatory protein. It regulates the spliceosome assembly. NA NA
chr2: 71558577 cg21843755 ZNF638 Promoter No 0.11 0.02 0.26 0.32 0.29 0.17 0.31 0.21 0.32 0.27 0.34 0.32
Nucleoplasmic protein associated with 
packaging, transferring, or processing 
transcripts.
NA NA
chr8: 42698936 cg03301282 THAP1 Promoter No 0.08 0.03 0.34 0.31 0.28 0.35 0.33 0.19 0.37 0.34 0.38 0.32 DNA-binding transcription regulator and proapoptotic factor. NA NA
chr12: 132196036 cg02470959 SFSWAP  Promoter Yes 0.05 0.01 0.23 0.25 0.23 0.22 0.24 0.23 0.26 0.26 0.25 0.23
Splicing regulatory protein. It regulates 
the splicing of fibronectin and CD45 
genes. 
NA NA
a Data retrieved from GeneCard (https://www.genecards.org/)     
b Data retrieved from cancer predisposition genes reported by Rahman et al.19   
c Data retrieved from Cancer Gene Census - COSMIC (https://cancer.sanger.ac.uk/census)       
SUPPLEMENTARY TABLE S2. Methylation levels (β-value) and cancer genes information of all 35 
significant downregulated CpGs in all subjects (n=10).
         
BIOS controls




genesbPosition CpG ID Gene ID Location 
In CpG 
island?
I_1 I_2 II_1 II_2 III_1 III_2 IV_1 IV_2 V_1 V_2
β-value SD β-value β-value
chr1: 28416532 cg24509398 EYA3 proximal promoter No 0.86 0.05 0.52 0.45 0.49 0.46 0.42 0.50 0.44 0.48 0.42 0.47 NA NA
chr1: 43752185 cg19086488 C1orf210 proximal promoter No 0.83 0.03 0.65 0.63 0.64 0.65 0.62 0.68 0.60 0.63 0.62 0.67 NA NA
chr2: 237412985 cg21740507 IQCA1 distal promoter No 0.85 0.03 0.56 0.53 0.56 0.60 0.50 0.64 0.48 0.57 0.56 0.66 NA NA
chr2: 39003850 cg25348336 GEMIN6 distal promoter No 0.86 0.04 0.44 0.63 0.60 0.63 0.57 0.57 0.62 0.61 0.56 0.59 NA NA
chr2: 230933934 cg25621735 SLC16A14 proximal promoter No 0.87 0.03 0.62 0.59 0.62 0.65 0.62 0.69 0.58 0.62 0.57 0.64 NA NA
chr3: 155860278 cg25924827 KCNAB1 proximal promoter No 0.86 0.04 0.62 0.61 0.58 0.64 0.56 0.64 0.59 0.62 0.67 0.69 NA NA
chr4: 39186234 cg16401578 WDR19 distal promoter No 0.86 0.04 0.61 0.63 0.56 0.64 0.63 0.69 0.67 0.64 0.63 0.62 NA NA
chr5: 39220260 cg18740872 FYB proximal promoter No 0.81 0.05 0.51 0.49 0.45 0.54 0.47 0.57 0.47 0.50 0.46 0.49 NA NA
chr5: 36149258 cg25013978 LMBRD2 distal promoter No 0.88 0.04 0.60 0.52 0.52 0.60 0.56 0.63 0.49 0.61 0.50 0.59 NA NA
chr6: 137366545 cg08823985 IL20RA proximal promoter No 0.79 0.07 0.37 0.36 0.34 0.39 0.33 0.37 0.32 0.36 0.32 0.39 NA NA
chr6: 167704188 cg08904369 UNC93A proximal promoter No 0.85 0.03 0.62 0.62 0.56 0.61 0.57 0.69 0.60 0.63 0.59 0.61 NA NA
chr6: 117748486 cg12631085 ROS1 distal promoter No 0.87 0.03 0.63 0.62 0.64 0.67 0.57 0.75 0.61 0.70 0.64 0.66 NA oncogene fusion partner in multiple cancers
chr6: 32785740 cg19811863 HLA-DOB proximal promoter No 0.88 0.03 0.60 0.54 0.56 0.62 0.58 0.69 0.55 0.59 0.57 0.66 NA NA
chr7: 93534693 cg07547788 GNGT1 proximal promoter No 0.84 0.03 0.63 0.61 0.68 0.71 0.63 0.77 0.60 0.65 0.68 0.72 NA NA
chr7: 123294503 cg15313859 LMOD2 distal promoter No 0.77 0.07 0.32 0.30 0.35 0.33 0.28 0.35 0.28 0.28 0.26 0.32 NA NA
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SUPPLEMENTARY TABLE S2 CONTINUED.
         
BIOS controls




genesbPosition CpG ID Gene ID Location 
In CpG 
island?
I_1 I_2 II_1 II_2 III_1 III_2 IV_1 IV_2 V_1 V_2
β-value SD β-value β-value
chr7: 123564016 cg24641201 SPAM1 distal promoter No 0.87 0.02 0.65 0.63 0.66 0.75 0.63 0.73 0.63 0.65 0.68 0.69 NA NA
chr10: 123748615 cg22562363 TACC2 proximal promoter No 0.87 0.04 0.61 0.60 0.59 0.65 0.59 0.68 0.61 0.61 0.60 0.66 NA NA
chr11: 47585888 cg00214780 PTPMT1 proximal promoter No 0.83 0.03 0.59 0.59 0.59 0.61 0.58 0.70 0.56 0.60 0.57 0.64 NA NA
chr11: 119054921 cg00395990 PDZD3 proximal promoter No 0.91 0.02 0.64 0.58 0.57 0.70 0.56 0.69 0.56 0.63 0.60 0.69 NA NA
chr11: 57436966 cg13582500 ZDHHC5 distal promoter No 0.83 0.04 0.59 0.54 0.52 0.55 0.54 0.55 0.52 0.55 0.51 0.55 NA NA
chr11: 125649040 cg15229773 PATE2 proximal promoter No 0.88 0.03 0.59 0.57 0.62 0.66 0.56 0.67 0.58 0.56 0.59 0.62 NA NA
chr12: 117348108 cg26332016 FBXW8 proximal promoter No 0.90 0.02 0.63 0.62 0.64 0.67 0.60 0.71 0.67 0.69 0.62 0.73 NA NA
chr13: 39564046 cg05380910 STOML3 distal promoter No 0.89 0.03 0.77 0.81 0.76 0.74 0.78 0.81 0.78 0.83 0.68 0.68 NA NA
chr14: 20710881 cg24137472 OR11H4 proximal promoter No 0.91 0.03 0.91 0.91 0.92 0.89 0.90 0.93 0.89 0.92 0.52 0.64 NA NA
chr15: 42750798 cg09240555 ZNF106 proximal promoter No 0.84 0.04 0.63 0.64 0.60 0.62 0.64 0.71 0.64 0.64 0.64 0.64 NA NA
chr15: 54052305 cg13131111 WDR72 proximal promoter No 0.82 0.04 0.58 0.51 0.54 0.62 0.51 0.64 0.49 0.56 0.55 0.53 NA NA
chr16: 31270808 cg09736526 ITGAM proximal promoter No 0.83 0.03 0.62 0.60 0.61 0.63 0.60 0.69 0.61 0.65 0.60 0.67 NA NA
chr17: 41278712 cg20185525 BRCA1 proximal promoter No 0.86 0.04 0.57 0.56 0.56 0.57 0.54 0.60 0.59 0.57 0.54 0.60 breast and ovarian cancer
tumour suppressor gene 
in breast and ovarian 
cancer
chr19: 9360855 cg11396122 OR7E24 proximal promoter No 0.85 0.04 0.70 0.64 0.65 0.70 0.58 0.66 0.64 0.62 0.57 0.63 NA NA
chr19: 57678865 cg13472369 DUXA proximal promoter No 0.81 0.05 0.63 0.68 0.57 0.48 0.51 0.63 0.43 0.56 0.45 0.41 NA NA
chr19: 45174671 cg20559736 CEACAM19 proximal promoter No 0.83 0.03 0.54 0.50 0.53 0.59 0.52 0.55 0.51 0.56 0.53 0.62 NA NA
chr19: 12986352 cg21908038 DNASE2 5’UTR No 0.85 0.05 0.52 0.50 0.48 0.56 0.44 0.56 0.46 0.52 0.47 0.53 NA NA
chr20: 33758526 cg23101469 PROCR proximal promoter No 0.83 0.04 0.49 0.51 0.54 0.52 0.48 0.52 0.49 0.48 0.46 0.58 NA NA
chr22: 27016806 cg15559737 CRYBA4 proximal promoter No 0.83 0.03 0.62 0.59 0.60 0.68 0.58 0.70 0.58 0.67 0.58 0.65 NA NA
chr22: 25594918 cg19288514 CRYBB3 proximal promoter No 0.81 0.06 0.42 0.43 0.41 0.39 0.45 0.52 0.40 0.39 0.38 0.46 NA NA
a Data retrieved from cancer predisposition genes reported by Rahman et al. 19
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BIOS controls




genesbPosition CpG ID Gene ID Location 
In CpG 
island?
I_1 I_2 II_1 II_2 III_1 III_2 IV_1 IV_2 V_1 V_2
β-value SD β-value β-value
chr7: 123564016 cg24641201 SPAM1 distal promoter No 0.87 0.02 0.65 0.63 0.66 0.75 0.63 0.73 0.63 0.65 0.68 0.69 NA NA
chr10: 123748615 cg22562363 TACC2 proximal promoter No 0.87 0.04 0.61 0.60 0.59 0.65 0.59 0.68 0.61 0.61 0.60 0.66 NA NA
chr11: 47585888 cg00214780 PTPMT1 proximal promoter No 0.83 0.03 0.59 0.59 0.59 0.61 0.58 0.70 0.56 0.60 0.57 0.64 NA NA
chr11: 119054921 cg00395990 PDZD3 proximal promoter No 0.91 0.02 0.64 0.58 0.57 0.70 0.56 0.69 0.56 0.63 0.60 0.69 NA NA
chr11: 57436966 cg13582500 ZDHHC5 distal promoter No 0.83 0.04 0.59 0.54 0.52 0.55 0.54 0.55 0.52 0.55 0.51 0.55 NA NA
chr11: 125649040 cg15229773 PATE2 proximal promoter No 0.88 0.03 0.59 0.57 0.62 0.66 0.56 0.67 0.58 0.56 0.59 0.62 NA NA
chr12: 117348108 cg26332016 FBXW8 proximal promoter No 0.90 0.02 0.63 0.62 0.64 0.67 0.60 0.71 0.67 0.69 0.62 0.73 NA NA
chr13: 39564046 cg05380910 STOML3 distal promoter No 0.89 0.03 0.77 0.81 0.76 0.74 0.78 0.81 0.78 0.83 0.68 0.68 NA NA
chr14: 20710881 cg24137472 OR11H4 proximal promoter No 0.91 0.03 0.91 0.91 0.92 0.89 0.90 0.93 0.89 0.92 0.52 0.64 NA NA
chr15: 42750798 cg09240555 ZNF106 proximal promoter No 0.84 0.04 0.63 0.64 0.60 0.62 0.64 0.71 0.64 0.64 0.64 0.64 NA NA
chr15: 54052305 cg13131111 WDR72 proximal promoter No 0.82 0.04 0.58 0.51 0.54 0.62 0.51 0.64 0.49 0.56 0.55 0.53 NA NA
chr16: 31270808 cg09736526 ITGAM proximal promoter No 0.83 0.03 0.62 0.60 0.61 0.63 0.60 0.69 0.61 0.65 0.60 0.67 NA NA
chr17: 41278712 cg20185525 BRCA1 proximal promoter No 0.86 0.04 0.57 0.56 0.56 0.57 0.54 0.60 0.59 0.57 0.54 0.60 breast and ovarian cancer
tumour suppressor gene 
in breast and ovarian 
cancer
chr19: 9360855 cg11396122 OR7E24 proximal promoter No 0.85 0.04 0.70 0.64 0.65 0.70 0.58 0.66 0.64 0.62 0.57 0.63 NA NA
chr19: 57678865 cg13472369 DUXA proximal promoter No 0.81 0.05 0.63 0.68 0.57 0.48 0.51 0.63 0.43 0.56 0.45 0.41 NA NA
chr19: 45174671 cg20559736 CEACAM19 proximal promoter No 0.83 0.03 0.54 0.50 0.53 0.59 0.52 0.55 0.51 0.56 0.53 0.62 NA NA
chr19: 12986352 cg21908038 DNASE2 5’UTR No 0.85 0.05 0.52 0.50 0.48 0.56 0.44 0.56 0.46 0.52 0.47 0.53 NA NA
chr20: 33758526 cg23101469 PROCR proximal promoter No 0.83 0.04 0.49 0.51 0.54 0.52 0.48 0.52 0.49 0.48 0.46 0.58 NA NA
chr22: 27016806 cg15559737 CRYBA4 proximal promoter No 0.83 0.03 0.62 0.59 0.60 0.68 0.58 0.70 0.58 0.67 0.58 0.65 NA NA
chr22: 25594918 cg19288514 CRYBB3 proximal promoter No 0.81 0.06 0.42 0.43 0.41 0.39 0.45 0.52 0.40 0.39 0.38 0.46 NA NA
a Data retrieved from cancer predisposition genes reported by Rahman et al. 19
b Data retrieved from Cancer Gene Census - COSMIC (https://cancer.sanger.ac.uk/census)
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A. Family I 
B. Family II 






SUPPLEMENTARY FIGURE S1. Dutch melanoma families included in the whole-genome sequencing 
analysis. Left quarter red panel: cutaneous malignant melanoma (CMM) only; left quarter yellow panel: 
multiple melanoma (patient number I_2 and III_1 included in our study, see Table 1); right quarter blue 
panel: other cancer(s). The melanoma cases subjected to whole-genome sequencing included in this 
study are indicated by ‘WGS’. Age at CMM diagnosis is given between brackets. A. Family I B. Family II 
C. Family III D. Family IV and E. Family V. 
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SUPPLEMENTARY FIGURE S2. Methylation levels (β-value) across the entire sequence of all imprinted 
genes (http://www.geneimprint.com/site/genes-by-species, accessed August 2019) assessed by 450K 
array. In the upper part of each plot, the gene structure is represented in dark red and promoter 
region (“Promoter_associated” feature retrieved from Illumina annotation) in blue. The light grey arrow 
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represents the transcription direction of the gene. For each CpG, the BIOS values are represented by 
the black vertical line with upper (average + 1 SD) and lower limits (average – 1SD). The families are 
represented as a X of different colours (Family I – green, Family II – blue, Family III – yellow, Family IV – 
light purple, Family V – dark blue). To be considered as significantly different from the BIOS, the families 
symbols must go beyond the small black horizontal line (average ± 5.65 SD). Genes with more than 10 










in melanoma reveals major 
differences with nevus
Genes Chromosomes Cancer. 2020 Jun;59(6):366-374.





Melanoma demonstrates altered patterns of DNA methylation that are associated 
with genetic instability and transcriptional repression of numerous genes. Active DNA 
demethylation is mediated by TET enzymes that catalyze conversion of 5-methylcytosine 
(mC) to 5-hydroxymethylcytosine (hmC). Loss of hmC occurs in melanoma and correlates 
with disease progression. Here we analysed the genomic distribution of hmC along with 
mC in nevus and melanoma using oxidative bisulfite chemistry combined with high-density 
arrays. HmC was enriched relative to mC at enhancers, 5’UTR regions and CpG shores in 
nevus and melanoma samples, pointing to specific TET enzyme activity. The proportion of 
interrogated CpG sites with high hmC levels was lower in melanoma (0.54%) than in nevus 
(2.0%). Depletion of hmC in melanoma was evident across all chromosomes and intragenic 
regions, being more pronounced in metastatic than in non-metastatic tumours. The patterns 
of hmC distribution in melanoma samples differed significantly from those in nevus samples, 
exceeding differences in mC patterns. We identified specific CpG sites and regions with 
significantly lower hmC levels in melanoma than in nevus that might serve as diagnostic 
markers. Differentially hydroxymethylated regions localized to cancer-related genes, 
including the PTEN gene promoter, suggesting that deregulated DNA hydroxymethylation 
may contribute to melanoma pathogenesis. 
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Cutaneous melanoma is a malignant tumour derived from melanocytes residing in the skin. 
Clinically melanoma needs to be distinguished from melanocytic nevus, a benign lesion 
composed of melanocytes in a stable growth arrest.1 Integrative genomic and transcriptomic 
analysis has identified common mutations and recurrent signaling perturbations yielding 
insight into melanoma biology.2 In addition to accumulated genetic alterations, epigenetic 
mechanisms drive the development and evolution of melanoma.3,4 DNA methylation, histone 
modifications and chromatin remodeling complexes regulate chromatin accessibility to 
transcription factors, thereby controlling gene expression programs. DNA methylation at CpG 
dinucleotides is mediated by DNA methyltransferases and additionally governed by DNA 
demethylation. Passive DNA demethylation can occur through insufficient methyltransferase 
activity during replication. Active demethylation involves the oxidation of 5-methylcytosine 
(mC) to 5-hydroxymethylcytosine (hmC) performed by the Ten Eleven Translocase (TET) 
family of dioxygenase enzymes.5 In mammalian cells approximately 4% of all cytosines are 
methylated, and depending on cell type 0.1% - 0.7% of cytosine bases are hydroxymethylated.6 
Epigenetic deregulation is a universal characteristic of malignant tumours implicated in 
tumourigenesis. Cancer genomes are characterized by widespread loss of DNA methylation 
that contribute to genomic instability, and gain of DNA methylation at promoter CpG islands is 
associated with transcriptional repression.7 In melanoma, selected tumour suppressor genes 
with a critical role in malignant transformation and metastatic behaviour, including CDKN2A, 
PTEN and CDH11, show frequent promoter hypermethylation and associated transcriptional 
silencing.8 In addition, variation of methylation density at enhancer regions contributes to 
melanoma cell plasticity and correlates with patient survival.9 
Different tumour types demonstrate loss of DNA hydroxymethylation and in certain instances 
this epigenetic event can be attributed to mutations in TET or IDH genes. Although the 
functional relevance of hmC loss remains to be resolved, studies in melanoma suggest its 
involvement in tumour progression.10 Accordingly, low hmC levels were associated with worse 
survival from melanoma. Thus, in melanoma and other tumour types hmC loss might have 
diagnostic as well as prognostic significance. Hydroxymethylation mapping of melanoma 
samples using hydroxymethylated DNA immunoprecipitation showed hmC clusters in gene-
rich regions and loss at specific loci.10 In glioblastoma hmC depletion was shown to be 
most pronounced at enhancer regions.11 To understand the functional consequences of 
aberrant hydroxymethylation and to apply it in the diagnosis and prognosis of melanoma, 
it is essential to obtain precise maps of the distribution of this epigenetic mark. Here we 
characterized the genomic distribution of hmC and mC in nevus and melanoma using 
oxidative bisulfite chemistry combined with arrays that simultaneously interrogate hmC 
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and mC at 850,000 CpG sites. This methodology is not affected by bias associated with 
antibody-based DNA capture methods and provides robust estimates of hmC and mC.12 
We sought to identify differentially hydroxymethylated CpG sites and regions by comparing 
nevus and melanoma hmC patterns. In addition, we compared the hmC patterns between 
primary melanoma samples that differ with respect to metastatic behavior. The genomic 
landscapes of hmC show depletion of hydroxymethylation in melanoma across various 
intragenic and intergenic regions compared to nevus. The hydroxymethylation patterns 
show more differences between nevus and melanoma than the methylation patterns, which 
has potential implications for biomarker discovery. 
MATERIAL & METHODS
PATIENT SAMPLES 
Fresh-frozen biopsy samples were obtained from patients diagnosed with common nevus 
(n=8), non-metastatic primary melanoma (n=8), and metastatic primary melanoma (n=8) 
(Supplementary Table S1). Only tissue samples containing at least 50% nevus or melanoma 
cells were included. Genomic DNA from all samples was extracted using the Genomic-tip 
kit (Qiagen, Hilden, Germany). The study was approved by the Leiden University Medical 
Center institutional ethical committee (05-036) and was conducted according to the 
Declaration of Helsinki Principles.
BISULFITE AND OXIDATIVE BISULFITE CONVERSION AND HYBRIDIZATION
Genomic DNA (1μg) was subjected to BS and OxBS conversion using the TrueMethyl 96 Kit 
(CEGX, Cambridge, UK) and applied to the Infinium MethylationEPIC BeadChip Kit (Illumina, 
San Diego, USA) at GenomeScan (Leiden, The Netherlands). The BeadChip images 
were scanned on the iScan system and the data quality was assessed using the R script 
MethylAid.13 
850K BEADCHIP DATA ANALYSIS
Data were processed using the ChAMP package,14,15 normalized using the default BMIQ 
algorithm and analysed as described previously with genome build GRCh37/hg19.12 The 
ratio of the signal for the cytosine sequence to the combined intensity is the β-value, 
reflecting the methylation level on a scale from 0 (unmethylated) to 1 (fully methylated). To 
obtain the hydroxymethylation fraction oxBS β-values are subtracted from BS beta values, 
generating Δβ-values.12,16 To define CpGs with high hmC we established a cut-off based on 
the average of absolute Δβ-value for all probes (0.008 plus 3 standard deviations, 0.166). To 




test using the Limma R package17 was used with multiple testing corrections applying a 
stringent p-value <0.005.18 The Bump Hunting Algorithm was used to identify differentially 
hydroxymethylated regions with closely positioned probes.19 The rate of hmC, the average 
of Δβ-values for a specific group of CpGs, was calculated according to intragenic location, 
to CpG-context regions and at enhancer regions (melanocytic cell-specific and general) 
retrieved from FANTOM5 project (http://FANTOM5.gsc.riken.jp/5/).20
VALIDATION OF CANDIDATE LOCI 
Validation of hydroxymethylation at the PTEN promoter was performed in an independent 
sample group (4 nevi and 4 melanoma metastases). Genomic DNA (1μg) was subjected to BS 
and OxBS conversion using TrueMethyl oxBS Module (NuGEN Technologies, Redwood City, 
USA). DNA was amplified using the PCRX Enhancer System (Thermo Fisher Scientific, Waltham, 
USA) and subjected to capillary sequenced (primers: GGGGTTGTAAATAGATTTGATAGG and 
AAAAATATCTCCTACTACAACCCAAAA) and deep paired-end sequencing (tailed primers: 
GATGTGTATAAGAGACAGGGGGTTGTAAATAGATTTGATAGG and CGTGTGCTCTTCCGAT-
CTAAAAATATCTCCTACTACAACCCAAAA) using a MiSeq system (Illumina).
RESULTS
OBTAINING GENOME-WIDE 5-HYDROXYMETHYLCYTOSINE PATTERNS
Twenty-four DNA samples were analysed, including 8 aggressive primary melanomas 
with metastatic behaviour (M+), 8 primary melanomas with no metastatic behaviour (M-) 
during long-term follow-up and 8 benign nevi (N) (Table 1, Supplementary Table S1). To 
detect methylcytosine (mC) and hydroxymethylcytosine (hmC), different states of the CpG 
sites, we applied oxidative bisulfite (oxBS) chemistry, calculating hmC levels based on 
differences between bisulfite (BS) and oxBS-treated samples, using arrays as described 
previously.11,12,21 Bisulfite (BS) converts unmethylated cytosines to uracil, while methylated 
and hydroxymethylated cytosines are protected. The prior oxidative step in oxBS 
conversion allows the distinction between methylated and hydroxymethylated cytosines. 
Only hydroxymethylated but not methylated cytosines are oxidated into formylcytosines 
(5fC), which are converted to uracil. Arrays that interrogate over 850,000 CpG sites 
representing 99% of the RefSeq genes, encompassing more than 90% of interrogated sites 
of 450K arrays plus 333,265 CpGs located at enhancer regions were used.22 After quality 
control and exclusion of X-chromosomal CpGs 743,016 CpGs were analysed. As a measure 
of DNA methylation, the fluorescence ratio (β-value, ranging from 0 to 1) for each CpG of 
the bisulfite-treated DNA sample was used. Subtraction of the normalized β-value of the 
oxBS-treated sample from that of the BS-treated replicate analysed in parallel (Δβ-value) 
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was used as a measure of hydroxymethylation (Supplementary Figure S1). The average 
Δβ-value for CpGs at different genomic locations (hmC rate) was calculated. In addition, we 
considered as CpGs with high hmC levels those having a Δβ-value exceeding the average 
plus 3 standard deviations (Δβ>0.166). 











  Female 6 4 4
  Male 2 4 4
Age at diagnosis in years, median (range) 42 (29-57) 39 (34-68) 63 (45-79)
Location
  Head/neck 4 1 3
  Trunk 2 4 2
  Extremities 2 3 3
Breslow depth in mm, median (range) 1.0 (0.73-4) 9.7 (1.9-17)
First, we compared the number of hydroxymethylated CpGs in the nevus, non-metastatic and 
metastatic melanoma sample groups. The number of CpGs with high hmC levels was significantly 
higher in nevus (2.0% of interrogated CpGs) than in melanoma (0.54%) samples as was the 
average Δβ-value for the sample groups (0.017 vs 0.004), consistent with earlier reports of hmC 
loss in melanoma (Figure 1a)10 Comparative analysis of melanoma and nevus samples revealed 
21,767 CpGs with significantly lower hydroxymethylation in melanoma than in nevus samples, 
whereas 397 CpGs showed higher levels of hmC in melanoma (FDR <0.005). However, the 
variation of hmC levels of these CpGs within sample groups was high (Supplementary Figure 
S2). In spite of heterogeneity certain CpG sites showed consistent hmC loss in melanoma. The 
50 most differentially hydroxymethylated CpGs are presented in a heatmap in Supplementary 
Figure S3. When comparing metastatic and non-metastatic primary melanoma samples there 
were no interrogated CpGs with statistically significant different hmC level. 
To capture the distribution of hmC, principal component analysis revealed that the hmC 
patterns of melanoma samples were distinct from those of nevus samples (Figure 1b). The 
differences between the sample groups were more pronounced for hmC than for mC 
patterns. The hmC patterns of metastatic and non-metastatic melanoma samples were 
not distinct in this analysis. The hmC levels at different chromosomal regions were almost 
uniformly higher in nevus than in melanoma samples, with no evident clustering of aberrant 




FIGURE 1. Genome-wide distribution of DNA hydroxymethylation in nevus, non-metastatic and 
metastatic melanoma. (a) Boxplot showing the counts of CpGs with high hmC (Δβ>0.166) for each 
group. (b) Principal component analysis of hmC and mC for 1% of probes with highest variation across 
samples. Numbers refer to individual samples. Blue – nevi; yellow – non-metastatic melanomas; red 
– metastatic melanomas. (c) Chromosomal distribution of hmC in nevi (black) and melanomas (red). 
The scheme of each chromosome represents the measurement baseline (null hmC level), the vertical 
distance between chromosomes is 10%, bin size is 1 Mb. (d) Mean of hmC level over 4 Kb around the 
transcription start sites for nevi (blue) and melanomas (red). 
DEPLETION OF HMC IN DIFFERENT GENOMIC REGIONS 
Since methylation of promoter, intragenic and intergenic regions has distinct associations 
with gene transcription, we determined the location of hmC and mC within these regions. 
First, we assessed the average hmC rate across 4Kb at promoter regions around the 
canonical transcription start site of all genes and observed slightly lower hmC levels in 
melanoma throughout the entire region compared to benign nevus (Figure 1d). TET proteins 
generate hmC as an intermediate from mC in active DNA demethylation; hmC levels tend to 
follow mC levels therefore. Accordingly, both mC and hmC levels were considerably lower 
at CpGs in the proximal promoter and first exon. However, the distal promoter (200-1500 bp 
upstream of transcription start site) and 5’UTR regions are exceptions that show high hmC 
4
GENOME-WIDE CHARACTERIZATION OF 5-HYDROXYMETHYLCYTOSINE IN MELANOMA REVEALS MAJOR 
DIFFERENCES WITH NEVUS
84
in spite of moderate mC levels in all sample groups (Figure 2a, b). Whereas the mC levels 
were only marginally lower in melanoma than in nevus, we observed a striking loss of hmC 
not only in promoters but across all gene regions. The levels of hmC were also significantly 
lower in the metastatic than in the non-metastatic melanomas in most gene regions. 
Higher variation of hmC at enhancer regions in tumour has been reported in glioblastoma.11 
Therefore, we analysed the average rate of hmC at melanocyte-specific and at general 
enhancer regions retrieved from the FANTOM5 project.20 We found higher hmC levels 
in enhancer compared to non-enhancer regions among the different sample groups 
(Supplementary Figure S4). The depletion of hmC at enhancer regions in melanoma 
compared with nevus was proportional to that at non-enhancer regions.
CpG islands, particularly located at promoter regions, are mostly protected from methylation. 
The regions adjacent to CpG islands, termed shores and shelves have also been found 
to demonstrate specific methylation patterns associated with transcriptional states.23,24 
Subsequently we calculated the hmC and mC levels of cytosines located in these regions 
and found that the mC levels were lower in CpG islands and shores than in shelves and open 
sea (Figure 2c, d). Again the loss of hmC in melanoma compared to nevus was much larger 
than the difference in mC across the CpG islands, shores, shelves and open sea. Whereas 
generally the hmC levels follow the mC levels, the CpG shores are another exception 
demonstrating high hmC in spite of moderate mC levels, especially in nevus samples. 
Taken together, in nevus and melanoma hmC levels differ markedly across genomic regions 
and not following mC levels, which points to specific enzymatic activity in shaping hmC 
patterns. The hmC levels are substantially lower in melanoma than in nevus across all 
intragenic regions. This is in line with dilution through replication and insufficient active TET-
mediated hydroxymethylation. Differences of hmC levels and distribution are much more 
pronounced than of mC levels.
DIFFERENTIALLY HYDROXYMETHYLATED REGIONS IN MELANOMA 
Although the modification of a single CpG site may impact on gene expression, regions 
containing multiple CpG sites in promoters and enhancers commonly work as units of 
transcriptional regulation. Therefore, we sought to identify and examine regions with 
differential hydroxymethylation (DhMRs). When comparing melanoma and nevus samples, 68 
regions were statistically significant differentially hydroxymethylated (p<0.005). In all 68 DhMR 
hmC levels were lower in melanoma compared to nevus (Figure 3, Supplementary Table 
S2). No significantly differentially hydroxymethylated regions were identified when comparing 




established cancer-related genes (http://cancer.sanger.ac.uk/census, accessed October 
2019), namely in the GNAS, GAS7, PTEN, TPM4 and DAXX (Supplementary Table S2). Notably, 
for the PTEN and TPM4 tumour suppressor genes the DhMR is located in the promoter region. 
FIGURE 2. Average rate of hmC and mC at intragenic locations and CpG-context regions. (a) hmC levels 
in the N, M- and M+ sample groups at intragenic regions presented as average Δβ-values. (b) mC level 
presented as average β-values. Untranslated regions (3’UTR and 5’UTR), proximal promoter (TSS-200bp 
and 1stexon), distal promoter (TSS-1500bp), gene body, and intergenic region (IGR). (c) hmC levels in 
the N, M- and M+ sample groups at CpG-context regions presented as average Δβ-values. (d) mC level 
presented as average β-values. CpG island, shore (<2Kb flanking CpG Islands), shelves (<2Kb flanking 
outwards from CpG shore) and open sea (>4Kb from CpG island). Blue – nevi; yellow – non-metastatic 
melanomas; red – metastatic melanomas. The error bars represent standard errors among samples.
PTEN PROMOTER HYDROXYMETHYLATION IN NEVUS AND MELANOMA
PTEN is an established tumour suppressor gene, inactivated in melanoma and other 
tumour types through genetic and epigenetic mechanisms. Therefore, we further analysed 
hydroxymethylation at this locus in nevus and melanoma. In our study, a region in the PTEN 
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promoter (chr10:89621419-89622084) was found to show hydroxymethylation in all nevus 
samples, but higher methylation levels in the melanoma samples (Figure 4a). 
FIGURE 3. Heatmap depicting hmC levels for 68 significantly differentially hydroxymethylated regions 
in nevus and melanoma samples. Each row represents a DhMR with the associated gene and each 
column represents a different sample. Average hmC level, measured as Δβ-value, is indicated by 
variable colour (low hmC – red, high hmC – yellow). 
Methylation of this specific region in the PTEN promoter, located from -1400 to -800bp 
upstream of the transcription start site, has been reported as being associated with 
transcriptional repression of PTEN in various malignancies and worse survival in melanoma 
patients (Supplementary Figure S5).25-27 Capillary sequencing of the region following BS and 
oxBS conversion of DNA from nevus and melanoma samples subjected to hmC profiling, 
along with a normal skin sample, confirmed the presence of hydroxymethylation in nevus 
and normal skin samples (higher T peak upon oxBS) and methylation in a melanoma sample 




in the PTEN promoter using an independent quantitative BS/oxBS deep sequencing method 
in an independent set of 4 nevi and 4 metastatic melanoma samples. The 6 CpGs analysed 
using BS/oxBS NGS (chr10:89621419-89621537) confirmed the hydroxymethylation profile in 
nevi and a predominant methylation status in melanomas (Figure 4c). 
FIGURE 4. Differentially hydroxymethylated region in the PTEN promoter region. (a) DhMR (rectangle; 
chr10:89621419-89622084) located within the promoter region of PTEN gene with hydroxymethylation 
and methylation levels for the three sample groups. (b) Validation of a selected CpG site from PTEN 
DhMR by capillary sequencing upon BS and oxBS conversion. After oxBS a higher T peak appears in 
normal skin and nevus samples, while in melanoma sample there is a higher C peak. (c) BS/OxBS deep 
sequencing of 6 CpG sites at the PTEN DhMR (chr10:89621419-89621537) in 4 independent nevi and 4 
melanomas (mean ± SD, *p<0.05, two-tailed Mann-Whitney U test). Blue – nevi; yellow – non-metastatic 
melanomas; red – metastatic melanomas.
DISCUSSION
Loss of hmC is an established feature of melanoma and other tumour types, with potential 
diagnostic and prognostic significance.10,28 Here we provide a genome-wide landscape of hmC 
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and mC in nevus and melanoma by applying robust oxidative bisulfite chemistry combined 
with high-density arrays. Unsupervised analysis revealed significant differences in the global 
hmC patterns of melanoma and nevus samples, exceeding those of mC patterns. Numerous 
published studies have aimed to identify diagnostic and prognostic DNA methylation markers 
for melanoma.29-31 Our study shows that analysis of hmC levels and distribution can equally 
be used to aid in distinguishing melanoma from benign melanocytic lesions. Accordingly, 
determination of hmC levels using immunohistochemistry in the diagnosis of melanoma has 
been proposed.32 We identified thousands of single differentially hydroxymethylated CpG sites 
and 68 regions that might be used as specific diagnostic markers for melanoma. Although 
the levels of hmC were uniformly lower in metastatic than in non-metastatic melanoma, the 
patterns of distribution were not significantly different. 
We observed a striking loss of hmC in melanoma relative to nevus, consistent with findings 
in other tumour types, across all autosomes, intragenic and intergenic regions, within and 
outside of CpG islands.11,33 This phenomenon may be explained by passive dilution of the 
hmC mark due to DNA replication in proliferating melanoma cells and by insufficient active 
demethylation. Downregulation of IDH and TET family enzymes in melanoma has been shown 
previously, involving deregulation of active TET-mediated DNA demethylation in shaping the 
melanoma epigenome.10 Within the pattern of global hmC depletion, specific CpG sites and 
regions could be identified with significantly lower hydroxymethylation in melanoma than 
in nevus, pointing to epigenetic deregulation at specific loci. In nevus and melanoma the 
hydroxymethylation levels were particularly low at the proximal promoter (TSS200) and first 
exon, corresponding with lower levels of methylation at promoter CpG islands. However, 
at CpG shores we observed high levels of hydroxymethylation disproportionate to the 
methylation levels at these sites in nevus and melanoma. Enrichment of hmC at CpG shores, 
regions that regulate gene expression, has been reported in non-small cell lung cancer and 
liver cancer previously.24 
In melanoma and other tumour types, the methylation landscape demonstrates marked 
alterations at enhancer regions, which can impact on gene expression programmes and 
tumour aggressiveness.9 Oxidation of mC into hmC is associated with enhancer activation.34 
Hydroxymethylation at these critical regulatory regions in tumours could induce functional 
demethylation and activation. In this study, we observed enrichment of hmC at enhancer 
regions in nevus and melanoma, as was reported for glioblastoma, but no excess depletion 
of hmC at enhancers in melanoma.11 
The hmC mark is associated with an open chromatin configuration, affecting gene 




from methylation-associated silencing. Loss of hmC might therefore contribute to malignant 
progression. Among the 68 DhMRs, 5 localized to the cancer-related genes PTEN, DAXX, 
GAS7, GNAS and TPM4. PTEN is an essential tumour suppressor gene in melanoma. Here, we 
demonstrate the presence of hydroxymethylation in the promoter region of the PTEN gene 
(chr10:89621419-89622084) in nevi and its absence in melanomas. It has been reported that 
PTEN expression is uniformly high in nevus and markedly lower in melanoma samples.10,35,36 
In melanomas, PTEN is functionally inactivated through genetic and epigenetic mechanisms, 
including promoter hypermethylation.25,37 Loss of PTEN expression in murine nevi accelerates 
melanoma formation by allowing escape from oncogene-induced senescence.38 It is 
tempting to speculate that hmC depletion at the PTEN regulatory region in melanoma has 
functional significance by affecting expression of this tumour suppressor gene. Accordingly, 
it was recently found that ablation of the TET2 gene, resulting in genomic hmC loss, drives 
malignant transformation and melanoma progression.39 In the genetically engineered mouse 
models studied deregulated expression of CDKN2A was observed. Even partial PTEN loss 
due to epigenetic mechanisms has biological relevance in melanoma.36 Of note, the CpG 
sites showing hypermethylation in the study by Giles et al.36 are located within the DhMR that 
we identified. The potential role of depletion of hmC at the PTEN promoter as an epigenetic 
mechanism driving melanoma progression requires further investigation. 
In conclusion, we have resolved the genome-wide hmC and mC distribution in melanoma 
and nevus, of potential relevance for biomarker discovery and understanding of epigenetic 
deregulation in melanoma. We identified specific CpG sites and regions with significantly lower 
hydroxymethylation in melanoma than in nevus. Our results merit further investigation into the 
functional relevance of hydroxymethylation at the PTEN promoter in nevus and depletion 
at this locus in melanoma. Methods used in previous studies to analyse DNA methylation 
that rely on bisulfite conversion may have overestimated methylation, since part of the 
observed protection from conversion to uracil is caused by hydroxymethylation. However, we 
can assume that this potential error on melanoma is minor. Following on this genome-wide 
analysis of hmC, the value of the identified differentially hydroxymethylated CpG sites and 
regions should be tested in a large cohort of dysplastic melanocytic nevi and melanomas. 
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SUPPLEMENTARY TABLE S1. Tumor samples characteristics.
Nr Tumour type Site
Breslow 
(mm) Ulceration Mitoses Gender Age
Color 
code
1 Naevus leg       F 29 blue
2 Naevus head & neck       F 52 blue
3 Naevus trunk       F 43 blue
4 Naevus upper leg       M 55 blue
5 Naevus trunk       F 40 blue
6 Naevus head & neck       F 39 blue
7 Naevus head & neck       M 57 blue
8 Naevus head & neck       F 30 blue
1 Met- primary melanoma lower leg 2.08 yes yes M 68 orange
2 Met- primary melanoma back 0.91 no no F 42 orange
3 Met- primary melanoma foot 4 yes yes M   orange
4 Met- primary melanoma buttock 0.73 no no F 35 orange
5 Met- primary melanoma trunk 2.05 no yes F   orange
6 Met- primary melanoma ear 0.81 no yes M 58 orange
7 Met- primary melanoma shoulder 0.94 yes yes F 34 orange
8 Met- primary melanoma back 1.06 no yes M 65 orange
1 Met+ primary melanoma scalp 3.46 no yes M   red
2 Met+ primary melanoma foot 1.9 no yes F   red
3 Met+ primary melanoma back 3.09 no yes F 45 red
4 Met+ primary melanoma neck, desmoplastic 
melanoma
15.6 no yes M   red
5 Met+ primary melanoma thigh 9.2 yes yes F   red
6 Met+ primary melanoma vulva 10.2 yes yes F 56 red
7 Met+ primary melanoma scalp 17 yes yes M 79 red
8 Met+ primary melanoma axilla 12 no yes M 70 red
Met- primary melanoma – non-metastatic primary melanoma
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SUPPLEMENTARY TABLE S2. 68 differentially hydroxymethylated regions (DhMRs).
Hydroxymethylation Methylation
Chr start end p.valueArea fwerArea Gene ID Naevus Melanoma Naevus Melanoma In CpG island? Cancer-related genes?a
chr4 1201588 1203168 0.00E+00 0.00E+00 LOC100130872 LOC100130872-SPON2 0.09 -0.02 0.36 0.61 shore island
chr7 94285642 94287211 0.00E+00 0.00E+00 SGCE PEG10 0.02 -0.02 0.32 0.34 island shore
chr20 57462798 57464129 0.00E+00 0.00E+00 GNAS 0.04 -0.01 0.38 0.44 island shore oncogene in pituitary adenoma, pancreatic 
intraductal papillary mucinous neoplasm, fibrous 
dysplasia
chr20 36148133 36149455 0.00E+00 0.00E+00 BLCAP 0.03 -0.01 0.81 0.77 island shore
chr12 58012960 58013942 0.00E+00 0.00E+00 SLC26A10 LOC101927583 0.09 0.01 0.29 0.38 island shore
chr6 33282885 33283317 0.00E+00 0.00E+00 ZBTB22 0.10 0.00 0.35 0.50 island shore
chr6 33130696 33132442 0.00E+00 0.00E+00 COL11A2 0.07 0.00 0.52 0.64 shore shelf
chr6 3848634 3849818 0.00E+00 0.00E+00 FAM50B 0.05 0.00 0.25 0.38 island shore
chr1 201708419 201709675 9.23E-06 8.00E-03 NAV1 0.11 0.00 0.26 0.41 shore island
chr6 10419016 10421069 1.85E-05 1.60E-02 TFAP2A 0.07 -0.01 0.23 0.36 shore island
chr7 27208285 27209828 1.85E-05 1.60E-02 MIR196B HOXA10-AS 0.05 -0.01 0.22 0.35 island shore
chr16 67232921 67234167 1.85E-05 1.60E-02 ELMO3 0.13 0.00 0.34 0.54 island shore
chr11 86382900 86383940 1.85E-05 1.60E-02 ME3 0.07 0.00 0.26 0.35 island shore
chr7 95025194 95027158 1.85E-05 1.60E-02 PON3 0.03 -0.01 0.27 0.39 island shore
chr1 25257505 25258332 1.85E-05 1.60E-02 RUNX3 0.08 0.01 0.30 0.47 island
chr7 1022643 1023156 1.85E-05 1.60E-02 CYP2W1 0.08 -0.03 0.42 0.59 shore
chr20 61446962 61447623 1.85E-05 1.60E-02 COL9A3 0.10 0.02 0.23 0.27 shore
chr11 61062665 61063378 1.85E-05 1.60E-02 VWCE 0.11 0.00 0.31 0.41 island shore
chr16 68270129 68271177 2.77E-05 2.40E-02 ESRP2 0.14 0.02 0.18 0.35 island
chr11 35546824 35548139 3.23E-05 2.80E-02 PAMR1 0.09 0.00 0.29 0.38 island shore
chr17 9862752 9863293 3.23E-05 2.80E-02 GAS7 0.10 0.00 0.31 0.40 opensea fusion partner in acute myeloid leukemia
chr6 31598379 31599955 3.23E-05 2.80E-02 BAT2 0.04 0.01 0.80 0.86 shore island
chr1 32169701 32170433 3.69E-05 3.20E-02 COL16A1 0.19 0.02 0.14 0.26 island shore
chr8 145728138 145728630 4.15E-05 3.60E-02 GPT 0.13 -0.01 0.33 0.63 shore
chr15 93616894 93617402 4.62E-05 4.00E-02 RGMA 0.18 0.04 0.22 0.30 island shore
chr2 63275509 63276833 5.08E-05 4.40E-02 LOC100132215 OTX1 0.04 -0.01 0.16 0.21 island
chr16 67918001 67918965 5.08E-05 4.40E-02 EDC4 NRN1L 0.10 0.00 0.42 0.60 shore island
chr15 41061384 41062224 5.08E-05 4.40E-02 DNAJC17 C15orf62 0.12 0.00 0.30 0.41 opensea
chr17 19648846 19649293 5.08E-05 4.40E-02 ALDH3A1 0.07 -0.02 0.42 0.61 shore
chr11 392903 394545 5.08E-05 4.40E-02 PKP3 0.07 0.00 0.44 0.56 shore island
chr19 13135318 13135808 5.08E-05 4.40E-02 NFIX 0.12 0.01 0.10 0.20 island
chr1 2461278 2461929 5.08E-05 4.40E-02 HES5 0.12 0.01 0.25 0.24 island
chr1 59042931 59044110 5.08E-05 4.40E-02 TACSTD2 0.08 0.00 0.17 0.22 island shore
chr16 31227800 31228720 5.08E-05 4.40E-02 TRIM72 PYDC1 0.08 0.01 0.25 0.28 island shore
chr11 7695165 7695809 5.08E-05 4.40E-02 CYB5R2 0.12 0.00 0.21 0.33 island shore
chr10 89621419 89622084 5.08E-05 4.40E-02 PTEN KILLIN 0.08 0.01 0.08 0.18 island shore tumor suppressor gene in glioma, prostate, 
endometrial carcinomas 
chr5 80528581 80529340 5.08E-05 4.40E-02 RNU5E CKMT2 0.10 -0.01 0.37 0.51 opensea
chr2 25391505 25391911 5.08E-05 4.40E-02 POMC 0.10 0.00 0.25 0.32 island shore
chr20 43936663 43937467 5.54E-05 4.40E-02 MATN4 RBPJL 0.02 -0.02 0.45 0.51 shore
chr12 53298383 53299310 5.54E-05 4.40E-02 KRT8 0.15 0.01 0.45 0.67 shore
chr20 19866743 19867423 5.54E-05 4.40E-02 RIN2 0.09 0.00 0.41 0.49 opensea
chr12 16757954 16758465 6.92E-05 4.80E-02 LMO3 0.10 0.00 0.20 0.24 opensea




SUPPLEMENTARY TABLE S2. 68 differentially hydroxymethylated regions (DhMRs).
Hydroxymethylation Methylation
Chr start end p.valueArea fwerArea Gene ID Naevus Melanoma Naevus Melanoma In CpG island? Cancer-related genes?a
chr4 1201588 1203168 0.00E+00 0.00E+00 LOC100130872 LOC100130872-SPON2 0.09 -0.02 0.36 0.61 shore island
chr7 94285642 94287211 0.00E+00 0.00E+00 SGCE PEG10 0.02 -0.02 0.32 0.34 island shore
chr20 57462798 57464129 0.00E+00 0.00E+00 GNAS 0.04 -0.01 0.38 0.44 island shore oncogene in pituitary adenoma, pancreatic 
intraductal papillary mucinous neoplasm, fibrous 
dysplasia
chr20 36148133 36149455 0.00E+00 0.00E+00 BLCAP 0.03 -0.01 0.81 0.77 island shore
chr12 58012960 58013942 0.00E+00 0.00E+00 SLC26A10 LOC101927583 0.09 0.01 0.29 0.38 island shore
chr6 33282885 33283317 0.00E+00 0.00E+00 ZBTB22 0.10 0.00 0.35 0.50 island shore
chr6 33130696 33132442 0.00E+00 0.00E+00 COL11A2 0.07 0.00 0.52 0.64 shore shelf
chr6 3848634 3849818 0.00E+00 0.00E+00 FAM50B 0.05 0.00 0.25 0.38 island shore
chr1 201708419 201709675 9.23E-06 8.00E-03 NAV1 0.11 0.00 0.26 0.41 shore island
chr6 10419016 10421069 1.85E-05 1.60E-02 TFAP2A 0.07 -0.01 0.23 0.36 shore island
chr7 27208285 27209828 1.85E-05 1.60E-02 MIR196B HOXA10-AS 0.05 -0.01 0.22 0.35 island shore
chr16 67232921 67234167 1.85E-05 1.60E-02 ELMO3 0.13 0.00 0.34 0.54 island shore
chr11 86382900 86383940 1.85E-05 1.60E-02 ME3 0.07 0.00 0.26 0.35 island shore
chr7 95025194 95027158 1.85E-05 1.60E-02 PON3 0.03 -0.01 0.27 0.39 island shore
chr1 25257505 25258332 1.85E-05 1.60E-02 RUNX3 0.08 0.01 0.30 0.47 island
chr7 1022643 1023156 1.85E-05 1.60E-02 CYP2W1 0.08 -0.03 0.42 0.59 shore
chr20 61446962 61447623 1.85E-05 1.60E-02 COL9A3 0.10 0.02 0.23 0.27 shore
chr11 61062665 61063378 1.85E-05 1.60E-02 VWCE 0.11 0.00 0.31 0.41 island shore
chr16 68270129 68271177 2.77E-05 2.40E-02 ESRP2 0.14 0.02 0.18 0.35 island
chr11 35546824 35548139 3.23E-05 2.80E-02 PAMR1 0.09 0.00 0.29 0.38 island shore
chr17 9862752 9863293 3.23E-05 2.80E-02 GAS7 0.10 0.00 0.31 0.40 opensea fusion partner in acute myeloid leukemia
chr6 31598379 31599955 3.23E-05 2.80E-02 BAT2 0.04 0.01 0.80 0.86 shore island
chr1 32169701 32170433 3.69E-05 3.20E-02 COL16A1 0.19 0.02 0.14 0.26 island shore
chr8 145728138 145728630 4.15E-05 3.60E-02 GPT 0.13 -0.01 0.33 0.63 shore
chr15 93616894 93617402 4.62E-05 4.00E-02 RGMA 0.18 0.04 0.22 0.30 island shore
chr2 63275509 63276833 5.08E-05 4.40E-02 LOC100132215 OTX1 0.04 -0.01 0.16 0.21 island
chr16 67918001 67918965 5.08E-05 4.40E-02 EDC4 NRN1L 0.10 0.00 0.42 0.60 shore island
chr15 41061384 41062224 5.08E-05 4.40E-02 DNAJC17 C15orf62 0.12 0.00 0.30 0.41 opensea
chr17 19648846 19649293 5.08E-05 4.40E-02 ALDH3A1 0.07 -0.02 0.42 0.61 shore
chr11 392903 394545 5.08E-05 4.40E-02 PKP3 0.07 0.00 0.44 0.56 shore island
chr19 13135318 13135808 5.08E-05 4.40E-02 NFIX 0.12 0.01 0.10 0.20 island
chr1 2461278 2461929 5.08E-05 4.40E-02 HES5 0.12 0.01 0.25 0.24 island
chr1 59042931 59044110 5.08E-05 4.40E-02 TACSTD2 0.08 0.00 0.17 0.22 island shore
chr16 31227800 31228720 5.08E-05 4.40E-02 TRIM72 PYDC1 0.08 0.01 0.25 0.28 island shore
chr11 7695165 7695809 5.08E-05 4.40E-02 CYB5R2 0.12 0.00 0.21 0.33 island shore
chr10 89621419 89622084 5.08E-05 4.40E-02 PTEN KILLIN 0.08 0.01 0.08 0.18 island shore tumor suppressor gene in glioma, prostate, 
endometrial carcinomas 
chr5 80528581 80529340 5.08E-05 4.40E-02 RNU5E CKMT2 0.10 -0.01 0.37 0.51 opensea
chr2 25391505 25391911 5.08E-05 4.40E-02 POMC 0.10 0.00 0.25 0.32 island shore
chr20 43936663 43937467 5.54E-05 4.40E-02 MATN4 RBPJL 0.02 -0.02 0.45 0.51 shore
chr12 53298383 53299310 5.54E-05 4.40E-02 KRT8 0.15 0.01 0.45 0.67 shore
chr20 19866743 19867423 5.54E-05 4.40E-02 RIN2 0.09 0.00 0.41 0.49 opensea
chr12 16757954 16758465 6.92E-05 4.80E-02 LMO3 0.10 0.00 0.20 0.24 opensea
chr1 203320190 203320732 6.92E-05 4.80E-02 FMOD 0.07 0.00 0.35 0.33 opensea
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SUPPLEMENTARY TABLE S2 CONTINUED.
Hydroxymethylation Methylation
Chr start end p.valueArea fwerArea Gene ID Naevus Melanoma Naevus Melanoma In CpG island? Cancer-related genes?a
chr16 57831745 57832309 6.92E-05 4.80E-02 KIFC3 0.08 0.00 0.43 0.65 shelf opensea
chr19 16178030 16178570 6.92E-05 4.80E-02 TPM4 0.05 -0.01 0.36 0.53 shore island fusion partner in anaplastic large-cell lymphoma 
chr16 66400320 66400599 6.92E-05 4.80E-02 CDH5 0.08 -0.01 0.31 0.40 opensea
chr16 54972078 54973128 7.38E-05 4.80E-02 0.10 0.00 0.31 0.30 island shore
chr5 140864020 140864834 7.38E-05 4.80E-02 PCDHGA4 PCDHGC4 0.08 -0.01 0.26 0.29 island shore
chr16 31146682 31147199 7.38E-05 4.80E-02 PRSS8 0.11 -0.01 0.36 0.55 opensea
chr22 46481603 46482023 7.38E-05 4.80E-02 LOC400931 MIRLET7BHG 0.10 0.00 0.28 0.39 island shore
chr17 76128481 76129099 7.38E-05 4.80E-02 TMC8 0.21 0.04 0.28 0.38 shore
chr2 85640762 85641438 7.38E-05 4.80E-02 CAPG 0.04 -0.02 0.31 0.38 island shore
chr6 32119616 32120324 7.38E-05 4.80E-02 PRRT1 PPT2 0.11 0.01 0.35 0.46 shore
chr11 105479843 105480979 7.38E-05 4.80E-02 GRIA4 0.07 0.00 0.28 0.32 shore
chr8 16859451 16860121 7.38E-05 4.80E-02 FGF20 0.12 0.01 0.28 0.36 shore island
chr7 87935979 87936923 7.38E-05 4.80E-02 STEAP4 0.05 0.00 0.35 0.38 opensea
chr6 31590513 31590736 7.38E-05 4.80E-02 SNORA38 BAT2 0.11 0.02 0.36 0.53 shore
chr5 191127 192103 7.38E-05 4.80E-02 LRRC14B 0.05 0.01 0.23 0.31 island shore
chr1 234667087 234667549 7.38E-05 4.80E-02 LINC01354 0.06 -0.04 0.30 0.59 opensea
chr6 30698584 30698987 7.38E-05 4.80E-02 FLOT1 0.17 0.04 0.29 0.42 opensea
chr8 145729106 145729799 7.38E-05 4.80E-02 GPT 0.06 -0.02 0.54 0.73 shore
chr2 102091048 102091755 7.38E-05 4.80E-02 RFX8 0.09 0.01 0.29 0.28 shore island
chr2 54785178 54785795 7.38E-05 4.80E-02 SPTBN1 0.08 0.00 0.11 0.20 island
chr6 30850309 30851086 7.85E-05 4.80E-02 DDR1 0.16 0.04 0.28 0.51 shore
chr17 6898315 6899888 5.08E-05 4.40E-02 ALOX12 0.02 -0.03 0.37 0.57 island shore
chr6 33263805 33265016 5.54E-05 4.40E-02 RGL2 0.02 0.00 0.78 0.81 shelf shore
chr6 33288366 33289280 4.62E-05 4.00E-02 DAXX 0.02 -0.01 0.65 0.71 island shore oncogene or tumor suppressor gene in pancreatic 
neuroendocrine tumour, paediatric glioblastoma 
chr7 27142100 27143806 5.08E-05 4.40E-02 HOXA2 0.04 0.00 0.26 0.35 island shore




SUPPLEMENTARY TABLE S2 CONTINUED.
Hydroxymethylation Methylation
Chr start end p.valueArea fwerArea Gene ID Naevus Melanoma Naevus Melanoma In CpG island? Cancer-related genes?a
chr16 57831745 57832309 6.92E-05 4.80E-02 KIFC3 0.08 0.00 0.43 0.65 shelf opensea
chr19 16178030 16178570 6.92E-05 4.80E-02 TPM4 0.05 -0.01 0.36 0.53 shore island fusion partner in anaplastic large-cell lymphoma 
chr16 66400320 66400599 6.92E-05 4.80E-02 CDH5 0.08 -0.01 0.31 0.40 opensea
chr16 54972078 54973128 7.38E-05 4.80E-02 0.10 0.00 0.31 0.30 island shore
chr5 140864020 140864834 7.38E-05 4.80E-02 PCDHGA4 PCDHGC4 0.08 -0.01 0.26 0.29 island shore
chr16 31146682 31147199 7.38E-05 4.80E-02 PRSS8 0.11 -0.01 0.36 0.55 opensea
chr22 46481603 46482023 7.38E-05 4.80E-02 LOC400931 MIRLET7BHG 0.10 0.00 0.28 0.39 island shore
chr17 76128481 76129099 7.38E-05 4.80E-02 TMC8 0.21 0.04 0.28 0.38 shore
chr2 85640762 85641438 7.38E-05 4.80E-02 CAPG 0.04 -0.02 0.31 0.38 island shore
chr6 32119616 32120324 7.38E-05 4.80E-02 PRRT1 PPT2 0.11 0.01 0.35 0.46 shore
chr11 105479843 105480979 7.38E-05 4.80E-02 GRIA4 0.07 0.00 0.28 0.32 shore
chr8 16859451 16860121 7.38E-05 4.80E-02 FGF20 0.12 0.01 0.28 0.36 shore island
chr7 87935979 87936923 7.38E-05 4.80E-02 STEAP4 0.05 0.00 0.35 0.38 opensea
chr6 31590513 31590736 7.38E-05 4.80E-02 SNORA38 BAT2 0.11 0.02 0.36 0.53 shore
chr5 191127 192103 7.38E-05 4.80E-02 LRRC14B 0.05 0.01 0.23 0.31 island shore
chr1 234667087 234667549 7.38E-05 4.80E-02 LINC01354 0.06 -0.04 0.30 0.59 opensea
chr6 30698584 30698987 7.38E-05 4.80E-02 FLOT1 0.17 0.04 0.29 0.42 opensea
chr8 145729106 145729799 7.38E-05 4.80E-02 GPT 0.06 -0.02 0.54 0.73 shore
chr2 102091048 102091755 7.38E-05 4.80E-02 RFX8 0.09 0.01 0.29 0.28 shore island
chr2 54785178 54785795 7.38E-05 4.80E-02 SPTBN1 0.08 0.00 0.11 0.20 island
chr6 30850309 30851086 7.85E-05 4.80E-02 DDR1 0.16 0.04 0.28 0.51 shore
chr17 6898315 6899888 5.08E-05 4.40E-02 ALOX12 0.02 -0.03 0.37 0.57 island shore
chr6 33263805 33265016 5.54E-05 4.40E-02 RGL2 0.02 0.00 0.78 0.81 shelf shore
chr6 33288366 33289280 4.62E-05 4.00E-02 DAXX 0.02 -0.01 0.65 0.71 island shore oncogene or tumor suppressor gene in pancreatic 
neuroendocrine tumour, paediatric glioblastoma 
chr7 27142100 27143806 5.08E-05 4.40E-02 HOXA2 0.04 0.00 0.26 0.35 island shore
aData retrieved from Cancer Gene Census - COSMIC (https://cancer.sanger.ac.uk/census)
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Figure S1. Cumulative distribution of hmC and mC across all CpG sites analysed. Red 
line for hmC; black line for mC. All CpG sites show a hmC value between -0.2 and 0.3. The 
mC distribution is bimodal since there are non-methylated CpGs  (0-0.2) or fully methylated 










SUPPLEMENTARY FIGURE S1. Cumulative distribution of hmC and mC across all CpG sites analysed. 
Red line for hmC; black line for mC. All CpG sites show a hmC value between -0.2 and 0.3. The mC 





Figure S2. Venn diagram of the GC-probes for which at least 1 sample within a group showed 
a Δβ value exceeding the average plus 3 standard deviations (Δβ>0.166).   
 
SUPPLEMENTARY FIGURE S2. Venn diagram of the GC-probes for which at least 1 sample within a 







Figure S3. Heatmap. The top50 CpG sites statistically significant between nevi and 






SUPPLEMENTARY FIGURE S3. Heatmap. The top50 CpG sites statistically significant between nevi 
and melanomas in order of hmC value.
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Figure S4. Averaged rate of hmC at enhancer regions retrieved from FANTOM5 
project (http://FANTOM5.gsc.riken.jp/5/). Blue – nevi; yellow – non-metastatic melanoma; 
red – metastatic melanoma. Comparison of hmC rate at melanocyte-specific enhancer regions 
(2) (2593 probes were found in 2136 enhancers) and at general enhancer regions (1) with 
hmC rate at non-enhancer regions (0).  
  
SUPPLEMENTARY FIGURE S4. Averaged rate of hmC at enhancer regions retrieved from FANTOM5 
project (http://FANTOM5.gsc.riken.jp/5/). Blue – nevi; yellow – non-metastatic melanoma; red – 
metastatic melanoma. Comparison of hmC rate at elanocyte-specific enhancer regions (2) (2593 
probes were found in 2136 enhancers) and at general enhancer regions (1) with hmC rate at non-




Figure S5. Schematic representation of the DhMR in the PTEN promoter region 
(chr10:89621419-89622084). Hypermethylation of the regions 1. (Mirmohammadsadegh et 
al., 2006)25  and 2. (Lahtz et al., 2010)26  have been previously associated with transcriptional 
repression of the PTEN gene in melanoma. Hypermethylation of region 3. (Roh et al., 2016, 
same as region 1.)27 was associated with worse survival in melanoma patients. 
 
SUPPLEMENTARY FIGURE S5. Schematic representation of the DhMR in the PTEN promoter region 
(chr10:89621419-89622084). Hypermethylation of the regions 1. (Mirmohammadsadegh et al., 2006) 
and 2. (Lahtz et al., 2010) have been previously associated with transcriptional repression of the PTEN 
gene in melanoma. Hypermethylation of region 3. (Roh et al., 2016, same as region 1.) was associated 
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Interplay between TERT 
promoter mutations and 
methylation culminates in 
chromatin accessibility 
and TERT expression 
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The telomerase reverse transcriptase (TERT) gene is responsible for telomere maintenance 
in germline and stem cells, and is re-expressed in 90% of human cancers. CpG methylation 
in the TERT promoter (TERTp) was correlated with TERT mRNA expression. Furthermore, two 
hotspot mutations in TERTp, dubbed C228T and C250T, have been revealed to facilitate 
binding of transcription factor ETS/TCF and subsequent TERT expression. This study aimed 
to elucidate the combined contribution of epigenetic (promoter methylation and chromatin 
accessibility) and genetic (promoter mutations) mechanisms in regulating TERT gene 
expression in healthy skin samples and in melanoma cell lines (n=61). We unexpectedly 
observed that the methylation of TERTp was as high in a subset of healthy skin cells, mainly 
keratinocytes, as in cutaneous melanoma cell lines. In spite of the high promoter methylation 
fraction in wild-type (WT) samples, TERT mRNA was only expressed in the melanoma cell 
lines with either high methylation or intermediate methylation in combination with TERT 
mutations. TERTp methylation was positively correlated with chromatin accessibility and 
TERT mRNA expression in 8 melanoma cell lines. Cooperation between epigenetic and 
genetic mechanisms were best observed in heterozygous mutant cell lines as chromosome 
accessibility preferentially concerned the mutant allele. Combined, these results suggest 
a complex model in which TERT expression requires either a widely open chromatin state 
in TERTp-WT samples due to high methylation throughout the promoter or a combination 
of moderate methylation fraction/chromatin accessibility in the presence of the C228T or 
C250T mutations.
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Approximately 90% of all human cancers share a transcriptional alteration: reactivation of 
the telomerase reverse transcriptase (TERT) gene.1,2 TERT encodes the catalytic subunit of 
the ribonucleoprotein telomerase and is capable of extending the repetitive, non-coding 
DNA sequence on terminal ends of chromosomes, the telomeres. As the single-stranded 
5’ ends of chromosomes are shortened with each cellular division, telomeres prevent loss 
of coding chromosomal DNA.3-6 Telomerase is only transcribed in a subset of stem cells in 
growing or renewing tissues, but through reactivation of telomerase expression, cells can 
extend telomeres or prevent telomeres shrinkage. This is termed telomere maintenance, 
which is one of the hallmarks of cancer, and allows subsequent indefinite proliferation and 
immortalization.3,6-8 
Since the MYC oncogene has firstly been identified to activate telomerase, a variety of 
epigenetic or genetic mechanisms in the gene body or TERT promoter (TERTp) have 
followed, such as CpG methylation, histone modifications, mutations, germline genetic 
variations, structural variations, DNA amplification or chromosomal rearrangements.3,5,7 
A widely investigated mechanism that could induce TERT reactivation is the presence of 
mutations in the gene promoter.7,9 Horn and Huang et al. identified two mutually exclusive 
TERTp point mutations that are correlated to TERT mRNA expression by creating binding 
motifs for the transcription factor E26 transformation-specific/ternary complex factor (ETS/
TCF).7,9 These mutations, chr5:1,295,228 C>T and chr5:1,295,250 C>T in hg19 (−124 bp and 
−146 bp from the translation start site), henceforth respectively dubbed C228T and C250T, 
were first identified in melanoma. Furthermore, these mutations showed high prevalence in 
and were correlated with poor prognosis of cutaneous melanomas.4,5,10-12
An additional mechanism by which a gene can be made accessible to transcription factors, 
facilitating gene expression, is hypomethylation of promoter CpG islands, a hallmark of 
euchromatin.13,14 Methylation located in the gene body, however, shows a positive correlation 
with active gene expression.15 In stark contrast to most genes, TERTp hypermethylation may 
also allow gene expression since transcriptional repressors rely on unmethylated promoter 
CpGs, such as CCCTC-binding factor (CTCF)/cohesin complex or MAZ.16-18 As such, in 
combination with transcription factor binding, dissociation of the repressor may result in 
TERT expression.3,16,19,20 Castelo-Branco et al. proposed that methylation of a specific CpG 
site in TERTp, cg11625005 (position 1,295,737 in hg19) was associated with paediatric brain 
tumours progression and poor prognosis.20 This finding was later supported by the study 
from Barthel et al., in which the CpG methylation was found to be correlated with TERT 
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expression in samples lacking somatic TERT alterations and to be generally absent in 
normal samples adjacent to tumour tissue.3 
Chromatin organisation, its plasticity and dynamics at TERTp region have been reported as 
relevant players in regulation of gene expression by influencing the binding of transcription 
factors.21,22 Cancer cells are positively selected to escape the native repressive chromatin 
environment in order to allow TERT transcription.23 
In the present study, we aim to elucidate the interaction of genetic and epigenetic 
mechanisms in regulation of TERTp. We approach this by using novel droplet digital PCR 
(ddPCR)-based assays.24 Human-derived benign skin cells (keratinocytes, dermal fibroblasts, 
melanocytes, skin biopsy samples and naevi) and melanoma cell lines were analysed. The 
TERTp mutational status was assessed along with the absolute presence of methylation 
in the TERTp at a CpG-specific resolution. The effect of chromatin accessibility in TERT 
expression was evaluated in a subset of cultured melanoma cell lines.
RESULTS
NGS-BASED DEEP BISULFITE SEQUENCING AND DEVELOPMENT OF A DDPCR ASSAY 
TO ASSESS TERTp METHYLATION FRACTION 
We first aimed to quantitatively measure the TERTp methylation at a CpG-specific resolution 
in primary skin samples and melanoma cell lines. DNA of 44 primary skin biopsy samples 
and melanoma cell lines was bisulfite-converted (BC) and analysed using NGS-based 
deep bisulfite sequencing to assess the methylation fraction (MF) in a region of TERTp 
encompassing 31 CpG sites. The TERTp MF was high in some healthy skin samples, such 
as normal skin (~30%), naevi (~30%) and cultured keratinocytes (~50%). In the latter group, 
in fact, the MF was as high as in cutaneous melanoma cell lines (Figure 1 and Figure 7a). 
In contrast, the fibroblasts and low-passage cultured melanocytes show the lowest MF 
observed in this cohort. Since the cutaneous melanoma originates from melanocytes of the 
skin, we found the difference in MF between normal melanocytes and cutaneous melanoma 




FIGURE 1. Methylation fraction (MF) of 31 CpG sites around cg11625005 in 35 primary skin samples 
and 9 melanoma cell lines. DNA samples were bisulfite-converted (BC) and analysed through NGS-
based deep sequencing. Connected scatter plot representing the MF per cell type group in absolute 
distance between measured CpG sites. Blue arrow: cg11625005 (position 1,295,737). Samples 
included: fibroblasts (n=5), melanocytes (n=5), naevi (n=6), normal skin samples (n=11), keratinocytes 
(n=8), cutaneous melanoma cell lines (n=6) and uveal melanoma cell lines (n=3). 
In order to validate the TERTp MF obtained through NGS in a quantitative manner, we 
have developed a ddPCR assay (Figure 2a) using methylation-sensitive restriction enzymes 
(MSREs) HgaI and AvaI, which recognise the CpG on position 1,295,737 (cg11625005) 
and 1,295,731 in hg19, respectively. Castelo-Branco et al. showed that methylation of the 
cg11625005 in TERTp, was associated with tumour progression and poor prognosis of 
childhood brain tumours.20 Barthel et al. affirmed a correlation between methylation and 
TERT expression in samples lacking somatic TERT alterations and a lower methylation 
level in normal samples.3 Indeed, in our study, the MF of fibroblasts was as low as that of 
the unmethylated control DNA, whereas that of the keratinocytes was higher than most of 
the cutaneous melanoma cell lines (Figure 2b). The MF of cg11625005 (position 1,295,737) 
obtained through NGS and by ddPCR were highly correlated (R2=0.82, p<0.001) (Figure 2c). 
The MF of 1,295,731 assessed through ddPCR even yielded a stronger correlation (R2=0.96, 
p<0.001) (Figure 2d).
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FIGURE 2. Methylation fraction (MF) analysed through ddPCR. MDNA and UDNA are commercially 
available methylated and unmethylated DNA, respectively. (a) Calibration curve using different expected 
ratios (25%, 50% and 75%) of methylated DNA and F332 to demonstrate the quantitative capacity 
of ddPCR. Linear regression and correlation analysis were performed to compare the expected to 
observed ratios (F(1,3)=209.2, r=0.99, p<0.001). (b) MF of cg11625005 in a subset of healthy primary skin 
samples – fibroblasts (F332 and F537) and keratinocytes (K060 and K409) and cutaneous melanoma 
cell lines (A375, 94.07 and 518A2) incubated with MSRE HgaI. MF was plotted with 95% CI through 
RoodCom WebAnalysis (version 1.9.4).(c & d) Correlation plots between MF obtained through golden 
standard NGS-based deep bisulfite sequencing versus ddPCR using either the MSRE HgaI (c) or AvaI 
(d), which digest unmethylated CpG in position 1,295,737 and 1,295,731, respectively, in a batch of 44 
samples: fibroblasts (n=5), melanocytes (n=5), naevi (n=6), normal skin samples (n=11), keratinocytes 
(n=8), cutaneous melanoma cell lines (n=6) and uveal melanoma cell lines (n=3). Linear regression and 




ABSENCE OF CORRELATION BETWEEN METHYLATION FRACTION AND TERT 
EXPRESSION 
Cancer cells are commonly characterised by hypermethylation of promoter CpG islands 
resulting in repression of tumour suppressor genes. However, in TERT, promoter 
hypermethylation was found to be associated with higher expression, since CTCF repressors 
of TERT transcription do not bind methylated sequences.3,16,17,19 In our sample cohort, there 
was no correlation between TERT methylation of cg11625005 and mRNA expression (n=31, 
Figure 3 and Figure 7b). 
FIGURE 3. Correlation between methylation fraction (%) and TERT mRNA expression in total of 31 
samples: fibroblasts (n=3), melanocytes (n=1), keratinocytes (n=2), cutaneous melanoma cell lines (n=19) 
and uveal melanoma cell lines (n=6). Linear regression and correlation analysis were performed to 
compare (F(1,29)=1.13, r=0.19, ns p=0.297).
EVALUATION OF TERTp MUTATIONS IN A COLLECTION OF SKIN SAMPLES AND 
MELANOMA CELL LINES
Besides promoter methylation, somatic mutations are also known to be correlated with 
TERTp reactivation. Therefore, we characterised the TERTp mutational status of the sample 
cohort. Sanger sequencing on one naevus, fresh skin and cutaneous melanoma cell lines 
518A2, 607B, A375, 94.07 and 93.08 revealed melanoma-associated TERT C250T and 
C228T mutations (Figure 4a). Aiming to use the ddPCR method to evaluate the mutational 
load of the samples, the TERT C250T and C228T mutation assays were validated in three 
samples of which the mutation was identified in sequencing analysis, 518A2, 607B and 
A375 (Figure 4b). Following the test runs, the C228T and C250T assays were used on the 
extended sample cohort (n=61) (Supplementary Table S5 and Figure 7c). All TERTp-mutated 
samples were cutaneous melanoma cell lines, however OCM8 and 94.13 cutaneous cell 
lines tested wild-type. The C250T mutation was not present in combination with the C228T 
mutation in any sample, confirming that the mutations are mutually exclusive. 
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FIGURE 4. TERTp mutational status of primary skin samples and cutaneous melanoma cell lines. (a) 
The TERTp region encompassing the C228T and C250T mutations was sequenced through Sanger 
sequencing using McEvoy’s25 TERTp forward primer. The TERTp region of fresh skin 1, Naevus 1, 
518A2, 607B, A375, 94.07, 93.08 is shown. The left and right arrows respectively indicate the positions 
1,295,228 and 1,295,250. R: one-letter code for bases G or A; Green arrow: wild-type; red arrow: C>T 




Rad TERT assays in 518A2, 607B and A375 melanoma cell lines. 2D ddPCR plots of the results from 
the C228T mutation assay (left) and C250T mutation assay (right). The blue cloud represents mutant 
copies; the green cloud represents WT copies. 
ABSENCE OF CORRELATION BETWEEN MUTATIONAL STATUS AND TERT EXPRESSION 
As the presence of mutations in the gene promoter induces TERT reactivation, we assessed 
the correlation between mutational status with TERT mRNA expression (n=31). When WT 
and mutated samples (either C228T or C250T) were compared, regardless of origin of 
the tissue, no significant differences for TERT mRNA expression were found (Figure 5). 
Moreover, TERT expression was exclusive to the melanoma cell lines, either with or without 
TERTp mutations (Figure 7b). 
FIGURE 5. Correlation between TERTp mutational status and TERT mRNA expression in total of 31 
samples: fibroblasts (n=3), melanocytes (n=1), keratinocytes (n=2), cutaneous melanoma cell lines (n=19) 
and uveal melanoma cell lines (n=6) (One-way ANOVA, F(2,28)=1.75, ns p=0.192). 
TERT EXPRESSION IS CORRELATED TO CHROMATIN ACCESSIBILITY 
In contrast to most genes, methylation of the TERTp positively correlates with its mRNA 
expression.3,16,17,19 Although we were not able to confirm this finding, we investigated 
whether besides promoter methylation, other mechanisms could contribute to chromatin 
accessibility to transcription factors affecting TERTp regulation. Therefore, we analysed 
chromatin state in a subset of melanoma cell lines (cutaneous, 518A2, 607B, 94.07, A375, 
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93.08 and OCM8; and uveal, OMM2.5 and Mel270) by ddPCR methodology instead of 
qPCR for an accurate quantification. The positive control gene GAPDH, a housekeeping 
gene that is generally expressed in all conditions, and thus 100% accessible, was used. The 
accessibility in the region around cg11625005 shows a high variability, being over 90% in 
uveal cell lines while being intermediate to low in cutaneous melanoma cell lines (Figure 
6a, Figure 7d and Supplementary Table S6). When comparing the accessibility around 
cg11625005 to the methylation fraction of this CpG, a significant positive correlation was 
observed (R2= 0.89, p<0.001) (Figure 6b). Another positive correlation (R2=0.59, p<0.05) was 
found when comparing the accessibility of the same region to the normalised TERT mRNA 
expression levels in these samples (Figure 6c). In actuality, in this subset of 8 cell lines, the 
TERTp methylation and gene expression show a statistically significant (p<0.05) positive 
correlation (Figure 6d). The 3 cell lines with higher MF are those with the highest chromatin 
accessibility (OMM2.5, Mel270 and OCM8). Remarkably, these are also the cell lines with 
WT-TERTp, in which the chromatin accessibility was significantly higher than in the mutated 
subgroup (Figure 6e). 
In addition, we investigated whether the TERT accessibility originated from the mutant or 
the wild-type allele. For this purpose, we assessed the fractional abundance of mutated 
allele, in the subgroup of 4 TERTp-mutated cutaneous cell lines before and after nuclease 
digestion. 607B cell line was not included since it is homozygous for the mutation and not 
informative. In 3 out of 4 cell lines preferential digestion of the mutant allele showed that 




FIGURE 6. Accessibility of TERTp around cg11625005 in 8 melanoma cell lines. Cell lines (518A2, 607B, 
94.07, A375, 93.08, OMM2.5, Mel270 and OCM8) were analysed with the EpiQ chromatin kit, and 
ddPCR was performed using primers and probes for positive control gene GAPDH and for the TERT 
methylation region, a 231-bp amplicon around cg11625005. Accessibility (%) was calculated by the ratio of 
the digested sample to its matched undigested sample, subtracted from 1, and subsequently normalised 
against the positive control GAPDH. (a) Accessibility of the TERT methylation region relative to GAPDH 
(mean ± SD, multiple t-tests, one t-test per cell line, *p<0.001, ns p=0.149). (b and c) Correlation plots of 
gene accessibility around cg11625005 with the MF (%) of cg11625005 obtained through ddPCR (b), or with 
normalised expression levels via qPCR (c). Linear regression and correlation analysis were performed 
(F(1.6)=49.9, r=0.95, p<0.001 and F(1,6)=8.6, r=0.77, p<0.05, respectively). (d) Correlation plot between MF (%) 
of cg11625005 obtained through ddPCR and normalised expression levels via qPCR. Linear regression 
and correlation analysis were performed (F(1.6)=16.92, r=0.86, p<0.05). (e) Comparison of WT (OMM2.5, 
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Mel270 and OCM8) and mutated (518A2, 607B, 94.07, A375, 93.08) TERT-expressing cell lines subsets 
regarding chromatin accessibility (two-tailed unpaired t-test; t=4.63, df=6; p<0.005). (f) Accessibility of 
mutant allele (%) in a subset of 4 TERTp-mutated cutaneous cell lines (518A2, 94.07, A375 and 93.08) 
calculated as described in Material and Methods (mean ± SD, multiple t-tests, one t-test per cell line, ns 
p=0.171; *p<0.001) and the TERT mRNA expression in the respective cell lines (mean ± SEM).
FIGURE 7. Results overview. Schematic representation of TERTp with the relative positions of 
cg11625005 (position 1,295,737 in hg19) to the TERTp mutations (position 1,295,228 and 1,295,250) 
and the transcription start site (TSS). (a) Heat-map of methylation fraction (MF) in 31 CpG sites (top) in 




Blue-marked CpG in 1,295,731 is recognised by MSRE AvaI. Black rectangle: MF at the cg11625005 
measured either by NGS (clear squares, n=44) and by ddPCR (patterned squares, n=17; these samples 
were not included in the 44-sample batch subjected to NGS). (b) TERT mRNA expression in 31 samples 
by qPCR analysed through the ΔΔCT method in Bio-Rad CFX manager software (version 3.1, Bio-Rad). 
(c) TERTp mutations evaluated through ddPCR with commercial TERT C250T and C228T Mutation 
Assays in total 61 samples. (d) Analysis of the chromatin accessibility in 8 cultured cell lines for TERT 
methylation region using GAPDH as a positive control.
DISCUSSION
By using advanced quantitative methods, we investigated the epigenetic and genetic 
regulation of TERTp in benign and malignant skin cells. Innovative ddPCR-based assays were 
developed and validated to assess TERT promoter methylation and chromatin accessibility. 
These methods avoid semi-quantitative qPCR and provide absolute quantification even in 
samples that are challenged by CG-rich DNA sequences, low concentration and integrity. 
In the present study the methylation fraction was assessed by NGS interrogating 31 CpGs 
in the TERTp region across 44 healthy, benign and malignant tumour samples. Remarkably, 
high methylation levels were observed in a variety of normal samples. Mainly in keratinocytes 
methylation levels exceeded those of cutaneous melanoma cell lines. Previous studies 
on brain tumours and skin melanoma, observed a general absence of methylation in a 
specific CpG in TERTp, cg11625005, in healthy control samples.3,20 Of note, although the 
authors state absence of methylation we can observe a β-value of ~0.4 (fluorescence ratio 
provided by Illumina 450K array, ranging from 0 to 1) in their normal samples.3 In our cohort, 
the methylation fraction at this CpG was quantified by ddPCR, which validated our results 
obtained through NGS. Moreover, in our study, methylation of cg11625005 did not stand 
out across the CpGs in TERTp but seemed to be affected along with adjacent CpGs in 
this genomic region in all samples (Figure 7a). This result suggests that context-related 
methylation around cg11625005 is biologically relevant as opposed to methylation of one 
specific CpG. 
TERTp mutations has been described as a genetic mechanism responsible for induction 
of TERT reactivation.7,9 Over the years that followed, a variety of epigenetic or genetic 
alterations in the gene body or TERTp have been identified, such as promoter methylation, 
mutations, structural variations, DNA amplification, or promoter rearrangements.3,5,19
In accordance with previous studies, regardless of the methylation status, human benign 
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cells neither harbour TERTp mutation nor express TERT, thereby supporting the principal 
oncological concept that a benign cell does not undergo undefined proliferation (Figure 8). 
Although we have not found a positive correlation between presence of TERTp mutations 
or TERTp methylation levels and mRNA expression values, all tumour cell lines showed 
TERT expression, supporting that these mechanisms contribute to telomerase-activation in 
cancer, separate or in combination.7,9,19 
A plethora of histone modifications result in chromatin remodelling that may change 
accessibility of the TERTp to transcription factors, such as ETS/TCF.7 Schwartz et al. state 
that the degree of chromatin folding is correlated with gene transcription and is thought 
to impact the regulation of DNA-dependent processes.26 Therefore, we explored the level 
of chromatin accessibility and its interaction with methylation levels and mRNA expression 
in 6 cutaneous and 2 uveal melanoma cell lines. In fact, we found a positive correlation 
between chromatin accessibility and methylation levels as well as mRNA expression that 
ultimately explains the correlation between methylation fraction and TERT expression. 
Then, we investigated whether both wild-type and mutant alleles were equally affected 
by similar patterns of chromatin organization and assessed the mutational fraction upon 
digestion with nuclease in heterozygous cell lines, assuming that the nuclease only digests 
DNA open chromatin regions. We could infer that, mutated alleles are more accessible, 
possibly favouring the binding of transcription factors and consequently TERT mono-allelic 
expression. Our findings in the 518A2 cell line, harbouring the C228T TERTp mutation, 
are similar to the results from a study by Stern et al., in which it was found that the active 
mutant allele is hypomethylated.27 These observations are consistent with the canonical 
influence of methylation on transcriptional regulation. In contrast, 94.07 cell line also 
presents a very small methylation fraction. However both alleles were equally resistant 
to nuclease digestion, which might explain the lowest TERT expression levels among all 
cell lines. Therefore, it still supports the link between local chromatin accessibility and 
gene regulation.26 To fully disclose the molecular mechanisms behind TERT expression the 
heterozygous mutant cell lines A375 and 93.08 provide good models as they allow to study 
a repressed and expressed allele within the same cell. 
Another remarkable observation in our study is that in WT TERT-expressing uveal melanoma 
cell lines, the methylation of the whole TERTp region is close to 100% with a significantly 
higher chromatin accessibility compared to TERTp-mutated cell lines. Accordingly, Stern 
et al. also demonstrate that cell lines with WT TERTp display much higher levels of 
methylation.27 These characteristics of WT TERTp cell lines may lead to biallelically TERT 




Interestingly, these results suggest a complex model in which TERT expression requires 
either a widely open chromatin state in TERTp-WT samples due to hypermethylation 
throughout the promoter or mono-allelic expression of the accessible mutated allele in 
combination with moderate (probably allele-specific) methylation fraction (Figure 8). 
FIGURE 8. Proposed model of TERT transcriptional regulation. Regardless of MF at the TERTp 
methylation region, both keratinocytes and melanocytes do not show TERT expression. In TERTp-
mutated cell lines, an intermediate MF positively correlated with chromatin accessibility, in combination 
with C228T/C250T TERT mutations allows monoallelic TERT expression. In TERTp-WT cell lines, the 
MF is close to 100% with a significantly higher chromatin accessibility leading to high expression levels. 
Chromatin schemes adapted from Schwartz et al.26 
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Furthermore, Huang and colleagues reported that some cancer cell lines show mono-allelic 
expression of TERT even in the absence of TERTp mutations.28 
Previous studies have reported the association between TERTp hypermethylation and 
poor patient survival in melanoma and other cancers, indicating that it might be a relevant 
prognostic marker.20,27,29-31 In primary melanoma it needs to be assessed if TERTp methylation 
is predictive of worse prognosis. Thus, the quantification of TERT methylation through 
ddPCR might be relevant in the clinic to assess patient prognosis. 
The dynamics of epigenetic mechanisms in TERT genetic regulation is complex. Further 
investigations are needed to address the correlation of allele-specific differences in 
chromatin accessibility and promoter methylation with allele-specific mRNA expression. 
MATERIAL AND METHODS
SAMPLES, DNA EXTRACTION AND PCR 
Surplus female breast skin and nevi tissues were obtained from 11 and 6 anonymous patients 
that underwent cosmetic surgery, respectively. Surgeries for mama reduction (performed 
between 2010 and 2018) and naevi (performed between 2008 and 2009), were conducted 
according to declaration of Helsinki principles. Epidermis and dermis were separated after 
removal of adipose tissue followed by enzymatic digestion and primary fibroblast (n=5) 
and keratinocyte (n=8) cell suspensions were obtained and cultured as described before.32 
Keratinocytes were used at passage 2, while fibroblasts were used at passage 3-5. 
Low-passage cultured melanocytes (n=5) – m003, m003A, m002, m004A and 0398A – 
were cultured as previously described.33 HEMs were cultured more recently in the medium 
254 supplemented with HMGS-2 (Gibco/ThermoFisher) and Penicillin (100 U/ml), and 
Streptomycin (100 μg/ml; both from Lonza, Verviers, Belgium). 
We also included 19 early-passage cutaneous melanoma cell lines derived from metastatic 
lesions cultured for research purposes and adoptive T-cell transfer.34 Cell lines were 
cultured and DNA and RNA extracted between 2017 and 2019. The 518A2, 607B, 04.01, 
04.04, 94.13, 93.05, 94.07, 93.08, 634, 01.05, and 06.24 cell lines were a kind gift from Dr. 
Els Verdegaal (Department of Medical Oncology, LUMC). Meljuso was obtained from Prof. 
Neefjes (Department of Cell and Chemical Biology, LUMC). WM1361A, WM3506, WM1960 
cell lines were a kind gift from Dr. KL Scott (Baylor College of Medicine, Houston, USA). 




and OCM1 were provided by Dr. Mieke Versluis (Department of Ophthalmology, LUMC).35 
All cell lines were cultured with Dulbecco’s modified eagle medium (DMEM, low glucose, 
pyruvate; Gibco/ThermoFisher) supplemented with 10% FCS, Penicillin (100 U/ml), and 
Streptomycin (100 μg/ml; both from Lonza, Verviers, Belgium) and glutamax (100X, Gibco). 
For the 6 uveal cell lines provided by Dr. Mieke Versluis (Department of Ophthalmology, 
LUMC), the establishment and culturing conditions have been described before: OMM 136, 
OMM 2.3, OMM 2.5 and Mel27037, Mel20238, 92.139. All cell lines used in our study were 
tested negative for mycoplasm and recently subjected to STR profiling.
The batch thus consisted of 36 primary skin type samples and 25 melanoma cell lines, 
totalling 61 samples (Table 1). 
TABLE 1. Samples overview
Control samples Melanoma cell lines
Skin biopsy samples Fibroblasts Melanocytes Keratinocytes Naevi Cutaneous Uveal
LB627 F537 m003 K590 Naevus 1 04.01 OMM 2.3 
LB470 F544 m002 K409 Naevus 2 WM1361A OMM 1
LB579 F332 m003A K549 Naevus 3 93.05 OMM 2.5
LB576 F334 m004A K514 Naevus 4 WM3506 Mel270
LB584 F628 0398A K060 Naevus 5 WM1960 Mel202
LB586   HEM K627 Naevus 6 Meljuso 92.1
LB625     K516   634  
LB381     K550   OCM8  
LB628         OCM1  
LB629         518A2  
Fresh skin 1         607B  
          94.07  
          A375  






DNA was isolated using the QIAamp DNA Blood Mini Kit and the DNeasy Blood & Tissue Kit (both from Qiagen, Hilden, 
Germany). 
Conventional PCR was performed using the PCR-sequencing kit (Thermo Fisher 
Scientific,  Waltham, MA, USA), containing 10X reaction buffer, MgCl2 (50mM), dNTP 
mix (10nM, Fermentas/Thermo Fisher Scientific), primer mix (900nM each), PlatinumX 
Taq enzyme (2.5U), 50ng DNA and Aqua B. Braun RNase-free water. A PCR for CG-rich 
sequences was performed on 50ng DNA using the PCRX Enhancer System (Thermo Fisher 
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Scientific), containing 10X PCRX amplification buffer, MgSO4 (50mM), dNTP mix (10nM), 
primer mix (900nM each), PlatinumX Taq enzyme (2.5U) and Aqua B. Braun RNase-free 
water. The samples were amplified in C1000 Touch Thermal Cycler (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). 
PROMOTER METHYLATION DETERMINATION 
Bisulfite conversion and next-generation sequencing (NGS)-based deep bisulfite 
sequencing
In this experiment 44 samples were included: fibroblasts (n=5), melanocytes (n=5), naevi 
(n=6), normal skin samples (n=11), keratinocytes (n=8). cutaneous melanoma cell lines (n=6) 
an uveal melanoma cell lines (n=3). DNA was bisulfite-converted (BC) using the EZ DNA 
Methylation™ Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer protocol 
(version 1.2.2). BC samples were amplified using the PCRX Enhancer System in the program: 
1 cycle of 95°C for 3 minutes, 8 cycles of 95°C for 30 seconds, 58°C for 30 seconds, reducing 
1°C/cycle, and 68°C for 1 minute, then 36 cycles of 95°C and 53°C for 30 seconds each, and 
68°C for 1 minute, followed by 1 cycle of 68°C for 3 minutes. Tailed primers were used for 
amplification (900nM each; S1 Table). Samples were sequenced through next-generation 
sequencing (NGS), MiSeq, 2x300bp paired-end, at Leiden Genome Technology Centre 
(LGTC). Bisulfite sequencing reads were quality trimmed using PRINSEQ (v0.20.4 lite) and 
aligned to GRCh37 using Bismark (v0.20.0) and Bowtie 2 (v2.3.4.3).40-42 
Novel design of a ddPCR assay using methylation-sensitive restriction enzymes 
(MSREs) to determine TERTp methylation fraction
The methylation fraction (MF) of the CpG (cg11625005) in position 1,295,737 was determined 
by an in-house designed ddPCR assay in combination with HgaI methylation-sensitive 
restriction enzyme (MSRE) that cleaves this CpG when unmethylated, as described by Nell 
et al.24 100ng DNA sample was incubated with HgaI (2U/μl) and appurtenant 10X NEBuffer 
1.1 (both from New England Biolabs, Bioké, Leiden, The Netherlands) for 60 minutes at 37°C 
and 65°C for 20 minutes. To assess the MF of a CpG adjacent to cg11625005, located in 
1,295,731, the MSRE AvaI (10U/μl; New England Biolabs) was employed, which recognises 
this CpG and cleaves it when unmethylated. Incubation of the DNA samples with AvaI was 
performed with 10X CutSmart buffer for 15 minutes at 37°C and subsequently 65°C for 
20 minutes. For ddPCR reaction, 60ng DNA digested or undigested by HgaI, 2x ddPCR 
SuperMix for Probes (no dUTP), primers (900nM each), a FAM-labelled in-house-designed 
probe for the CpG site of interest (250nM, Sigma, St. Louis, MO, USA), and 20X HEX-labelled 
CNV TERT reference primer/probe (Bio-Rad) for total TERT amplicon count. The primers and 
probe sequences are presented in S2 Table. The amplification protocol used: 1 cycle of 




98°C for 10 minutes, all at ramp rate 2°C/s. Droplets were analysed through a QX200 droplet 
reader (Bio-Rad) using QuantaSoft software version 1.7.4 (Bio-Rad). Raw data was uploaded 
in online digital PCR management and analysis application Roodcom WebAnalysis (version 
1.9.4, https://www.roodcom.nl/webanalysis/)24, in which the MF was calculated by dividing 
the CNV of the digested sample with that of the paired undigested sample.
ASSESSMENT OF MUTATIONAL STATUS 
Sanger sequencing
The presence of the C228T and C250T TERTp mutations in some samples was evaluated 
by conventional Sanger sequencing. DNA samples were amplified through the PCRX 
Enhancer System (Thermo Fisher Scientific) using primers (Sigma-Aldrich) and amplification 
program described by McEvoy et al.25
Mutation analysis using commercial TERT C250T and C228T mutation assays
For most of the samples, the TERTp mutations were detected by the ddPCR technique 
according to protocol described by Corless et al.43, using the TERT C250T_113 Assay 
and C228T_113 Assay (unique assay ID dHsaEXD46675715 and dHsaEXD72405942, 
respectively; Bio-Rad). Both assays include FAM-labelled probes for the C250T and C228T 
mutations respectively, HEX-labelled wild-type (WT) probes, and primers for a 113-bp 
amplicon that encompasses the mutational sites. The ddPCR reaction mix comprised 1X 
ddPCR Supermix for Probes (No dUTP), Betaine (0.5M; 5M stock), EDTA (80mM; 0.5M stock, 
pH 8.0, Thermo Fisher Scientific), CviQI restriction enzyme (RE; 2.5U; 10U/μl stock, New 
England BioLabs), the TERT assay, and 50ng DNA. Droplets were generated in QX200 
AutoDG system (Bio-Rad) and amplified in T100 Thermal Cycler (Bio-Rad) according to the 
recommended cycling conditions and analysed through a QX200 droplet reader (Bio-Rad) 
using QuantaSoft software version 1.7.4 (Bio-Rad).
CHROMATIN ACCESSIBILITY 
Cell culture and treatment to assess chromatin states
Cutaneous melanoma cell lines A375, 518A2, 607B, 94.07, 93.08, OMM2.5, Mel270 and 
OCM8 were cultured for 22 days in 9-cm Cellstar® cell culture dishes (Greiner Bio-One 
GmbH, Frickenhausen, Germany) with Dulbecco’s modified eagle medium (DMEM; Sigma-
Aldrich) supplemented with 10% FCS, Penicillin (100U/ml), and Streptomycin (100μg/ml; 
both from Lonza, Verviers, Belgium) until roughly 95% confluent. Then, different densities 
(10,000, 20,000, 40,000 and 80,000 cells) of the above-mentioned cell lines were seeded 
in duplicate into a 48-well plate (Corning Costar, Sigma-Aldrich) required for the EpiQ 
chromatin assay. The EpiQTM Chromatin Analysis Kit (Bio-Rad) was performed according to 
manufacturer’s instructions. Briefly, after 2 days each cell line was 85%-95% confluent. The 
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cells were permeabilised and treated with EpiQ chromatin digestion buffer with or without 
nuclease for 1 hour at 37°C. Following incubation with EpiQ stop buffer for 10 minutes at 
37°C, the DNA samples were purified using alcohol and DNA low- and high-stringency wash 
solutions. The genomic DNA was eluted in DNA elution solution. 
Novel design of a ddPCR assay to assess chromatin opening state
The analysis was performed using ddPCR rather than qPCR, to achieve quantifiable results 
using GAPDH expression as positive control. The reaction mix consisted of 2x ddPCR 
Supermix for Probes (No dUTP, Bio-Rad), 20x HEX-labelled CNV TERT reference primer/
probe (Bio-Rad), 50ng DNA, and primers (900nM each) and FAM-labelled probes (250nM) for 
GAPDH, or the methylation region around cg11625005 (S3 Table). Samples were amplified 
according to the program of the CNV TERT reference primer/probe as described. Gene 
accessibility was quantified by the digestion fraction between the digested and undigested 
samples, subtracted from 1, multiplied by 100. 
Allele-specific chromatin accessibility
The mutational fraction upon digestion with nuclease (EpiQTM Chromatin Analysis Kit 
aforementioned) was assessed in cutaneous melanoma cell lines with heterozygous TERTp 
mutations, 518A2, 94.07, A375 and 93.08. The analysis was performed by ddPCR using the 
TERT C250T_113 Assay and C228T_113 Assay (unique assay ID dHsaEXD46675715 and 
dHsaEXD72405942, respectively; Bio-Rad) as described above. The mutation fraction from 
undigested and digested samples were compared and the accessibility of mutant allele 
was calculated as follows:
 
RNA ISOLATION, CDNA SYNTHESIS AND QUANTITATIVE REAL-TIME PCR 
RNA was obtained using the FavorPrep Tissue Total RNA Extraction Mini Kit (Favorgen 
Biotech, Vienna, Austria) according to manufacturer’s instructions for animal cells. cDNA was 
synthesised through the iScript™ cDNA Synthesis Kit (Bio-Rad) according to recommended 
protocol. TERT mRNA expression was assessed by qPCR performed with 3.5ng DNA, IQ 
SYBR Green Supermix (2x; Bio-Rad), and 0.5μM PCR primers (Sigma-Aldrich; Supplementary 
Table S4) in a Real-Time PCR Detection System CFX96 (Bio-Rad) and normalised to 
reference gene expression (RPS11, TBP and CPSF6, Supplementary Table S4). Data was 





In this study we used the GraphPad Prism software (version 8.0.1 for Windows, GraphPad 
Software, CA, USA) to perform all the statistical tests. Prism 8 has a wide library of analysis 
and in our paper we have used the linear regressions and correlations (in Figure 2a,c and 
d; Figure 3; Figure 6b,c and d), one-way ANOVA (Figure 5) and multiple t-tests without 
correction for multiple comparisons, one t-test per cell line, *p<0.001 (Figure 6a and f) and 
two-tailed unpaired t-test (Figure 6e). A p-value<0.05 was considered statistically significant.
The methylation fraction obtained using ddPCR was calculated with 95% confidence interval 
by dividing the CNV of the digested sample with that of the paired undigested sample. Raw 
data was uploaded in online digital PCR management and analysis application Roodcom 
WebAnalysis (version 1.9.4, https://www.roodcom.nl/webanalysis/)24 (in Figure 2b). 
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SUPPLEMENTARY TABLE S1. Tailed primers used for amplification of 325-bp region in bisulfite-
converted samples.
Forward primer (5’-3’) [GATGTGTATAAGAGACAG]AGGGGTTATGATGTGGAGGT
Reverse primer (5’-3’) [CGTGTGCTCTTCCGATCT]TTACTCATAATAAAAACCCCTC
Note: Primer tail between square brackets
SUPPLEMENTARY TABLE S2. Primers and probe sequences to amplify the 106-bp amplicon in a novel 
design of a ddPCR assay to determine the methylation fraction. 
Forward primer (5’-3’) GTGAAGGGGAGGACGGAGG
Reverse primer (5’-3’) GTGTTGCAGGGAGGCACT
Probe (5’-3’) TAGACGCGGCTGGGGACGAA
SUPPLEMENTARY TABLE S3. Primers and probe sequences to amplify the 231-bp region encompassing 
31 CpG sites around the cg11625005 in a novel ddPCR assay to assess the chromatin state. 
Forward primer (5’-3’) Reverse primer (5’-3’) Probe (5’-3’)




SUPPLEMENTARY TABLE S4. Primer and probe sequences for TERT expression in qPCR.
Forward primer (5’-3’) Reverse primer (5’-3’)
TERT ex9-10 ATCCTCTCCACGCTGCTCT CCAACAAGAAATCATCCACCA
Reference genes RPS11 AACATCGGTCTGGGCTTC AGTGAAGGGGCATTTCTTGT
TBP CACGAACCACGGCACTGATT TTTTCTTGCTGCCAGTCTGGAC
  CPSF6 AAGATTGCCTTCATGGAATTGAG TCGTGATCTACTATGGTCCCTCTCT
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SUPPLEMENTARY TABLE S5. Overview of the methylation fraction (measured by ddPCR and NGS), 
mutational status and TERT mRNA expression of our sample cohort (n=61). 
Type of 
samples Sample ID
Methylation fraction (cg11625005) TERTp mutation TERT expression




OMM 2.3 103.8% 96% WT 0.59
2 OMM 1 103.4% WT 0.04
3 OMM 2.5 103.8% 97% WT 1.65
4 Mel270 103.2% WT 1.72
5 Mel202 107.8% WT 0.02




04.01 100.0% C250T 1.06
8 WM1361A 35.9% C228T 0.16
9 93.05 53.4% C250T 2.06
10 WM3506 78.8% C228T 0.59
11 WM1960 87.3% C250T hom 0.71
12 Meljuso 74.4% C250T 0.64
13 634 4.4% C250T 0.70
14 OCM8 67.3% 56% WT 0.41
15 OCM1 36.2% 37% C250T 1.08
16 518A2 4.3% 8% C228T 0.44
17 607B 36.5% 86% C228T hom 1.05
18 94.07 2.3% 5% C250T 0.06
19 A375 52.4% 41% C250T 0.97
20 93.08 19.0% C250T 0.29
21 01.05 7.5% C250T 1.00
22 04.04 102.6% C250T 0.18
23 94.13 23.7% WT 1.17
24 MM057 55.1% C250T 1.10




LB627 21.9% 29% WT
27 LB470 26.0% 36% WT
28 LB579 23.4% 30% WT
29 LB576 18.3% 30% WT
30 LB584 10.1% 15% WT
31 LB586 31.0% 34% WT
32 LB625 25% WT
33 LB381 26.3% 29% WT
34 LB628 22.7% 28% WT
35 LB629 24.3% 28% WT
36 fresh skin 1 25.8% 33% WT
37
Keratinocytes
K590 41.5% 54% WT 0.00
38 K409 49.4% 49% WT 0.00
39 K549 34.0% 56% WT
40 K514 43.5% 59% WT
41 K060 41.4% 56% WT
42 K627 42.0% 59% WT
43 K516 41.1% 59% WT




SUPPLEMENTARY TABLE S5 CONTINUED.
Type of 
samples Sample ID
Methylation fraction (cg11625005) TERTp mutation TERT expression
ddPCR (n=59) NGS (n=44) ddPCR (n=61) qPCR (ΔΔCq) (n=31)
45
Melanocytes
m003 9.5% 29% WT
46 m002 7.1% 44% WT
47 m003A 7% WT
48 m004A 3.6% 2% WT
49 0398A 4.3% 9% WT
50 HEM 43.9% WT 0.00
51
Fibroblasts
F537 3.7% 5% WT
52 F544 4.0% 7% WT
53 F332 3.5% 9% WT 0.00
54 F334 4.4% 8% WT 0.00
55 F628 3.3% 8% WT 0.00
56
Naevi
Naevus 1 26.4% 31% WT
57 Naevus 2 13.8% 20% WT
58 Naevus 3 26.9% 33% WT
59 Naevus 4 25.8% 31% WT
60 Naevus 5 10.2% 15% WT
61 Naevus 6 23.1% 33% WT
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SUPPLEMENTARY TABLE S6. Overview of the methylation fraction (measured by ddPCR and NGS), 
mutational status and TERT mRNA expression and chromatin accessibility in the subset of melanoma 







TERTp mutation TERT expression Gene accessibility




OMM 2.3 103.8% 96% WT 0.59
2 OMM 1 103.4% WT 0.04
3 OMM 2.5 103.8% 97% WT 1.65 99.6% 100.0%
4 Mel270 103.2% WT 1.72 90.9% 99.7%
5 Mel202 107.8% WT 0.02




04.01 100.0% C250T 1.06
8 WM1361A 35.9% C228T 0.16
9 93.05 53.4% C250T 2.06
10 WM3506 78.8% C228T 0.59
11 WM1960 87.3% C250T hom 0.71
12 Meljuso 74.4% C250T 0.64
13 634 4.4% C250T 0.70
14 OCM8 67.3% 56% WT 0.41 87.6% 100.0%
15 OCM1 36.2% 37% C250T 1.08
16 518A2 4.3% 8% C228T 0.44 36.2% 96.3%
17 607B 36.5% 86% C228T hom 1.05 66.6% 99.5%
18 94.07 2.3% 5% C250T 0.06 25.5% 97.8%
19 A375 52.4% 41% C250T 0.97 54.6% 98.6%
20 93.08 19.0% C250T 0.29 50.6% 99.0%
21 01.05 7.5% C250T 1.00
22 04.04 102.6% C250T 0.18
23 94.13 23.7% WT 1.17
24 MM057 55.1% C250T 1.10
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Melanoma is an aggressive form of skin cancer, causing significant mortality, due to its 
capacity for metastatic dissemination. It develops from the pigment-producing cells, the 
melanocytes. In order to become malignant, these cells accumulate multiple genetic and 
epigenetic alterations. 
During the last decade the advent of next generation sequencing methodology has allowed 
the identification of novel inherited pathogenic gene variants in patients with familial 
melanoma and patterns of somatic alterations in sporadic cases. 
In the present thesis, we explored inherited and acquired epigenetic alterations in 
melanoma susceptibility and development. Epigenetics literally means ‘on top of genetics’ 
and refers to mechanisms that regulate gene expression not involving alterations in the 
DNA.1 There are 3 main epigenetics mechanisms: DNA (hydroxy)methylation (covalent 
modifications of DNA bases), histone modifications (post-translational modifications on the 
amino-terminal tail of histones) and chromatin remodelling (repositioning of nucleosomes 
by protein complexes).2 The epigenetic enzymes can be classified as writers, readers and 
erasers depending on their function and have different implication in cancer. The writers 
add various chemical modifications on DNA and histone tails; the readers are the proteins 
that bind the modifications and interpret them; and the erasers are responsible for removing 
these chemical tags.3
We aimed to address epigenetic alterations in melanoma susceptibility by studying a 
novel putative melanoma-susceptibility gene encoding a histone 3 lysine 79 (H3K79) 
methyltransferase, a writer according to the above-mentioned classification, was functionally 
assessed. In addition, epimutations as a putative cause of familial melanoma using genome-
wide analyses. We also aimed to explore the epigenetic regulation of an essential gene in 
melanoma pathogenesis, TERT. Finally, we analysed the genomic distribution and functional 
significance of DNA hydroxymethylation in melanoma.  
CAN A MUTATED EPIGENETIC ENZYME BE RESPONSIBLE 
FOR MELANOMA PREDISPOSITION?
To reveal new candidate susceptibility genes in melanoma we performed whole exome 
sequencing (WES) on DNA isolated from blood cells from two members of a family with four 
melanoma cases, not explained by established high penetrance melanoma-susceptibility 
genes. WES identified 10 rare, co-segregating, predicted deleterious missense gene variants. 




the SLCO4C1 (P597A) genes were present in the other two affected members of this family. 
The lack of expression of SLCO4C1 in melanocytes combined with gene function did not 
encourage us to explore this gene variant further. In Chapter 2, we describe a new germline 
missense variant in the DOT1L gene co-segregating with melanoma in all affected members 
of a Dutch melanoma family. DOT1L is the unique histone methyltransferase responsible 
for methylating the nucleosome core on lysine 79 of histone H3 (H3K79).4-6 In addition, 
DOT1L regulates transcription elongation, establishes cell cycle checkpoints, and maintains 
genomic stability.7,8 Dysregulation of DOT1L has been associated with a number of cancers 
either as an oncogene or tumour suppressor gene.4 In ovarian cancer cells, when DOT1L 
expression was knocked-out by CRISPR/Cas9 technology, cell invasion and cancer stem-
like cell properties were significantly promoted.9 Studies in gastric cancer showed that 
DOT1L  expression is significantly higher in gastric malignant tumours correlating to the 
degree of differentiation, lymph node metastasis and TNM staging.10 Recently, in colorectal 
cancer DOT1L has been described as an important player in DNA double-stand break repair 
via homologous recombination.11
Three new somatic mutations (M55L, P271L, and P505L) in the DOT1L gene that negatively 
affect the catalytic activity of the methyltransferase were identified in melanoma cells.12 Loss 
of DOT1L (by silencing or mutation) impaired the DNA damage repair induced by UV-B 
radiation, thereby promoting melanoma development in vivo. Accordingly, we found that 
mouse ES cells express a catalytically inactive DOT1L mutant (G165R) were more sensitive 
to UV radiation, consistent with a protective role of DOT1L. However, when we functionally 
explored the germline R409H variant, we could neither detect histone methyltransferase 
activity reduction in melanoma and mESCs nor an effect on UV-induced survival in mESCs. 
Different explanations for this lack of effects can be pointed out: the dynamic changes in and 
alternative functions of H3K79me were missed in the assays used; the R409H mutant is not 
by itself pathogenic; the role of the R409H variant in melanocytes is not recapitulated in the 
cell model used in our study; the R409H variant affects a methyltransferase-independent 
function of DOT1L. However, in mammalian cells this activity of DOT1L has been shown 
to be required for several critical functions, such as reactivation of repressed genes, cell 
cycle progression in lung cancer cell lines, and leukemic transformation in CALM-AF10 MLL-
rearranged leukemia.13-15
Subsequently, several variants in DOT1L gene have been observed in independent familial 
and sporadic melanoma cases from the UK (personal communication, Dr. Harland, Leeds 
University). The variants G1320R and Y115F, both assessed as damaging/deleterious by 
Polyphen and SIFT prediction tools, were described in a family with 2 cases of melanoma. 




Furthermore, two somatic variants in the DOT1L gene (S1440T and L871P) were found in 
independent sporadic patients with early-onset of melanoma and no family history (see 
Table 2, Chapter 216). 
Although our studies on the R409H variant do not conclusively prove pathogenicity, we 
believe that a variant co-segregating with melanoma in a family with four affected members 
reinforce the findings by Zhu et al. of DOT1L as a melanoma susceptibility gene. We consider 
it worthwhile to examine whether this variant has methyltransferase-independent functional 
consequence and to investigate DOT1L variants in future studies involving large familial 
melanoma cohorts. 
MAY HERITABLE EPIGENETIC EVENTS EXPLAIN 
MELANOMA SUSCEPTIBILITY?
Whole exome and whole genome sequencing analyses of familial melanoma have 
identified a few rare pathogenic gene variants, but failed to explain the cause of melanoma 
predisposition in more than half of the families.17 This might be due to the fact that most 
of the identified variants are extremely rare and segregate in only a few families, along 
with polygenic inheritance mechanisms as well as the effects of UV radiation. In addition 
hereditary epigenetic alterations have been proposed to explain the ‘missing heritability’ of 
melanoma susceptibility. 
Over the years, the focus has been redirected to epigenetic mechanisms that may explain 
the melanoma predisposition in these families. Holliday defined epimutations as heritable 
promoter hypermethylation leading to gene silencing.18 In hereditary nonpolyposis colorectal 
cancer (HNPCC, Lynch syndrome) not caused by mutations in DNA mismatch repair genes, 
epimutation of the MLH1 gene has been identified as causative mechanism in multiple 
families.19 Subsequently, epimutation of the MSH2 mismatch repair gene was demonstrated 
in another family with HNPCC.20 In several other cancer types with familial occurrence, 
including ovarian cancer and retinoblastoma, candidate epimutations have been found.21,22
Whether a heritable epimutation can be the result of transgenerational epigenetic 
inheritance in the absence of an underlying genetic cause is controversial.23,24 In fact, 
epimutations were described as primary, those occurring in the absence of an underlying 
DNA sequence alteration, or secondary, where genetic variation drives the propensity for 
hypermethylation at a specific locus.25 The extent to which heritable epigenetic alterations 




Therefore, besides the putative genetic cause, we have aimed to assess whether heritable 
epigenetic events could account for melanoma predisposition in families where no genetic 
cause could be found. Possible epimutation of the CDKN2A gene has been explored as 
a mechanism to explain the melanoma susceptibility in melanoma families. For this gene, 
our group and others concluded that in 64 Swedish, 22 Dutch and 114 American patients 
with  hereditary  melanoma, CDKN2A epimutation was not the causative mechanism for 
melanoma susceptibility.26-28
In Chapter 3, we evaluated 5 families with a history of melanoma in multiple generations 
where no pathogenic gene variants in any of the currently established or candidate high 
penetrance melanoma susceptibility genes had been found. DNA from peripheral blood 
of 2 affected members of each family was assessed by 450K Illumina arrays.29 In this 
study we made use of DNA methylation data from a valuable reference group of 1000 
healthy individuals from the Biobank-based Integrative Omics Studies (BIOS) consortium. 
The occurrence of epimutation of the recently established melanoma susceptibility genes 
(CDKN2A, CDK4, BAP1, TERT, POT1, TERF2IP, ACD, MBD4, POLH, POLE, EBF3, GOLM1, MC1R 
and MITF) was examined in these familial melanoma patients. Secondly, loss-of-imprinting, a 
distinct epigenetic mechanism of inheritance by which certain genes are silenced based on 
its parental origin epigenetic mark, was examined.30 Genomic imprinting is involved in fetal 
growth and plays a role in carcinogenesis31, being the association between the IGF2–H19 
locus and Wilms tumour the best-described in cancer.32 Thirdly, a genome-wide analysis of 
approximately 450,000 CpGs located in all human gene promoters was performed. This 
unbiased genomic analysis of single CpG sites was complemented by investigation of 
differentially methylated regions (dmrs).
In summary, there was no significant difference from the reference group in methylation 
level at any of the melanoma susceptibility genes. Nor did we find any indication of loss-of-
imprinting at the CpG sites located at the imprinted loci. The exploratory analysis found 6 
hypermethylated CpGs in both affected members of a melanoma family compared to a healthy 
cohort as well as 35 hypomethylated CpGs. Although we did find the 6 hypermethylated 
CpGs located in the promoter regions of RABGGTB, SND1, SCAF11, ZNF638, THAP1 and 
SFSWAP genes, none of them have been reported as a cancer predisposition gene or 
functions related to melanoma.33 Besides these also the dmrs in the promoters of CCNI, 
CD47 and USP46 genes showed minor differences compared to healthy controls. Two of 
35 hypomethylated CpGs were located in cancer-related genes, but were not found to 
be plausible candidates either. This was the first time that heritable epigenetic events in 
melanoma have been analysed in a genome-wide fashion interrogating 99% of human 




families provide a relevant pathogenic explanation for melanoma inheritance. However, 
it is still possible that pathogenic heritable DNA methylation alterations might occur in a 
minor proportion of melanoma families or that epimutations may affect other potentially 
regulatory regions. Recently, constitutional mosaic epimutations in MGMT, MLH1 and BRCA1 
genes have been reported as the epigenetic cause of a significant number of glioblastoma, 
colorectal and ovarian/breast cancers, respectively.34 Therefore, constitutional methylation 
of key tumour suppressor genes may represent an initiating event of carcinogenesis that 
might be present in a mosaic fashion due to a post-zygotic epigenetic event in melanocyte 
precursor cells and not be retrievable in DNA from blood.
Uncovering the causes of predisposition to melanoma in families is of major clinical 
relevance since it could improve the risk estimation, genetic counselling and testing and 
enable targeted clinical surveillance of patients at high risk of melanoma. Accordingly, further 
studies for such constitutional epigenetic events could aid cancer prevention programs.
CAN AN ALTERED DNA HYDROXYMETHYLATION 
PATTERN BE A BIOMARKER OF MELANOMA?
The role of DNA methylation in cancer has been widely explored. Cutaneous melanoma 
demonstrates altered patterns of DNA methylation that are associated with genetic instability 
and transcriptional repression of tumour suppressor genes. A more recently discovered 
epigenetic modification, that has since received increasing attention of the cancer research 
field, is DNA hydroxymethylation. Active DNA demethylation entails a hydroxymethylation 
step mediated by TET enzymes, which catalyze conversion of 5-methylcytosine (mC) to 
5-hydroxymethylcytosine (hmC). Hydroxymethylcytosine can thus be considered as an 
intermediate step in the active demethylation of DNA.
In Chapter 4, we aimed to identify CpG sites and regions with differential hydroxymethylation 
and methylation levels when comparing melanoma (metastatic and non-metastatic) and 
melanocytic nevus samples that might be used as diagnostic and prognostic markers. 
In addition we intended to gain insights into the functional significance of this DNA 
modifications by studying its distribution. A study from Lian et al. had previously reported 
the loss of hydroxymethylation as an epigenetic hallmark of melanoma.35 Oxidative bisulfite 
chemistry combined with arrays that simultaneously interrogate hmC and mC at 850,000 
CpG sites throughout the genome were used in our study. This methodology followed 
by bioinformatic analysis revealed significant differences in the global hmC patterns of 




levels of hmC were uniformly lower in metastatic than in non-metastatic melanoma, the 
patterns of distribution were not significantly different. DNA hmC loss may be explained by 
passive dilution of the hmC mark due to DNA replication in proliferating melanoma cells and 
by insufficient active demethylation.36,37 Within the pattern of global hmC depletion, specific 
CpG sites and regions could be identified with significantly lower hydroxymethylation in 
melanoma than in nevus, pointing to epigenetic deregulation at specific loci. We identified 
22,164 single differentially hydroxymethylated CpG sites and 68 regions that are strong 
candidate biomarkers for diagnosis.38-40 Among the 68 DhMRs, 5 localized to cancer-related 
genes: PTEN, DAXX, GAS7, GNAS and TPM4. PTEN is an essential tumour suppressor 
gene in melanoma. Many previous studies report downregulation of PTEN in melanoma 
compared to nevus, PTEN inactivation through promoter hypermethylation, and enhanced 
melanoma formation upon PTEN downregulation.35,41-45 These findings strengthen our 
hypothesis that hmC depletion at the PTEN regulatory region in melanoma has functional 
significance by affecting expression of this tumour suppressor gene. Briefly, in normal skin, 
the development of melanocytic nevi is caused by activating mutations of the BRAF or 
NRAS oncogenes, which provides a proliferative stimulus to the cells at first but eventuates 
in a state of stable cell cycle arrest (oncogene-induced senescence). We found that at this 
stage the PTEN promoter region shows high hmC and low mC levels. The accumulation 
of mC due to reduced active demethylation (loss of hmC) at this region regulating PTEN 
expression may lead to transcriptional silencing of this essential tumour suppressor gene 
facilitating escape from oncogene-induced senescence and contribute to malignant 
transformation.
Recently, Bonvin et al. made use of a well-established genetically engineered Nras 
mutation–driven mouse model of spontaneous melanoma to disclose the roles of specific 
epigenetic alterations in melanomagenesis. They showed that in mice, genetic ablation 
of Tet2 in combination with NrasQ61K-driven melanoma mouse model promotes melanoma 
initiation by an overall decrease in hmC and specific hmC gains in selected gene bodies, 
accelerates melanoma progression and decreases melanoma-free survival. They also 
suggest that the presence/absence of hmC modulates the binding of epigenetic factors 
resulting in changes in chromatin structure rather than directly affecting gene transcription.46 
Similar to our results a striking hmC depletion in melanoma compared to nevus samples 
was observed exceeding those of mC patterns. Altogether these studies suggest that active 
demethylation may protect promoter and enhancer regions from methylation-associated 
silencing and therefore loss of hmC might contribute to malignant progression. Our findings 
call for further functional studies of the role of DNA hydroxymethylation at the PTEN locus 




The reasons behind hmC reduction have been widely explored and some studies report 
that mutational inactivation and/or downregulation of TET2 might explain the loss of hmC as 
well as mutant IDH proteins.35,47 While wild-type IDH protein produce αKG, the co-substrate 
of TET enzymes, the mutant IDH transform it into 2-HG, an oncometabolite that is a 
competitive inhibitor of TET. Resetting the differential mC and hmC levels towards a functional 
demethylation pathway might be an interesting target to cancer therapy.48 Recently, a new 
combinatorial treatment between vitamin C and ML309, IDH1-mutant inhibitor, showed a 
synergistic effect in colon cancer cells, significantly decreasing the 2-HG levels to levels 
comparable with WT cells, leading to increased levels of global hydroxymethylation and 
even increased expression of tumour suppressors.49  
HOW IS TERT GENE EPIGENETICALLY REGULATED?
Located on chromosome locus 5p15.33, telomerase reverse transcriptase (TERT) encodes 
the catalytic subunit of the ribonucleoprotein telomerase and is capable of extending the 
repetitive, non-coding DNA sequence of telomeres following mitosis.50 Telomeres become 
shorter at each cell division, until reaching the Hayflick limit, which induces replicative 
senescence and growth arrest.51 Through TERT reactivation, the cells keep the ability of 
extending their telomeres or prevent their shortening allowing immortalization of malignant 
cells and tumour progression as occurs in 90% of human cancers. This limitless replicative 
potential by active telomere elongation is one of the hallmarks of cancer.52-54 
Expression of TERT is a key determinant of telomerase activity in human cells. Activating 
TERT promoter (TERTp) mutations are reported in 30−80% of familial and sporadic 
melanomas.55,56 The well-known influence of epigenetic mechanisms in the regulation of 
gene expression in cancer led us to explore how the TERT gene can be epigenetically 
reactivated. As mentioned above in this thesis the canonical effect of hypermethylation 
in the promoter regions of cancer cells is to repress genetic transcription.57,58 Contrary to 
common concepts, CpG methylation in the TERTp was previously correlated with higher 
TERT mRNA expression. 
In Chapter 5, we aimed to characterize the genetic-epigenetic interaction in the regulation 
of the TERT gene in healthy skin samples and melanoma cell lines. The two hotspot 
mutations in TERTp, dubbed C228T and C250T, together with TERTp methylation, chromatin 
accessibility and TERT expression were assessed. The methylation fraction was evaluated 
by NGS in a set of 31 CpGs in the TERT promoter region and validated by custom ddPCR-




in brain tumours and melanoma this CpG showed absence of methylation in normal 
cells.52,59 However, in our study, the methylation fraction was quite high in healthy skin 
samples, naevi and cultured keratinocytes. Furthermore, our results suggest that context-
related methylation of a genomic region might be biologically more relevant as opposed 
to methylation of one specific CpG. The two point mutations in the TERTp described in 
melanoma create new transcription factor binding motifs and correlate with upregulation 
of the TERT gene. In our cohort, we checked the presence of these mutations through 
ddPCR-based assays. Altogether, TERT expression was only found in tumour cell lines, with 
or without TERTp mutation and a broad range of promoter methylation levels (5%-100% 
methylation fraction). Thus, we hypothesise that another level of regulation was responsible 
for mRNA expression. Since distinct histone modifications influences chromatin remodelling 
and ultimately gene accessibility to transcription factors, such as ETS/TCF, we investigated 
to which extent the chromatin was accessible and whether this had occurred in a mono- 
or biallelic fashion. We observed a positive correlation between chromatin accessibility 
and methylation levels as well as mRNA expression leading us to conclude that mutated 
alleles were more accessible, possibly favouring the binding of transcription factors and 
consequently TERT mono-allelic expression of the mutant allele. Our results are in line 
with the study from Stern et al. and Huang et al., where the authors found that the mutant 
allele was hypomethylated and allowed monoallelic TERT expression.60,61 Thus, these 
observations are consistent with the canonical influence of methylation on transcriptional 
regulation. On the contrary, the WT TERT-expressing uveal melanoma cell lines show a 
methylation fraction close to 100% and significantly higher chromatin accessibility. These 
characteristics of WT TERTp cell lines may lead to biallelic TERT activation. In fact, in this 
case TERT seems to be an exception, since possible biallelic hypermethylation leads to 
upregulation. 
Taking everything into account we might conclude that TERT activation is under distinct 
epigenetic regulation in mutated and WT TERTp cell lines. While in mutant TERTp, 
methylation executes its canonical function, repressing transcriptional regulation, in WT 
TERTp, methylation carries out a non-canonical role, leading to transcriptional activation 
in these cell lines. The dynamics of epigenetic mechanisms in TERT genetic regulation is 
complex, however we believe that our results contribute to the full understanding of all (epi)
genetic mechanisms that collectively reactivate TERT.
TERT was first recognized for the telomere maintenance and over the years many other 
non-canonical roles have been reported, such as involvement in regulation  of non-
telomeric DNA damage responses, promotion of cell growth and proliferation and control of 




genetic transcription through chromatin modulation.62,63 Beyond the telomere maintenance, 
TERT is crucial to other aspects of the tumour microenvironment, such as angiogenesis, 
inflammation and cancer cell stemness.64 Although TERT repression may sensitize cells 
to conventional chemotherapy in a telomere independent manner65-67, due to the above 
mentioned telomere-independent functions this approach can lead to severe side effects.63 
Therefore, further study is required to elucidate the conventional and alternative molecular 
mechanisms of telomerase beyond telomere maintenance, in order to develop new 
anticancer strategies targeting telomerase or telomeres.63,68 
FIGURE 1. Proposed model of TERT transcriptional regulation. In TERTp-mutated cell lines, active 
mutant allele is hypomethylated, highly accessible and allows monoallelic TERT expression. In TERTp-
WT cell lines, the MF is close to 100% with a significantly higher chromatin accessibility leading to high 




HOW DO OUR FINDINGS CONTRIBUTE TO THE 
UNDERSTANDING OF EPIGENETIC ALTERATIONS IN 
THE SUSCEPTIBILITY TO AND DEVELOPMENT OF 
MELANOMA?
In our study, we discovered R409H variant in the DOT1L gene using WES in a family. 
Although we were not able to definitely prove the functional effect of the R409H variant in 
the DOT1L gene, encoding a H3K79 methyltransferase, our findings reinforce the ones by 
previous studies, which pointed to DOT1L as a melanoma susceptibility gene with a role 
in DNA damage repair.11,12 DOT1L is not involved in transcriptional regulation of the DNA 
repair genes, but rather promotes the assembly of the nucleotide excision repair complex 
on chromatin by interacting with XPC and stimulating its recruitment to DNA lesions.12 Loss 
of DOT1L impaired DNA damage repair induced by UV-B radiation, thereby promoting 
melanoma development in vivo. To fully disclose the functional consequences in regard to 
melanoma risk of the variant identified in our study, an engineered mouse model to harbour 
the DOT1L R409H variant might be valuable tool.
As previously observed in patients with hereditary nonpolyposis colorectal cancer and 
familial chronic lymphocytic leukemia, heritable epigenetic events might be a plausible 
explanation for melanoma predisposition.19,20,69-72 For the first time we performed genome-
wide analysis assessing all CpGs located in gene promoters of candidate and established 
susceptibility genes, imprinted genes and gene promoters throughout the genome. We 
conclude that none of the hypermethylated CpGs and differentially methylated regions 
identified do constitute a pathogenic epimutation in predisposition to melanoma in these 
families. Nevertheless, it is still possible that pathogenic heritable DNA methylation 
alterations might either exist in a mosaic pattern through a post-zygotic epigenetic event, 
potentially only affecting melanocytes or occur in other potentially regulatory regions rather 
than in promoters or in a small number of melanoma families.
Beyond the epigenetic silencing of tumour suppressor genes or inherited epigenetic 
alterations involved in the predisposition to cancer, we also explored how epigenetic 
alterations may contribute to progression towards malignancy. Specific CpG sites and 
regions identified with differential distribution and significantly lower hydroxymethylation 
levels in melanoma than in nevus can be used to aid in distinguishing malignant from benign 
melanocytic lesions.38-40 Moreover, the presence of hmC at the PTEN regulatory region in 
nevus, and its loss in melanoma, may signify that active demethylation can protect promoter 
and enhancer regions from methylation-associated silencing of tumour suppressor genes. 




depletion observed at the PTEN promoter region in melanoma. 
Genetic regulation comprises different processes and pathways. We have shown that 
a holistic model encompassing TERTp mutation, methylation and other epigenetic 
mechanisms as chromatin accessibility are crucial to dictate TERT gene expression. Either 
a widely open chromatin state in TERTp-WT samples due to hypermethylation throughout 
the promoter or mono-allelic expression of the accessible mutated (C228T or C250T) allele 
in combination with moderate (probably allele-specific) methylation fraction are required.
In general, the studies presented in this thesis show associations between epigenetic 
states and cellular gene expression patterns or phenotypes. However demonstration of 
causality would require methods to specifically introduce such epigenetic alterations and 
investigate their consequences. Whereas CRISPR/Cas9 technology has become a valuable 
tool to engineer genetic alterations, similar methods to introduce epigenetic changes still 
need further development. 
SUMMARY AND FUTURE PERSPECTIVES
Over recent years, our understanding of the genetic variation underlying cutaneous 
melanoma susceptibility has increased, with the discovery of pathogenic gene variants 
that explain half of melanoma susceptibility in families. The focus has been redirected to 
the epigenetic mechanisms that may either explain the melanoma predisposition in the 
remaining families and to reveal how certain genes are repressed or activated in melanoma. 
Nowadays, the integration of genomic/epigenomic/transcriptomic/metabolomic data seems 
to be of major importance. We generated a comprehensive view of interaction between 
genome and epigenome of cancer cells by addressing hydroxymethylation as a possible 
protection against hypermethylation-associated silencing at promoter regions of relevant 
genes as well as by revealing how mutations, methylation and chromatin organization may 
interact to regulate the expression of a gene involved in the immortalization of cancer cells. 
Many questions still remain for instance on hydroxymethylation distribution at the promoter 
region that may interfere with allele-specific chromatin accessibility and expression. We 
were also able to identify potential epigenetic diagnostic markers for melanoma and (epi)
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Melanoom is het meest agressieve en dodelijke type huidkanker, omdat het kan uitzaaien 
naar interne organen, waarna de ziekte nauwelijks meer genezen kan worden.
Het is gebruikelijk om te horen over cellen, chromosomen, DNA, genen en veranderingen 
hieraan wanneer men spreekt over kanker. De chromosomen bevinden zich in de celkern 
en bestaan uit lange DNA-strengen die veel genen bevatten. De meest voorkomende 
veranderingen, ofwel mutaties, die bij kanker in de DNA strengen voorkomen verstoren de 
structuur of de hoeveelheid en daarmee de functie van specifieke eiwitten in kankercellen. 
DNA mutaties kunnen verschillende gevolgen hebben voor de cel en erfelijke mutaties 
kunnen ook van invloed zijn op de vatbaarheid voor kanker.
WAAR STAAT EPIGENETICA VOOR?
Mutaties zijn veranderingen in volgorde van de nucleotiden waaruit de DNA-streng is 
opgebouwd. De structuur en functie van het DNA kan echter ook veranderd worden zonder 
dat deze nucleotiden veranderen. Het DNA kan gemodificeerd worden en daardoor op een 
andere wijze in de celkern opgevouwen worden. Deze wijzigingen die het functioneren van 
het DNA beïnvloeden worden tezamen ‘epigenetica’ genoemd. Het Griekse voorvoegsel 
“epi” betekent “bovenop” of “naast” de traditionele genetica. De term ‘epigenetica’ 
werd oorspronkelijk door Conrad Waddington in 1942 voorgesteld om de moleculaire 
mechanismen te beschrijven die onafhankelijk zijn van veranderingen in de DNA sequentie. 
Er zijn drie belangrijke epigenetische mechanismen: DNA (hydroxy)methylatie (covalente 
modificaties van DNA nucleotiden), histonmodificaties (posttranslationele modificaties 
aan het amino-uiteinde van histonen en chromatine-hermodellering (repositionering van 
nucleosomen door eiwitcomplexen).
In de studies opgenomen is dit proefschrift is onderzocht hoe verworven en geërfde 
epigenetische veranderingen een rol spelen bij de vatbaarheid voor en ontwikkeling van 
melanoom.
Ons doel is om nieuwe melanoom susceptibiliteitsgenen en erfelijke epigenetische 
alteraties te identificeren die een verklaring kunnen zijn voor melanoom aanleg in een 
significante proportie van de met melanoom aangedane families (familiair melanoom) 
waarbij de oorzaak nog onbekend is. Hiervoor hebben we de rol bestudeerd van een 
nieuwe vermoedelijke melanoom susceptibiliteitsgen die codeert voor histon 3 lysine 79 
(H3K79) methyltransferase. De mutatie in het DOT1L gen werd gevonden in een familie 
waarvan verschillende leden melanoom hadden ontwikkeld. We hebben experimenten 
met gekweekte cellen uitgevoerd om te achterhalen welke biologische processen werden 




concluderen dat erfelijke mutaties in het DOT1L gen invloed heeft op de gevoeligheid voor 
UV-blootstelling en zo een verhoogd risico op melanoom met zich mee kunnen brengen. 
Een ander onderzoeksproject had tot doel om na te gaan of erfelijke epigenetische 
veranderingen de oorzaak kunnen zijn van familiair melanoom in die gevallen waarvoor 
geen genetische oorzaak kan worden geïdentificeerd. Verschillende epigenetische 
mechanismen, zoals de aanwezigheid van epimutaties aan alle bekende melanoom 
susceptibiliteitsgenen, verlies van genomische imprinting, gevolgd door genoombrede 
promoter hypermethylatie, -werden onderzocht in het DNA van steeds 2 leden met 
melanoom uit 5 families. Onze resultaten tonen aan dat erfelijke DNA methylatie van 
genpromoters geen plausibele oorzaak zijn van familiair melanoom.
FIGUUR. Structuur van DNA. De chromosomen zijn gelokaliseerd in de celkern en bestaan uit lange 
DNA-strengen die vele genen bevatten. Chromosomen bevatten eiwitten die histonen worden 
genoemd, waar het DNA omheen is gebonden. DNA bestaat uit vier componenten die nucleotiden 
worden genoemd (hier weergegeven in geel, rood, blauw en paars). DNA-methylatie (m) en DNA-
hydroxymethylatie (hm) zijn de weergegeven epigenetische veranderingen [Aangepast overgenomen 
van TereseWinslow LLC]
Verder onderzochten we ook het voorkomen van bovengenoemde DNA methylatie (m 
in Figuur) en DNA hydroxymethylatie (hm in Figuur) betrokken bij de de-methylatie van 
DNA in het DNA van melanomen en goedaardige gepigmenteerde huidafwijkingen 
(nevus, moedervlek). Het doel was om meer inzicht te krijgen in de distributie van DNA 




kwaadaardige melanoomcellen. We waren in staat om specifieke nucleotiden en regio’s 
met hydroxymethylatie specifiek in het DNA van melanoomcellen te identificeren die 
zouden kunnen worden gebruikt bij de diagnostiek van dit tumortype. Daarnaast werden 
in het DNA van melanoomcellen regio’s met hydroxymethylatie gelokaliseerd die kunnen 
bijdragen aan de ontwikkeling van melanoom.
Aangezien zowel genetische als epigenetische modificaties vaak naast elkaar ‘werken’ 
om maligne transformatie te veroorzaken, hebben we ook de gecombineerde bijdrage 
onderzocht van epigenetische (DNA methylatie en chromatine hermodellering) en 
genetische (genpromotor mutaties) mechanismen bij het reguleren van een belangrijk gen 
dat betrokken is bij de vorming van melanoom, het TERT gen. Door activatie van het TERT 
gen kan celdood voorkomen worden en kunnen cellen ongelimiteerde capaciteit om te 
delen verkrijgen, twee belangrijke kenmerken van kankercellen. We konden een complex 
samenspel tussen mutaties, methylatie en veranderingen van de chromatinestructuur 
ter plaatse van het TERT gen waarnemen die correleren met activatie van dit gen in 








O melanoma é o tipo de cancro de pele mais agressivo e mortal devido à sua capacidade 
de metastização, o que o torna difícil de controlar.
Quando se fala de cancro, é muito comum ouvir falar de células, cromossomas, DNA, 
genes e alterações. Os cromossomas estão confinados aos núcleos das nossas células 
e consistem em longas cadeias de DNA contendo inúmeros genes. As alterações mais 
comumente descritas em cancro estão relacionadas com alterações na sequência de DNA, 
mutações, que dificultam a correta produção de proteínas. Estas apresentam diferentes 
implicações para a célula e podem estar envolvidas na predisposição para cancro. 
O QUE SIGNIFICA EPIGENÉTICA?
Além das mutações, os componentes da cadeia de DNA podem ser afetados por diversas 
modificações com um impacto negativo na geração de uma nova proteína. Ao conjunto 
destas modificações que afetam o “comportamento” dos componentes do DNA dá-se o 
nome de “epigenética”. O prefixo grego “epi” significa “em cima da” ou “além da” tradicional 
genética. O termo epigenética foi originalmente proposto por Conrad Waddington em 1942 
para descrever os mecanismos moleculares independentes das alterações na sequência 
de DNA. Existem 3 mecanismos epigenéticos principais: (hidroxi)metilação do DNA 
(modificações covalentes das bases de DNA); modificações das histonas (modificação pós-
traducional de histonas) e remodelação de proteínas (reposicionamento de nucleossomas 
por complexos proteicos).  
Nesta tese de doutoramento, pretendemos investigar o papel das alterações epigenéticas 
herdadas e adquiridas na suscetibilidade para melanoma e seu desenvolvimento. 
Alterações epigenéticas hereditárias podem explicar a predisposição para melanoma 
numa proporção significativa de famílias com história familiar desta doença, para as quais 
a causa é ainda desconhecida. Assim, estudámos o papel de uma mutação num potencial 
gene de suscetibilidade que codifica a metiltransferase do amino-ácido lisina 79 na histona 
3. Interessantemente, observámos que esta alteração no gene DOT1L co-segrega com 
melanoma em vários casos da mesma família, enfatizando o seu papel na transmissão da 
doença. Através de técnicas de biologia celular avaliámos que processos biológicos eram 
afetados ao incorporar esta alteração em determinadas células. Concluímos, baseados 
em estudos anteriores e nos nossos próprios resultados, que o estudo desta alteração 
merece ser mais aprofundado, uma vez que as mutações no gene DOT1L parecem afetar 
a sensibilidade à radiação UV, potenciando a transformação neoplásica. Além disso, 
investigámos se alterações epigenéticas podem ser a causa de melanoma numa grande 




Diferentes mecanismos epigenéticos foram investigados no DNA de 10 indivíduos de 5 
famílias: em particular estudámos 2 indivíduos diagnosticados com melanoma por família, 
procurando alterações de metilação hereditárias (epimutações) em todos os genes de 
suscetibilidade para melanoma, investigando perda de imprinting, e ainda avaliando a 
metilação dos respetivos promotores. Os nossos resultados mostram que epimutações 
não parecem constituir uma causa plausível de melanoma familiar nestas famílias. 
FIGURA. Estrutura de DNA. Os cromossomas estão confinados ao núcleo das células e são longas 
cadeias de DNA contendo diversos genes. Contém ainda proteínas chamadas histonas que se ligam 
ao DNA. O DNA é constituído por 4 nucleótidos diferentes (amarelo, vermelho, azul e roxo). A metilação 
(m) e hidroximetilação (hm) são as alterações epigenéticas representadas [adaptado de © 2015 Terese 
Winslow LLC, U.S. Govt. has certain rights and Dictionary of Cancer Terms PDQ Cancer Information 
Summaries, National Cancer Institute (US)].
Analisámos a distribuição genómica da metilação de DNA (m na Figura) e o processo 
oposto, desmetilação de DNA, também conhecido como hidroximetilação (hm na Figura), 
em amostras benignas (nevos normais, os comuns sinais na pele) e amostras cancerígenas 
(melanoma) de diferentes pacientes. O objetivo foi esclarecer como é que a hidroximetilação 
está envolvida na progressão maligna das células e que processos são, portanto, 
potencialmente modificáveis. Fomos capazes de identificar regiões genómicas específicas 




diagnóstico que parecem contribuir para a evolução de melanoma. 
Uma vez que as modificações genéticas e epigenéticas cooperam na promoção da 
transformação neoplásica, também examinámos de que forma a metilação de DNA 
e remodelação da cromatina (mecanismos epigenéticos) e mutações do promotor 
(mecanismos genéticos) contribuem para regulação de um gene essencial na patogénese 
de melanoma, TERT. O gene TERT participa no processo de proliferação descontrolada e 
na prevenção de morte celular, duas características importantes das células neoplásicas. 
Os nossos resultados sugerem um modelo complexo no qual a expressão do gene TERT 
requer um estado de cromatina descondensada devido à elevada taxa de metilação ao 
longo do promotor em amostras sem mutações do promotor, ou a combinação de uma 
fração moderada de metilação/acessibilidade da cromatina em amostras com mutações no 
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